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ABSTRACT 
Computer Aided Drug Design/Discovery methods became 
complementary to traditional and modern drug discovery approaches. 
Indeed CADD is useful to improve and speed up the detection and the 
optimization of bioactive molecules. The present study is focused on the 
application of structure-based approaches to the study of pharmaceutical 
relevant targets. The introduction provides a quick overview on the 
fundamentals of computational chemistry and structure-based methods, 
while in the successive chapters the main targets investigated through these 
methods are treated. In particular we focused our attention on Reverse 
Transcriptase of HIV-1, Monoamine oxidase B and VP35 of Ebola virus. The 
last chapter is dedicated to the validation of covalent docking performed 
with Autodock. 
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1 CHAPTER 
1.1 INTRODUCTION TO COMPUTER AIDED DRUG DESIGN 
 
During the last decades the interest on computational methodologies 
applied toward pharmaceutical targets became higher. These approaches 
became indispensable and increasingly combined with the traditional 
methods. In fact, Computer-aided Drug Design (CADD) methods, compared 
to the classical experimental procedures, allows to investigate the 
mechanism of action of various atomic or molecular phenomena with a 
remarkable saving of money and time.1 Hence, from the ’60 the 
improvements in this field have been remarkable and continuous in order to 
ensure reliable results related to the study of complex biological structures.2 
Previously computational studies were directed to the analysis of small 
molecules and were carried out by means of quantum mechanical 
approaches, based on the Schrödinger quantum mechanics concepts, then 
the advent of molecular mechanics made possible simulations of larger 
systems in reasonable time.3  
 
In a drug discovery campaign, CADD is usually used for three major 
purposes:4, 5 
1) Filter large compound libraries into smaller sets of 
predicted active compounds that can be tested.6-9 
2) Guide the optimization of lead compounds, to increase 
its affinity or to optimize drug metabolism and pharmacokinetics 
properties including absorption, distribution, metabolism, 
excretion and the potential toxicity (ADMET).4, 10, 11 
3) Explain the molecular basis of therapeutic activity of 
compounds and rationalize it through the study of the Structure 
Activity Relationships (SAR).12 
 
Of course there are also limitations and caveats to consider in the 
application of computational methods.1 These have to be keep in mind as in 
cerebro element is essential in the application of such techniques:13 It is 
famous the sentence of professor Hugo Kubinyi by warning students 
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approaching this field : “Don’t switch off the brain when you switch on the 
computer!”.  
Before gaining insight into each computational technique, it must be 
pointed out that CADD can be divided into two general categories: 
Structure-based and Ligand-based Drug Design. 
Structure-based methods relies on the availability of structural data of 
the target macromolecule to calculate interaction energies for tested 
compounds,14 whereas ligand-based methods exploit the knowledge of 
known active and inactive molecules through chemical similarity searches or 
construction of predictive, quantitative structure-activity relation (QSAR) 
models. The application of the latter ones is needed when no or little 
structural information of the target is available. Furthermore structure and 
ligand based methods can be also combined in more complex drug discovery 
workflows.15  
The goal of these applications is to validate the activity of compounds 
in vitro and in vivo and to predict their putative binding site, ideally this 
should be then supported through a co-crystal structure.16 Lead 
identification is often followed by several cycle of subsequent lead 
optimization using CADD.17 
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Figure 1. CADD in a Drug discovery pipeline and the available ligand-based and structure-
based methodologies.
18
 
 
In this dissertation I will focus my attention on structure-based 
methods which were applied for the different targets object of the studies 
carried out during my PhD. 
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1.2 BASIS OF COMPUTATIONAL CHEMISTRY 
 
Computational chemistry, or molecular modeling, comprehends a 
series of techniques for investigating chemical problems on a computer. The 
investigations could interest: molecular geometry, energies of molecules, 
transition states, chemical reactivity and so on. In addition more complex 
problems can be studied, like the protein-protein interactions or the binding 
mode of a substrate/drug with an enzyme in order to design new potent 
drugs.  
In order to describe a system we need four fundamental features: 
- System description: type of units or “particles” and their number; 
- Starting condition: information about particles position  and their 
velocities; 
- Interaction: mathematical forms necessary for describing the 
forces acting between the particles; 
- Dynamical equation: mathematical form used to describe the 
behaviour of complex system evolving in time. 
The choice of “particles” puts limitations on what we are ultimately 
able to describe: sub-atomic particle, atomic and residue level.  
Computational methods can be divided into two big categories 
depending on whether they are based upon the concepts of quantum 
mechanics or molecular mechanics. Nowadays the molecular mechanicals 
methods are mostly used because they allow to analyse systems with tens 
of thousands atoms like proteins or DNA.  
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1.2.1 Basic theory of quantum mechanical methods 
 
Quantum mechanical methods are mainly used in the computational 
chemistry field to collect essential parameters for the development of the 
molecular mechanicals methods.19 
The reasons behind this poor use of these methods can be founded in 
their impossibility to study complex molecular systems. This branch of 
computational chemistry is driven by the Schrödinger equation which is 
shown here in the simplified form: 3 
 
 
 
Where H is the Hamiltonian operator, Ψ a wave function and E the 
energy. 
In this equation electrons are considered as particles that have an 
undulatory behaviour which mathematical description is derived from the 
wave function Ψ. This is a probabilistic description of electrons behaviour. 
As such, it can describe the probability of electrons being in certain 
locations, but it cannot predict exactly where electrons are located.  
The solution of the equation allows to establish the position of 
electrons and nuclei and to define their energies. Unfortunately for 
molecular systems, these solutions can be only approximated. Depending on 
the level of this approximation, quantum mechanical methods can be 
divided into ab initio and semi-empirical methods. These latter, unlike the 
ab initio, substitute some terms with parameters derived from experimental 
measurements or derived from ab initio calculations upon smaller models. It 
is easy to guess that the ab initio methods are characterized by a higher 
accuracy compared to the semi-empirical methods.  
However this high accuracy requires a higher calculation cost, in fact 
with these methods only systems with tens of atoms can be studied, while 
the semi-empirical calculations allow to analyse even systems with hundreds 
of atoms.  
In both methods nuclei and electrons are considered separately in 
order to investigate their space distribution and their energies. 
Quantum mechanical methods are useful to calculate properties like: 
EψHψ                           
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 Energies of the molecular orbitals; 
 Total electronic energy; 
 Total repulsion energy of the nuclei; 
 Heat formation; 
 Atomic partial charges; 
 Electrostatic potential; 
 Dipole moment. 
1.2.2 Basic theory of molecular mechanical methods 
 
Molecular mechanical approaches are widespread in the medicinal 
chemistry field because of their ability to allow the molecular study of 
complex biological targets.  
Despite what happens in the quantum mechanical methods, in the 
molecular mechanics, nuclei and electrons are not treated separately but 
they are considered as spheres with radius and electronegativity previously 
determined through experimental observations or quantum mechanics 
calculation. Since electrons are not explicitly included, electronic processes 
cannot be modeled, therefore only the fundamental state can be studied.19 
The molecular mechanics energy expression consists of a simple 
algebraic equation for the energy of a compound. It does not use a wave 
function or total electron density. The constants in this equation are 
obtained either from spectroscopic data, other experimental techniques or 
ab initio calculations. The set of equations with their associated constants is 
called force field (FF). The fundamental assumption of the molecular 
mechanics methods is the applicability of parameters to different molecules. 
This means that, the energetic penalty associated with a defined molecular 
motion (e. g. the stretching of C-C single bond) will be the same from one 
molecule to the next. This assumption allows a very simple calculation that 
can be applied to large molecular systems. 
In molecular mechanic representations atoms are symbolized as balls 
and bonds as springs. 
Within a molecular system there are various components of the total 
energies, such as the phenomena of stretching, bending and torsion of 
bonds. An important role have also the non-bonding interactions. The term 
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non-bonding interactions includes the hydrogen bonds, the van der Waals 
and electrostatic interactions. 
Therefore the in a molecular mechanics simulation, the total energy of 
the system is the sum of all these components: 
 
Etot = Es + Eb + Et + Enb 
 
Where Es is the stretching energy, Eb is the bending energy, Et is the 
torsional energy and Enb is the non-bonding energy. 
Equations, that will be described later, and the necessary parameters 
for the calculation of the different energy components are included into 
specific database called FF. Therefore molecular mechanical methods are 
also referred as FF methods.  
Es (stretching energy) is the sum of the forces that are exerted through 
the bond axis of two atoms and it is described by the Hook equation, where 
the energy is directly proportional to the bond length compared to the 
equilibrium position and it is defined by this equation: 
 
 
bonds
bs rrkE
2
0 )(  
 
Where Kb represents the elastic constant of the spring that mimics the 
bond, r0 the equilibrium length and r the bond strength. According to this 
equation, the energy trend appears to be parabolic. 
Eb (binding energy) describes the deformation of the bond angle 
compared to his optimal value. Like the Es it is regulated by an equation 
based on the Hook equation: 
 
 
angles
b kE
2
0 )(   
 
Where kθ indicates the elastic constant of the spring, θ and θ0 
represent respectively, the reference position and the equilibrium one. The 
function that describes the bending energy has, like the stretching energy, a 
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parabolic trend that depends on the three atoms that define the bond 
angle.  
Both properties have a similar behaviour and for both of them there is 
a direct proportionality between the elastic constants, ks and kθ, and the 
energy variation as a function of the atoms shift. 
The torsional energy (Et), instead, has a completely different behaviour 
because it depends on the positioning of four atoms and how this can affect 
the energy of the system. Moreover it is usually used to obtain total energy 
values of the system close to reference data, experimental o quantum 
mechanical, relative to the rotation around a bond. This is the equation that 
describes this component: 
 
 
torsion
t nE )]cos(1[A   
 
Where A represents the coefficient obtained from the 
parametrization, n a symmetry factor, τ the dihedral angle and φ is the 
synchrony factor. Therefore, knowing that through an exes rotations of 360° 
are possible, the trend of the torsional energy is periodic.  
In order to gain a detailed description of the variation of the total 
energetic profile of a system, it is essential to take into consideration the 
energy contributions due to the interaction of non-bonded atoms, such as 
hydrogen bonds, van Der Waals and electrostatic interactions.  
Hydrogen bond takes place when particular conditions are fulfilled. 
First of all a donator, namely an electronegative atom to whom the 
hydrogen is bonded and an acceptor, represented by an electron-rich atom 
with, at least, one free electronic doublet must be present.  
The distance between the hydrogen and the acceptor must be 
between 2.3 and 3.0 Å and the angle between the donator, the hydrogen 
and the acceptor must be between 120° and 240°. Moreover the angle 
between the hydrogen, the acceptor and the atom to whom this is directly 
bonded should not be less than 90°.  
Another important non-bonded contribution is the van der Waals 
energy. This contribution is important when the distance between two 
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atoms is low, while loses its importance when this distance is higher. This 
energy is described by the Lennard-Jones equation: 
 
 
couple
ijijVdW rrE
6
ij
12
ij )/(R2)/ε[(R  
 
Where ε represents the maximum attraction, considered as energy 
minimum, between the atom couple i and j, R is the sum of their atomic ray 
and r their distance. In order to reduce the time calculations, the maximum 
value (cut-off) of the distance between atoms that can interact is set to 8 Å. 
The electrostatic energy, instead, is able to describe long distance 
interactions and this plays an important role in complex systems. This type 
of contribution represents the charge-charge interaction and the dipole-
dipole interactions.  
This is described by a modified Coulomb law:  
 
 
 
Where the electrostatic term depends from the distance. As seen 
above for the electrostatic energy, the cut-off value is set to 20 Å.  
As regards the charges of the atoms, they are calculated with 
quantum-mechanical ab initio or semi-empirical methods.  
Molecular mechanics FF enable the exploration of the ligand-protein 
structure for rational design and other tasks and to model conformational 
changes and non-covalent interactions quite accurately. A successful FF in 
drug design should work well both for biological molecules and the organic 
molecules that interact with them.20 The most used FF are: AMBER, 
CHARMM, OPLS and MMFF.  
The AMBER force field, was primarily developed for protein and 
nucleic acid systems, and it is now widely used for the study of biological 
targets. In this force field, not all hydrogens are included, but only polar 
hydrogens, while hydrogens combined with carbon are combined into 
united atoms. Charges are derived from quantum chemistry calculations. 
2
12
21
εr
qq
Eel  
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Force constants and idealized bond lengths and angles are taken from 
crystal structures and adapted to match normal mode frequencies for a 
number of peptide fragments. Finally torsion force constants are adjusted to 
match torsional barriers extracted from experiment of from quantum 
chemistry calculations. A general Amber force field (GAFF) was developed 
for organic molecules; it is designed to be compatible with existing Amber 
force field for protein and nucleic acids and has parameters for most organic 
and pharmaceutical molecules.21 
As with AMBER, the CHARMM FF (Chemistry at Harvard using 
Molecular mechanics) was originally developed in the early 1980s and 
initially used as an extended atom force field with no explicit hydrogens. By 
1985, this had been replaced by the CHARMM19 parameters, in which 
hydrogen atoms bonded to nitrogen and oxygen are explicitly represented, 
while hydrogens bonded to carbon or sulphur are treated as part of 
extended atoms.22  
Another largely applied FF is OPLS (Optimized Potentials for Liquid 
Simulations). It was developed by Jorgensen and co-workers to simulate 
liquid state properties, initially for water and for more than 40 organic 
liquids. This force field places a strong emphasis on deriving non-bonded 
interactions by comparison to liquid state thermodynamics. The initial 
applications to protein used a polar-hydrogen only representation, taking 
the atom types and the valence (bond, angle, dihedral) parameters from the 
Amber force field. The parameter choices were intended to be “functional 
group friendly”, so that they could be easily transferred to other molecules 
with similar chemical groups.23 
There are also other FF used for drug-like organic molecules like MMFF 
(Merck molecular force field).24 This FF was developed in the 1990's to 
incorporate quantum mechanical calculations of parameters for a variety of 
functional groups. MMFFs and OPLS-2005 force fields have a good 
description of electrostatic interactions. 
No force field has parameters for everything, therefore the reason to 
choose one instead another is considering the warnings about low-quality 
parameters issued in the log file. 
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1.2.2.1 Energy minimization 
 
When a molecule is built in a computational chemistry package, the 
initial geometry does not necessarily correspond to a stable conformer, 
therefore energy minimization is usually carried out to determine it.  
Energy minimization is a numerical procedure for finding a minimum 
on the potential energy surface starting from a higher energy initial 
structure. During the minimization, the geometry is changed in a stepwise 
manner where the energy of the molecule is reduced from step 2, to 3 to 4 
as shown in Figure 2. After a number of steps, a local or global minimum on 
the potential energy surface is reached. Most optimization methods 
determine the nearest stationary point, but a multidimensional function 
may contain many different stationary point of the same kind. The minimum 
with the lowest value is called global minimum, while all the other are local 
minima. 
 
 
Figure 2. The process of energy minimization changes the geometry of the molecule in a 
step-wise fashion until a minimum is reached. 
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Figure 3. Amino acid potential energy at different conformations, minima on a potential 
energy surface are indicated in blue color.
25
 
 
Most energy minimization methods proceed by determining the 
energy and the slope of a point. If the slope is positive the value of the 
coordinate is reduced until zero is reached, which means minimum is 
reached (Figure 2). There are numerous methods for varying the geometry 
to find the minimum. Many methods to find a minimum on the potential 
energy surface of a molecule use an iterative procedure to work in a step-
wise mode. 
 The Newton-Raphson method is the most computationally 
expansive per step of all the methods developed to perform 
energy minimization because it requires for each step the 
calculation of the matrix of the second derivative of the 
potential energy. This method it is able to retrieve in one step a 
stable conformation starting from distorted conformations but 
unluckily it becomes less efficient when it is applied to more 
complex systems.  
 The Steepest descendent method, rather than requiring the 
computation of numerous second derivatives, relies on an 
approximation. In fact, in this method, the second derivative is 
assumed to be a constant. This allows faster calculation than 
the previous. However, because of this approximation, it is not 
as efficient and therefore more steps are generally required to 
13 
 
find the minimum. It is named Steepest descendent because 
the direction in which the geometry is first minimized is 
opposite to the direction in which the gradient is largest at the 
initial point. Once a minimum in the first direction is reached, a 
second minimization is carried out starting from that point and 
moving in the steepest remaining direction. This process 
continues until a minimum has been reached in all directions 
within a sufficient tolerance. 
 In the Conjugate Gradient method, the first portion of the 
search takes place in the opposite direction of the largest 
gradient, just as in the Steepest Descendent method. However, 
to avoid some of the oscillating back and forth that often 
plagues the steepest descendent method as it moves toward 
the minimum, the conjugated gradient method mixes in a little 
of the previous direction in the next search. This allows the 
method to move rapidly to the minimum. The equations for 
the conjugate gradient method are more complex than those 
of the other two methods.  
 
1.2.2.2 Conformational analysis 
 
In medicinal chemistry, it is important to predict a compound 
behaviour into a biological structure. Indeed only some conformations 
allow a good interaction with the biological target. In fact, it can happens 
that the interacting ligands can assume conformations that are not the 
minimum energy conformation, but, in the overall complex are possible 
because they can lead to a minor total energy, if compared with the sum 
of the energy of the isolated molecules: ligand and receptor.  
Then, in order to comprehend the molecular mechanisms behind the 
activity of a drug it is of primary importance knowing the conformational 
properties of both the isolated molecule, and the molecule interacting 
with a biological target. The minimization can only lead to an optimization 
of the geometry and energy of a starting molecule, but does not allow the 
exploration of some possible conformational states. The conformational 
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space, is a space where are present some conditions of minimum energy 
(local minima) and only one condition of minimum absolute energy (global 
minima). 
Different approaches are available for the conformational space 
analysis.26 The most common strategies are systematic analysis, simulation 
methods (Monte Carlo and Molecular Dynamics) and genetic algorithm. 
The systematic approach can be used only for the analysis of small 
molecules. This method consists in the exploration of variation of total 
energy of the system during the rotation of bonds. It is not possible to 
analyse complex systems because the calculation is not efficient because 
in order to find the minimum energy it is necessary the exploration of all 
the other conformations. Alternatively, the molecule can be fragmented 
and treated with systematic algorithm, this variant is call model building.  
A more efficient method is the stochastic method, known as Monte 
Carlo method. It is a numeric method for the solution of mathematical 
problems by means of simulations based on variables, which value is 
attributed in a random way.  
In the computational chemistry application there are special values 
attributed to the torsions of the system. The process is repeated for 
several times (steps) and depending on this number, conformations are 
generated. Some of them can be not realistic and should be excluded from 
the simulation. The number of conformations is a function of the applied 
steps, the number of torsions and the complexity of the energy surface. 
The Monte Carlo method, does not guarantee to find the global minimum 
of the energy. The probabilities are directly proportional to the number of 
steps and inversely proportional to the complexity of the system. This 
method has some limitations because if the system is really complex, a big 
number of steps is necessary and as a consequence copious calculation 
resources are required.27  
Another methodology used for the exploration of the conformational 
space is the molecular dynamics. The main difference between MC and 
MD is in the way the conformational space is sampled. In MD methods, 
system configurations are given by integration of Newton’s laws for 
motion over a small time-step, and new atomic positions and velocities are 
determined.28 In some cases, a combination of these methods is used to 
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perform conformational search. Simulated annealing is an example. In this 
method, the system is initially set at a high temperature, which is gradually 
lowered until a configurational minimum is achieved. At each thermal step, 
equilibrium is reached by MC or MD implementation in the program.29 
Also Genetic Algorithm (GA) can be used to successfully find low-
energy conformations: a population of individuals (conformations) where 
individuals who are more “fit” (conformational energy) have a higher 
probability of surviving into subsequent generations. Therefore, in the 
course of a simulated evolution, the population produces conformations 
having increasingly lower energy.30 As result of conformational search one 
can save the global minimum or a certain number of conformations (often 
considering an energetic threshold) since only the more stable 
conformations are of interest for 3D investigation methods. 
 
1.3 STRUCTURE-BASED APPROACHES 
 
As previously said, computational chemistry can be divided into two 
big families, whether or not information about the target structure are 
available. In this dissertation I will discuss only about structure-based 
approaches, in order to match some theory with the applications in my 
work.  
Macromolecules coordinates for structure-based approaches are 
derived from crystallographic experiments, or NMR spectroscopy, but there 
is an increasing interest also in high quality homology structures.31-33 
Regarding our experiments, we retrieved our targets 3D structures from the 
Protein Data Bank,34 a free archive where 3D structures of proteins are 
available, with or without bounded ligands.  
Herein three of the main structures-based approached will be 
discussed: Molecular docking, Molecular dynamics and 3D-Pharmacophore 
methods. 
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1.3.1 Molecular docking 
 
Molecular docking is a key procedure in a structure-based drug design 
workflow. It is able to predict the ligand conformation and its orientation 
inside the target structure. The basis of molecular docking is the estimation 
of the free energy of binding of a ligand to a specific receptor site in a fixed 
environment. This tool is really useful but also has some scientific and 
mathematical issues. For example, it is currently much easier to calculate 
the energy/enthalpy of interaction than obtain the free energy because of 
the lack of efficient ways to obtain the entropic contributions. Secondly, the 
interactions of the ligand and the receptor with the solvent are not easy to 
estimate. 
Docking can be applied at different levels of a Drug Discovery pipeline. 
It can be applied in a virtual screening workflow, to retrieve inside of a large 
compound library the best compounds able to interact with a single protein. 
The combination of docking experiments considering other targets or anti-
targets (not desirable targets) could also help to find either compounds with 
multitarget properties, selective compounds, and compounds with less 
probability to have side effects.35-37 Docking approach can be used to study 
protein-protein interactions38 or protein-acid nucleic interactions.39, 40 
Furthermore it can give a rational explanation to biological activity and 
guide the lead optimization process,17 or help to identify possible binding 
site inside a protein (blind docking).41 
Another emerging application of docking method, often in 
combination with other approaches, is the study and prediction of 
compound metabolism.4, 42  
Docking can be carried out by placing manually the small molecule 
into the binding pocket or by placing it automatically. The latter is the 
easiest and most modern way. In our projects automated docking was 
always performed. 
Docking protocols consist of two steps: the first one is the search of 
the conformational space through a posing mechanism, where the ligand is 
placed inside the receptor in different orientations in order to identify the 
putative binding mode of the ligand. Several algorithms such as genetic 
algorithms, the Monte Carlo algorithm, evolutionary algorithms, simulated 
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annealing algorithms, empirical approaches, knowledge-based algorithms 
are used for the effective search of parameters space.43 While the second 
step involves the assignment of an energy based score, a ‘scoring function’ is 
applied to evaluate the proposed binding modes referred as poses. 
The purpose of the scoring function is to assess the binding affinity. 
However these scoring functions adopt various assumptions and 
simplifications. They can be listed as force-field based, empirical , 
knowledge-based and Consensus scoring functions.44 
Classical force-field-based scoring functions use classical molecular 
mechanics to calculate the energy as the sum of the non-bonded 
(electrostatic and van der Waals) interactions through a Coulombic 
formulation and a Lennard-Jones potential function respectively. These 
functions use parameters derived from experimental data or ab initio 
calculations. The limit of these scoring functions is the slow computational 
speed. Extensions of force-field-based scoring functions consider the 
hydrogen bonds, solvation and entropy contributions. 
In the empirical scoring functions, the binding energy is decomposed 
into several energy components, such as hydrogen bond interactions, ionic 
interactions, hydrophobic effect, desolvation effect and binding entropy. 
Empirical function terms are simple to evaluate and are based on the idea 
that binding energies can be approximated by a sum of individual 
uncorrelated terms experimentally determined. 
Finally knowledge-based scoring functions use statistical analysis of 
ligand-protein complexes crystal structures to obtain the interatomic 
contact frequencies and distances between the ligand and protein. They are 
based on the assumption that more favourable an interaction is, the greater 
the frequency of occurrence will be. The score is calculated by favouring 
preferred contacts and penalizing repulsive interactions between each atom 
in the ligand and the protein within a given cut off.45 
Sometimes scores can be used in parallel in order to find a consensus 
score between different scoring functions. Consensus scoring is a recent 
strategy that combines several different scores to assess the best docking 
conformations. A ligand could be accepted when its scores are well under a 
number of different scoring schemes. This allows to improve the reliability 
of docking scores and improving the probability of identifying accurately 
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docked poses.46 In the combined approach each scoring function 
compensates for the other’s weaknesses.47  
It is important, before docking a molecule into the target structure, to 
validate the procedure. This consists usually in finding a complex of a known 
inhibitor with target structure from the PDB, and to dock this known 
inhibitor into the target (Re-Docking). The comparison of docked pose and 
experimental (i.e. calculating the Root Mean Square Deviation (RMSD)) can 
help to understand if the protocol is reliable. When this procedure is carried 
out considering different compounds available in different pdb entries of 
the same target, the validation is made through Cross-docking. The second 
validation is preferable whenever is possible and the structure of the target 
allows it (i.e. target not too flexible).9, 48 
However it is always better to evaluate the goodness of the structure 
and check (if available) the electron density map of available complexes, 
since often ligands are not well defined.49-51 Otherwise in case of bad pdb 
structure docking validation is questionable. 
The docking programs that have been used for my PhD research work 
are Glide,52 Autodock.53  
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Table 1. Most popular Docking programs.54 
Program Algorithm Reference 
AutoDock Lamarckian Genetic Algorithm 53, 55 
DOCK Shape matching 56, 57 
FlexX Incremental construction 58 
FRED Shape matching (gaussian 
functions) 
59 
Glide Descriptor matching/MC 52 
GOLD GA 60 
FlapDock Flexible fragment-based 
docking 
61 
Surflex 
Dock 
Surface-based molecular 
similarity 
62 
 
Glide (Grid Based Ligand Docking with Energetics) uses a series of 
hierarchical filters to search for possible locations of the ligand inside the 
active site of a protein. The successive step produces a set of initial ligand 
conformations that are selected from an enumeration of the minima in the 
ligand torsion angle space (Figure 4). Given these conformations, initial 
screens are performed over the entire phase space available to the ligand to 
locate. Glide developed techniques of exhaustive systematic search, though 
approximations and truncations are required to achieve acceptable 
computational speed. Starting from the poses selected by the initial 
screening, the ligand is minimized in the field of the receptor using a 
standard molecular mechanics energy function: In this case, OPLS2005 force 
field. Finally, lowest poses obtained are subjected to a Monte Carlo 
procedure that examines nearby torsional minima.52 
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Figure 4. Glide docking “funnel”, showing the Glide docking hierarchy. 
 
A novel protocol has been implemented in Glide: The QMPLD 
(Quantum Mechanics Polarized Ligand Docking), that uses ab initio 
methodology to calculate ligand charges within the protein environment.63 
The QMPLD workﬂow consists of three steps: ﬁrst, the protein-ligand 
complex is generated with Glide. Poses passed through these initial screens 
enter a stage, which involves the evaluation and minimization of a grid 
approximation to the OPLS non-bonded ligand-receptor interaction energy. 
Final scoring is then carried out on the energy-minimized poses. Finally, the 
minimized poses are rescored using Schrödinger’s proprietary GlideScore 
scoring function. 
In the second step, a mixed quantum mechanical molecular mechanics 
method is used to compute the ligand charge distribution. For quantum 
mechanical molecular mechanics calculations, the QSITE program is used. 
The protein is deﬁned as the MM region, and the ligand is deﬁned as the 
QM region.64 Evaluation is performed with NDDO (Neglect of Diatomic 
Differential Overlap) semiempirical method in MOPAC (Molecular Orbital 
PACkage) using Coulson charges.65 In the third step, the ligand is submitted 
21 
 
to another Glide docking run where the ligand charges are substituted with 
the new charge sets calculated in the second step. This workflow was 
successfully applied for several targets.66 
Another widely used docking program is Autodock. To allow searching 
of the large conformational space available to a ligand around a protein, 
Autodock uses a grid-based method that allows a rapid evaluation of the 
binding energy of trial conformations. In this method, the target protein is 
embedded in a grid (Figure 5). Then, a probe atom is sequentially placed at 
each grid point, the interaction energy between the probe and the target is 
computed, and the value is stored in the grid. This grid of energies may then 
be used as a lookup table during the docking simulation. The primary 
method for conformational searching is a Lamarckian genetic algorithm:67 a 
population of trial conformations is created, and then in successive 
generations these individuals mutate, exchange conformational parameters, 
and compete in a manner analogous to biological evolution, ultimately 
selecting individuals with lowest binding energy. This allows individual 
conformations to search their local conformational space, finding local 
minima, and then pass this information to later generation. AutoDock uses a 
semi empirical free energy force field to predict free energy of small 
molecules to macromolecular target.53 
With AutoDock Vina a higher speed of calculation is achieved.55  
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Figure 5. Graphical interface of AutoDockTools with the macromolecule embedded in a 
grid. 
 
Many docking programs exist, however no one outperforms all others 
in all cases. Generally, programs are good on generating correct ligand poses 
(binding modes), but the scoring functions need improvement in order to 
improve the correlation between calculated and observed binding affinities. 
There are available different docking methodologies: rigid ligand and rigid 
receptor, flexible ligand and rigid receptor and flexible ligand and flexible 
receptor.68 
When the ligand and receptor are both treated as rigid bodies, the 
searches space is very limited, considering only three translational and three 
rotational degrees of freedom. In this case, ligand flexibility could be 
addressed by using a set of ligand conformations. 
Most common docking approaches treat the ligand as flexible while 
the receptor is kept rigid during docking because the computational cost is 
very high when the receptor is flexible. However flexibility can be taken into 
account modeling the conformational changes induced by ligand binding 
with the induced fit docking protocol. This procedure combines docking with 
sidechains rearrangements and minimization of the residues within the 
binding pocket.69  
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Other programs incorporate receptor flexibility in ligand docking by 
using ‘soft’ receptors, thus limiting penalties due to steric clashes, or 
allowing a selection of a few critical degrees of freedom in the binding site. 
Another strategy could be the selection (when is possible) of multiple and 
diverse receptor structures from the PDB to use for parallel docking 
experiments (Ensemble Docking).70  
As previously mentioned a limit of the docking procedure is that most 
of the times the receptor is fixed and there is a limited treatment of the 
solvation effect. Therefore often the docking simulations are not able yield 
the best correlation between predicted affinity and biological activity of a 
small molecule.71 To overcome this issue the docking simulations complexes 
are subjected to energy minimization and successive binding free energies 
calculations. The binding free energies are obtained by applying molecular 
mechanics and continuum or explicit solvation models using MM-PB/SA 
(Molecular mechanics/Poisson Boltzmann Surface Area) or molecular 
mechanics generalized Born/surface area (MM-GBSA) method.72 These 
assume that the free energy change in a receptor-ligand binding process can 
be computed by only considering the difference between the unbound state 
and the bound state. The calculated free energy of the binding of ligands to 
proteins can be calculated out considering implicit (continuum) or explicit 
solvent. For the latter one a brief MD simulation is carried out and a set of 
snapshot of the protein-ligand complex structure are saved and rescored 
with either the PB/SA or GB/SA scoring functions, and the average 
interaction score of the snapshots is taken as the free energy of binding for 
the ligand.73 When compared to docking scoring functions, the MM-GB/SA 
procedure is able to provide more accurate docking poses since the 
calculation of affinity is more precise.72  
In the MM-GB(PB)SA formulation, the binding free energy of a ligand 
(L) to a protein (P) to form the complex (PL) is calculated as the difference:74 

Gbind  G(PL)G(P)G(L) 
 
The free energy of each of the three molecular systems (ligand protein 
and complex) can be obtained considering different contributions: 
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G(X)  EMM(X)Gsolv(X)TS(X) 
 
In particular EMM is the total molecular mechanics energy of a generic 
molecular system X in the gas phase, and it is calculated considering 
molecular mechanics energy function (or force field); Gsolv is the solvation 
free energy, and S is the entropy of the system.  
EMM can be considered decomposed in bonded (internal), non-bonded 
electrostatic and van der Waals energies:  
 
EMM= Ebonded +(Eelec+ Evw) 
 
The solvation free energy term Gsolv is calculated considering  both 
polar and non-polar contributions. The polar contributions are accounted 
for the generalized Born, Poisson, or Poisson-Boltzmann model, and the 
non-polar are assumed proportional to the solvent-accessible surface area 
(SASA) 
 
Gsolv GPB(GB)  GSASA 
 
Finally, conformational entropy S, is further decomposed into three 
parts, the translational, the rotational and the vibrational entropies.  
 
Recent examples showed that MM-PBSA scoring can lead to an 
improvement compared to conventional scoring: re-ranking of the poses 
with MM-PBSA leads to a better separation between correct and incorrect 
poses.54 
This post-docking procedure can be applied to compare docking 
results derived from different programs consensus docking. It consists in 
docking the compounds with different programs, performing post-docking 
procedure (minimization of complexes) and G calculation using MM-GBSA 
method, then best scores can be averaged and will help to select most 
promising compounds. 
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1.3.2 Molecular dynamics 
 
Molecular dynamics was first developed in the late 197075 to 
overcome the computationally intensive quantum-mechanical calculations 
of the motions of big molecular systems. In fact this methodologies uses 
approximations based on the Newtonian physics to simulate atomic 
motions, thus reducing computational efforts.  
Molecular dynamics is based on thermodynamic and kinetic concepts. 
It investigates the motion of atoms and molecules as a function of energy 
and time. These two quantities, constitute a conformational change in the 
molecule. The move of the atoms takes place in response to a force 
application described by the second law of Newton: 
 
F = m x a 
 
Where F is the global force exercised upon the atom, m the mass of 
the atom and a its acceleration. The purpose of molecular dynamics is to 
calculate, for very short intervals of time, the force exercised upon the 
atoms and to use this data to derive the position of the atoms. 
During a simulation, a speed in the term of kinetic energy, is assigned 
to each atom of the system. At the beginning, the assumption is that the 
system has a speed equal to zero. 
To the system is applied energy in the term of heat, and this heat is 
transformed in kinetic energy and as a consequence the atoms get a motion. 
The force acting upon the atom can be obtained by analyzing the variations 
of the total energy during short movements. For a generic atom, the 
equation can be expressed in this way: 
 
 
Where Fi  is the force acting on the atom, dE the variation of energy 
and dri the shift of the atom.  
The data relative to the energy can be calculated with quantum 
mechanical methods, but normally are calculated with molecular mechanics 
i
i
dr
dE
F  
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methods. Knowing the force and the mass relative to the atom, is possible 
to calculate their position for short intervals of time, in the femtosecond 
order. 
The algorithm of the simulation proceeds first at the calculation of the 
acceleration, obtained from the product of the force and the mass of the 
atom i: 
 
ai  = Fi x mi 
 
Then, the velocity is obtained as the product between the acceleration 
and the time variation: 
 
vi  = ai x dt 
 
Finally, the atom position is obtained from the product between the 
velocity and the time variation: 
 
dr = vi x dt 
 
For each iteration, where the starting point coincides with the arrival 
of the previous, a positioning is obtained and the set of the positioning 
constitutes the trajectory assumed by the atom during the simulation.  
The heat and the duration of the simulation are really important in 
determining the efficacy of the simulation. In fact, the energy barriers that 
separate the different states of minimum energy can be exceeded with the 
applied heat. It is then, necessary to apply a sufficient temperature but not 
so high because that can cause a damage in the integrity of bonds. As the 
heat, also the duration of the simulation is important, because the 
exploration of the system, in particular the number of conformational and 
configurational conversions, depends on the duration of the simulation. 
When there are not variations of the energetic values or there is a periodic 
trend, it can be affirmed that the time of conformational search is sufficient.  
The Energy (E), as a function of the positioning of all the atoms of the 
system, is obtained from two components (Figure6): 
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Figure 6. Calculation of the total Energy as sum of bonded and non-bonded term.
76
  
 
Ebonded takes into account all the interactions between two covalent 
bonded atom that depend on the length, angles and rotations of the bonds. 
Enon-bonded instead, takes into account all the interactions between atoms 
non-covalently bonded such as Van der Waals and Coulomb interactions.77  
In order to reproduce the actual motion of molecules within a 
biological system, the energy terms described above are parametrized to fit 
quantum-mechanical calculations and experimental data. This parameters 
are again the Force fields that are able to describe the contributions of the 
various atomic forces that govern molecular dynamics. Several force fields 
are commonly used including AMBER, CHARMM and GROMOS. In the micro-
canonical, or NVE ensemble, the system is isolated from changes in moles 
(N), volume (V) and energy (E). It corresponds to an adiabatic process with 
no heat exchange. 
In the canonical ensemble, amount of substance (N), volume (V) and 
temperature (T) are conserved. A variety of thermostat algorithms are 
available to add and remove energy from the boundaries of a MD 
simulation. 
In the isothermal–isobaric ensemble, amount of substance (N), 
pressure (P) and temperature (T) are conserved (NPT). In addition to a 
thermostat, a barostat is needed. It corresponds most closely to laboratory 
conditions with a flask open to ambient temperature and pressure. 
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Figure 7. Process of molecular dynamic simulation. 
 
Molecular dynamics approach can be applied to every type of system 
but it has some limitations. In fact this method is affected by the complexity 
of the model and by the long duration of the simulations. Another limitation 
to consider is that the force fields used are also approximations of quantum-
mechanical calculations.  
Nevertheless molecular dynamics is unique in capturing dynamic 
events in biological systems. Many pharmaceutical phenomena of scientific 
interest occur on time scale that are computationally demanding but MD it 
is able to elucidate these important biological processes. Often MD has been 
used coupled with other tools, such as docking. 76  
 
1.3.3 Pharmacophore modeling 
 
The concept of pharmacophore is based on the assumption that the 
interaction between a ligand and a biological structure is possible when 
some features are complementary. These feature are hydrogen-bond 
1 
•Selection of  the initial atomic model. The starting target conformation is provided 
by a X-ray structure, NMR data, homology model or previous modeling studies. 
•Solvation: explicit or implicit solvent. 
2 
•Calculation of  molecular forces acting on each atom: a force field is applied. 
3 
•The structure is subjected to energetic minimization. 
• Initial  velocities are assigned.  
•The system is heat up to 300° K.  
4 
•Equilibration dynamic simulation. 
•Production dynamics. Each atom moves according to FF and  considering a 
sampling algorithm that generates the thermodynamical ensemble matching the 
experimental conditions for the system, e.g. N,V,T , N,P,T, ... 
5 
•Analysis of trajectory. 
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donors and acceptors, positively and negatively charged or polarizable, 
hydrophobic regions or metal-ion interactions. 
In particular: 
1. The pharmacophore describes the steric and electronic 
characteristics determining the interaction within the biological 
target. 
2. The pharmacophore does not represent a real molecule but an 
abstract concept that takes into account common features 
between the compound and its target structure.78 
This can be summarized by Wermuth definition of pharmacophore: “A 
pharmacophore is the ensemble of steric and electronic features that is 
necessary to ensure the optimal supra-molecular interactions with a specific 
biological target and to trigger (or block) its biological response”.79 
The most frequent use of pharmacophore approach is in virtual 
screening, where it is possible to filter large libraries of compounds based on 
the features selected. Several programs are used, such as Catalyst, Phase, 
LigandScout, Galahad, Flap and the pharmacophore module on Moe.80, 81  
The use of pharmacophore models presents some advantageous 
characteristics: the models are universal because they represent chemical 
functions valid for all the molecules. Furthermore, they are computationally 
efficient: in fact because of their simplicity they can be used for large scale 
virtual screening.  
A pharmacophore model can be built starting from ligand information 
or from target structure information. In the first case this can be achieved 
through the exploration of conformational space. 
When information about the target structure are available, it is 
possible to build a pharmacophore model through GRID interaction fields 
that convert regions of high interaction energy into pharmacophore point 
locations and constrains.82 
In alternative, starting from ligand-structure complex it is possible to 
convert interaction patterns into pharmacophore point locations and 
constraints.83 
Structure-based methods in pharmacophore-modeling aim to be 
complementary to docking procedure, but are less demanding in terms of 
computational effort and much more efficient. 
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During this project we applied this method by means of LigandScout 
software.83  
The first step, during the building of a pharmacophore model is the 
ligand perception and interpretation. This is performed through the 
perception and correction of plausible molecular topology including ring 
perception and through the interpretation and subsequent assignment of 
hybridization states and bonds types from geometrical information. 
After these preliminary steps, the pharmacophore model can be built 
with the introduction of general chemical features definitions such as charge 
transfers, lipophilic groups and H-bond interactions that are able to describe 
the binding mode in a general way. The resulting model is a universal model 
that can lack of selectivity. Therefore, in the common pharmacophore 
creation and validation process, general feature descriptions are changed in 
order to improve the selectivity. The pharmacophore tool created in 
LigandScout is useful to create a pharmacophore model that is still universal 
but yet selective enough to reflect the specific ligand-receptor interactions. 
The features that describe a pharmacophore are: Hydrogen-bond 
interactions, hydrophobic areas, aromatic  interactions and charge 
transfer interactions (Figure 8).  
 
 
Figure 8. Pharmacophoric features representation by LigandScout. 
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After the recognition of the feature in the ligand, the successive step, 
is the search for corresponding features in the protein, the addition of the 
interaction features to the model only if a corresponding feature pair is 
found in the complex and the addition of excluded volume spheres for 
opposite hydrophobic features.83 
Ligand-based pharmacophores are built considering the information 
relative to active and inactive compounds. Programs able to do it align the 
molecules in an automated way completely unbiased (Figure 9). This 
method allows medicinal chemists to see the key features in their small 
molecules data-set. After the building of the pharmacophore (ligand or 
structure based) the user can easily adapt his model, by omitting features 
for example considering only common feature (shared-pharmacophore) or 
by merging selective pharmacophore models. This interesting method can 
be used alone or in combination with other computational methods in 
complex workflows in successive or parallel way. 
 
Figure 9. Example of wrong and correct alignment of pharmacophore points.
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2 CHAPTER  
2.1 INTRODUCTION TO REVERSE TRANSCRIPTASE OF HIV-1 
 
According to UNAIDS, at the end of 2015, an estimated 37 million 
people were living with HIV worldwide. However the scenario is more 
optimistic than at the beginning of 2000s. In fact the number of people 
dying of AIDS-related causes fell to 1.2 million in 2014. Furthermore new HIV 
infections have fallen by 35% since 2000 (by 58% among children) and AIDS-
related deaths have decreased by 42% since the peak in 2004. As of June 
2015, 15.8 million people were accessing treatment. These results were 
considered impossible 15 years ago. The main priority for the next 15 years 
is ending the AIDS epidemic by 2030.1 
After the identification of HIV-1 as the causative agent of AIDS, more 
than 30 antiretroviral drugs have been approved for the clinical treatment of 
HIV infected patients targeting different steps of the HIV replication cycle.2  
However, although a number of drugs reached the market, there are 
still problems associated with drug toxicity and resistance, therefore the 
development of new HIV drugs is an ongoing process. 
In fact HIV virus is able to evolve sufficiently rapidly that, if the therapy 
is not well designed, resistance will develop in treated patients. A shortcut 
to overcome this problem is to use a combination of drugs to completely 
block the viral replication. Thus different drugs can be associated in the so 
called Highly Active Antiretroviral Therapy (HAART). This type of therapy 
changed the prognosis of HIV infected patients from high probability of 
mortality to a chronic infection. 
Usually these drugs are able to inhibit the virus replication cycle at 
different levels: by inhibiting the Reverse transcriptase, the Protease and the 
Integrase.3 
To overcome toxicity and resistance of existing drugs, new drugs 
characterized by a new mechanism of action are strongly needed. 
The replication cycle of HIV consists of different steps that are 
targeted by these drugs, leading to an inhibition of virus replication.2 Among 
these, one of the most attractive and explored target is the Reverse 
Transcriptase (RT) which is responsible for the retrotranscription. This 
crucial step of the HIV converts the viral single-stranded RNA genome into 
43 
 
integration-competent double stranded DNA through the formation of a 
RNA/DNA hybrid intermediate. This process requires both viral and cellular 
elements, among which the most important is the virus-coded RT protein.  
RT consists of two subunits of different lengths, p66 and p51 which are 
combined in a stable asymmetric heterodimer.2 The p66 domain possess the 
catalytic activity, while the p51 it is important in keeping the p66 in the 
correct folding. 
 
Figure 1. Structure of Reverse Transcriptase complexed with polypurine tract RNA:DNA 
(1hys pdb)
4
. In light blue the p66 subunit and in blue the p51 subunit. 
 
The subunit p66 comprises different domains: the polymerase domain, 
the connection domain and the RNAse H domain. The polymerase domain 
has the RNA-polymerase DNA-dependent (RDDP) function, which is able to 
synthesize double stranded DNA starting from viral RNA. While the RNAse H 
domain has a RNase-Hydrolase function, which task is to cleave the RNA 
from the double strand RNA-DNA. This conversion takes place in the 
cytoplasm of the infected cell and after DNA synthesis has been completed, 
the resulting linear double-stranded viral DNA is translocated to the nucleus 
where the viral DNA is inserted into the host genome by the Integrase.  
To exploit its function, the polymerase domain holds the nucleic acid 
in a cleft formed by its subdomains as a hand. Commonly the four 
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subdomains are identified as fingers, palm, connection and thumb (Figure 
2). P51 folds into the same four subdomains like the polymerase domain, 
however the positions of the subdomains relative to each other are different 
and the absence of the RNAse H domain make this subunit different form 
the p66 subunit. 
The connection and thumb subdomains of p51 form the floor of the 
binding cleft and throughout this the nucleic acid is directed towards RNAse 
H domain.3  
 
 
Figure 2. Structure of Reverse Transcriptase with indication of domains and subdomains. 
 
Currently two different classes of Reverse Transcriptase, targeting the 
RDDP function, have been approved for the treatment of HIV-1: 
nucleoside/nucleotide (NRTIs/NtRTIs) and non-nucleoside RT inhibitors 
(NNRTIs). NRTIs are analogs of the natural substrate (dNTP) and inhibit 
RDDP function by a competitive mechanism at the active site. 
To act on such a mechanism, these inhibitors must necessarily lack a 
free OH group in 3ʹposition. Zidovudine (AZT, 3’-azidothymidine) was 
identified as the first NRTI acting as pro-drug. It requires successive 
phosphorylation steps and operates through its triphosphate metabolite.5 
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The active form of the drug is used as a false substrate during reverse 
transcription of viral RNA. 
Currently eight NRTIs are clinically available, structurally resembling 
either pyrimidine or purine analogues. 
In the pyrimidine nucleoside analogues both thymidine and cytosine 
analogues are included. The most representative thymidine analogues are 
3’-azido-2’,3’-dideoxythymidine (zidovudine, AZT) and 2’,3’-didehydro-2’,3’-
dideoxythymidine (stavudine, d4T), while cytosine analogues are (-)-2’,3’-
dideoxy-3’-thiacytidine (lamivudine, 3TC), (-)-2’,3’-dideoxy-5-fluoro-3’-
thiacytidine (emtricitabine, FTC) and [(-)-2’-deoxy-3’-oxa-4’-thiacytidine) 
(dOTC), 2’,3’-dideoxycytidine (zalcitabine, ddC) which, however, is no longer 
recommended due to its peripheral neuropathy side effect,. Purine 
nucleoside analogues include (1S-4R)-4-[2-amino-6(cyclopropylamino)-9H-
purin-9yl]-2-cyclopentane-I-methanol (abacavir, ABC) and 2’,3’-
dideoxyinosine (didanosine, ddI) as guanosine and adenine analogues, 
respectively (Figure 3).  
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Figure 3. NRTIs clinically available 
 
Unfortunately drug resistant viral mutants can gain a competitive 
advantage over wild type virus under selective drug pressure, almost 
becoming the dominant species. 
Generally two different mechanisms lead to HIV-1 resistance to NRTIs. 
The first consists of NRTI discrimination leading to a reduction of 
incorporation rate, the second consists of NRTI excision that unblocks NRTI-
terminated primers. Typically discrimination occurs due to steric hindrance 
leading to a selective alteration of the NRTI binding and/or incorporation 
rate.6  
Regarding NRTI excision, it is mostly increased through mutations, 
located around the dNTP binding pocket and also in termed of thymidine 
analogues mutations (TAMs). 
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NRTI resistance could also be conferred by mutations in the 
connection and RNase H domains.7-11 
The NtRTIs, such as adefovir [9-(2-phosphonylmethoxyethyl) adenine 
(PMEA)] and tenofovir [(R)-9-(2- phosphonylmethoxypropyl) adenine 
(PMPA)] are acyclic phosphonate analogues of adenine, therefore, only need 
two phosphorylation steps to be converted into the active drug. 
As the NRTIs, they act as obligatory chain terminators.12  
Along with exploration of the NRTI binding pocket to obtain analogous 
molecules with improved drug-like properties and effective against many 
NRTI drug-resistant RT variants,13 recently, two families of compounds have 
been reported as new class of “nucleotide-competing RT inhibitors” 
(NcRTIs). The first is represented by indolopyridones (INDOPY) derivatives. 
Although structurally different from classical NRTI it seems that this series 
can occupy the active site of the enzyme (or a site in close proximity) and 
competes with natural dNTP substrates.14, 15 The second class includes 4-
dimethylamino-6-vinylpyrimidine derivatives (DAVP) whose binding site is 
close to the polymerase active site.16  
In contrast with the NRTI class, NNRTIs are a family of compounds 
characterized by a high variety of structures (Figure 4). 
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Figure 4. NNRTIs in the market and under clinical evaluation and relative examples of 
crystal structures pdb codes 
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Unlike the other class of compounds, they do not need intracellular 
activation. Many different classes of NNRTIs could be distinguished and five 
drugs, acting as NNRTIs, have been approved for HIV-1 treatment so far. 
It should be observed that, while in the case of first generation 
NNRTIs, like delavirdine and nevirapine, single mutations (Y181C, K103N and 
Y188C) could lead to drug resistance, in the case of the more bulky second 
generation NNRTIs, like efavirenz and dapivirine, more than one mutation is 
generally required to induce drug resistance.  
More than 30 NNRTIs have been reported even though resistance and 
toxicity are some of the most important disadvantages of this class of 
compounds.17, 18 More recently, molecules with a higher flexibility, although 
less favoured by a thermodynamic point of view, have been proposed as 
NNRTIs.19, 20 Molecules like etravirine and rilpivirine are successful examples 
of this new approach as well as dapivirine actually under clinical 
evaluation.21 
NNRTIs cause a distortion of the protein structure that inhibits the 
polymerase activity. They bind in a hydrophobic pocket (non-nucleoside 
inhibitors binding pocket, ) located in the palm domain of the p66 subunit of 
the heterodimeric RT, approximately 10 Å from the catalytic site of the 
enzyme. This pocket contains the side chains of aromatic and hydrophobic 
amino acid residues Y181, Y188, F227, W229, Y318, P95, L100, V106, V108, 
V179, L234, and P236 from the p66 subunit. It is flexible and its 
conformation depends on the size, shape, and binding mode of the different 
NNRTIs. It can accommodate a space of about 620-720 Å, which is 
approximately more than twice the volume occupied by most of the present 
NNRTIs.2 This explains the large variety of chemical scaffolds of this class of 
inhibitors whose shapes inspired authors to create imaginative names to 
describe them (e. g “butterfly”,22 “horseshoe”,19 and “dragon”23). 
 
All these classes of compounds act by inhibiting the DNA-polymerase 
of the Reverse Transcriptase, while in therapy no drugs targeting the RT 
associated RNAse H activity are available, even though some inhibitors have 
recently designed and studied.24 
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This target is crucial for the virus infectivity and it was reported that 
the block of this function through a single-point mutation could lead to a 
total loss of the virus infectivity.25 
Most of the RNAse inhibitors identified so far act by chelating the 
divalent metal ion Mg2+ that is coordinated in the active site by the catalytic 
residues D443, E478, D498 and D549. The issue with these compounds is 
that they showed toxicity due to lack of specificity. 
Recently new compounds with novel allosteric mechanisms of action 
have been discovered.  
Vinylogous urea derivatives, such as NSC727447, were proposed to 
bind to an allosteric pocket outside the RNAse H catalytic site. NSC727447 
does not inhibit the RT-associated RDDP activity and does not show metal-
chelating properties.26 
Furthermore it was reported that some hydrazones,27 
naphthyridinone28 and anthraquinone29 derivatives are able to inhibit the 
HIV-1 RNAse H function through the binding to an allosteric pocket located 
between the polymerase catalytic region and the NNRTIs binding pocket, 
which is 50 Å away from the RNAse H catalytic site.  
It seems that these compounds act through an innovative mechanism 
of action: by deviating the trajectory of the nucleic acid and preventing the 
bound with the RNAse H site (Figure 5).27, 28 
 
 
 
Figure 5. Putative mechanism of action of allosteric RNAse H inhibitors: a) the usual 
trajectory of nucleic allow the substrate to reach RNAse H catalytic pocket, b) compounds 
able to bind close to the primer grip, between polymerase catalytic site and NNRTI binding 
pocket, could be able to redirect the trajectory of the substrate (c) so that the RNA strand is 
not close enough to the RNAse H active site for cleavage to occur. 
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Taking into account this innovative mechanism, a combined shape, 2D 
fingerprint and pharmacophore-based Virtual screening (VS) has been 
conducted by our group using as a query the first crystallized compound in 
this new pocket, which has a hydrazone moiety (dihydroxy benzoyl naphthyl 
hydrazone (DHBNH)).30 
The overall VS protocol consisted of two consecutive screening 
processes. In the first, Rapid Overlay of Chemical Structures (ROCS)31, 32 was 
used to perform in silico shape-based similarity screening on the NCI 
compounds database (Figure 6).33, 34  
 
 
 
Figure 6. Workflow followed for the first selection after shape based VS 
 
As a result, 34 hit molecules were selected and assayed on both RT-
associated functions. Out of the 34 tested compounds, 10 inhibited the HIV-
1 RNAse H function with different potencies in the micromolar range, and 
were tested also for their effect on the RT-associated RDDP function. 
Subsequently, the four most active compounds toward RNAse H (IC50 values 
≤ 21 µM) were selected as queries for a second VS which combined three 
different ligand based methods: shape-based, 2D-fingerprint and 3D-
pharmacophore. 
The best-scored compounds with each method were selected and the 
results were analyzed and compared (Figure 7). Compounds were prioritized 
according to a consensus model: compounds predicted to be active by all 
three methods were selected, than the ones predicted by two methods, 
finally, we have also chosen some compounds retrieved by only one method 
based on proved strong points and complementarities of each approach in 
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finding active compounds.35 In particular, 27 compounds were selected by 
all three methods and, out of these, 11 were chosen based on their chemical 
structure and availability from NCI. A total of 287 compounds were selected 
by two methods (Figure 7), and based on their structures, 10 were obtained 
by NCI. Finally, 14 compounds were selected even though they were picked 
up by only one method based on their molecular diversity, according to 
visual inspection of clusters. 
Therefore, other 35 compounds were selected at the end of the 
second VS procedure and tested on the HIV-1 RT-associated  activities. 
 
Figure 7. Overall screening process applied for the second VS selection 
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Results showed that 8 out of the 11 compounds selected by all three 
methods inhibited both RT-associated functions. 
Among the 10 compounds selected by two VS methods, only one was 
active on both RT functions, compound 46 (numbered as in the paper)30 
(Figure 8) IC50 values were 2 µM for RNAse H activity and 1.4 for RDDP 
activity, which, noteworthy, was the most potent inhibitor among all the 
tested compounds.  
 
Figure 8. Compound 46: Most active compound found by second VS round. 
 
Considering the good results of this VS, new series of compounds were 
synthesized. 
The purpose was to confirm the hydrazonoindolin-2-one scaffold as 
promising for the development of dual inhibitors of RT both associated 
functions (scaffold validation), and to modify the scaffold in order to 
maintain the pharmacophoric features through bioisosteric substitutions. 
Furthermore we wanted understand the dual inhibition mechanism because 
this information could help further scaffold optimization. 
  
53 
 
2.2 DIARYLPROPENONES AS DUAL INHIBITORS OF HIV-1 RT 
 
On the basis of compound 46 (Figure 8) as a hit compound, 
bioisosteric substitutions have been applied for the design of novel 
compounds as potential dual inhibitors (Figure 9). Hence, a new series of 
1,3-diarylpropenones have been designed and synthesized.36 
 
 
 
Figure 9. Bioisosteric substitutions starting from the compound 46 
 
The main structural features are an aromatic portion (A ring) a 
hydrazine spacer (B) and a thiazole ring (C) bearing a second aromatic ring 
(D) at the 4 position.  
The indolinone ring was replaced by the 1-methoxynaphtalene moiety, 
the hydrazine spacer was substituted by a vinyl group, and the thiazole was 
replaced by the bioisosteric carbonyl feature.37 The entire series had the E 
configuration, according to the coupling constants for the proton on the C=C 
bond (see Material and Methods). 
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Scheme 1. Synthetic pathway to compounds EMAC 2000-2005. 
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Figure 10. Diarylpropenones derivatives EMAC2000-2005. 
 
The ability of the synthesized 1,3-diarylpropenone derivatives of 
inhibiting both RT-associated functions was measured by biochemical assays 
using RDS164338 and efavirenz as positive controls (Table 1). Most potent 
inhibitors were EMAC2005 and EMAC2002. Preliminary structure–activity 
relationships analysis showed that although the RDDP activity was not 
affected by variation of the substituent at the 4-position of the D ring, the 
RNase activity was strongly influenced. In particular, bulky and 
strongly/weakly activating groups (e.g., methoxy and phenyl) were 
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preferred with respect to deactivating substituents (e.g., halogens). The 
introduction of a nitro group at the 3-position of the D ring was slightly more 
tolerated, probably because of its minor conjugative electron-withdrawing 
effect. 
 
Table 1.HIV-1 RT-associated activity inhibition by 1,3-dyarilpropenones 
derivatives. 
 
Compound R 
a
IC50 (µM) RNase H 
b
IC50 (µM) RDDP 
EMAC2000 -4 Br 47 ± 1 6 ± 1 
EMAC2001 -4 F 23 ± 3 5 ± 1 
EMAC2002 -4 OCH3 9 ± 2 6 ± 2 
EMAC2003 -4 Cl 76 ± 11 5 ± 1 
EMAC2004 -3 NO2 31 ± 4 5 ± 1 
EMAC2005 -4 C6H5 6 ± 2 4 ± 1 
RDS1643 13 ± 4 > 100 
Efavirenz > 10 0.003 ± 0.002 
a
Compound concentration required to reduce the HIV-1 RT associated RNase H 
activity by 50%. 
b
Compound concentration required to reduce the HIV-1 RT associated RDDP 
activity by 50%. 
 
The activity of the compounds was tested on the replication ability of 
HIV-1 in a single round of infection in Jurkat cells. All compounds were not 
able to inhibit HIV-1 replication within these experimental conditions. Thus, 
we performed in vitro permeability assays to asses if a reduced or absent 
transmembrane permeation could explain these results. As results we 
obtained that the trans-membrane permeation profile of EMAC2005 was 
characterized by a prolonged lag-time followed by a gradual permeation.  
However since our main goal was to gain more insight into the 
mechanism of dual inhibition we have carried out biochemical and 
computational experiments. 
 
 
O
O R
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2.2.1 Biochemical studies 
 
Since several classes of HIV-1 RNase H generally act by chelating the 
magnesium(II) (MgII) ions within the active site, the ability of EMAC2000-
EMAC2005 to chelate Mg ions was tested measuring the absorbance 
spectrum in absence and presence of MgCl2 observing no differences (Figure 
11). Thus we can exclude they will act with this mechanism. 
 
 
Figure 11. Spectrum of absorbance of the EMAC series in absence (blue) and 
presence of MgCl2 (red) EMAC2000-EMAC2005. 
 
Subsequently, we further investigated if EMAC2005 and the diketo 
acid derivative RDS1643, an RNase H catalytic site inhibitor,39 were able to 
simultaneously bind to RT. Such an evaluation was carried out by means of 
the Yonetani revised Yonetani-Theorell model that allows to determine 
when two inhibitors of a certain enzyme compete for the same binding site 
or act on two non-overlapping binding sites. In this revised model, the plot 
of the reverse reaction velocity (1/v) observed in the presence of different 
concentrations of the first inhibitor, in the absence or in the 
contemporaneous presence of the second inhibitor, leads to a series of lines 
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which are parallel if the two inhibitors compete for the same binding site, 
whereas they intersect if the inhibitors bind to different enzyme sites.40  
Therefore, the HIV-1 RT RNase H activity was measured in the 
presence of increasing concentrations of both EMAC2005 and RDS1643 and 
analysed with the Yonetani-Theorell plot (Figure 12). Results showed that 
the slope of the plots of 1/v versus EMAC2005 concentration decreased at 
increasing RDS1643 concentrations, confirming that the two compounds are 
not kinetically mutually exclusive. Overall, these data support the hypothesis 
that EMAC2005 does not bind to the HIV-1 RNase H catalytic site.  
 
 
Figure 12. Yonetani-Theorell plots of the interaction between EMAC2005 and RDS1643 on 
the HIV-1 RNase H activity. HIV-1 RT was incubated in the presence of different 
concentrations of EMAC2005 and in the absence (●) or in the presence of 2.5 µM (▼), 5 
µM (Δ) or 10 µM (■) RDS1643. 
 
Next, we evaluated the effects of EMAC2005 on Y181C and K103N 
mutated RTs, involved in NNRTIs resistance and located close to RNAse 
allosteric pocket and NNIBP (Table 2). Results showed that when tested on 
the K103N RT, EMAC 2005 was 10 fold less potent on the RNase H. On the 
contrary, no influence of K103N mutation on the RDDP activity was 
observed. In the case of Y181C mutation a more dramatic effect, with 
respect to K103N, was observed: the activity towards RNase H activity was 
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almost suppressed, while the activity towards the RT-associated RDDP was 
only slightly affected. This behaviour might be explained either by the 
binding of EMAC2005 to a single site close to Y181, the hydrazones pocket 
or the NNIBP, or by the interaction of the compound with an 
interdependent pocket, whose conformation is affected by the Y181C 
mutation.  
 
Table 2. Inhibition of drug resistant HIV-1 mutated RT associated functions 
by EMAC2005. 
 IC50 (µM) 
 Y181C RT K103N RT 
a
RNase H 
b
RDDP RNase H RDDP 
EMAC2005 > 100  8 ± 3 59 ± 8 3 ± 1 
Efavirenz -- 0.40 ± 0.03 -- 0.68 ± 0.05 
a
Compound concentration required to reduce the HIV-1 RT associated RNase H activity by 
50%. 
b
Compound concentration required to reduce the HIV-1 RT associated RDDP activity by 
50%. 
 
2.2.2 Molecular modeling 
 
We applied a computational strategy based on molecular docking and 
molecular dynamics to gain insight into the mechanism of action of this new 
class of 1,3-diarylpropenones. The studies were focused on the most active 
compound EMAC2005. According to the available literature information, 
dual inhibitory activity could be achieved either by inhibitor binding into two 
different sites27 or by its binding into a single site.27, 28, 30, 41 Therefore, we 
investigated both possibilities. 
NNRTIs are characterized by a high diversity of chemical structures. 
They are able to bind allosterically in the hydrophobic NNIBP and lock the 
enzyme into an inactive form. Due to the flexibility of the target and to the 
different shapes of known inhibitors (Figure 13a), the major conformational 
changes in the NNIBP were taken into account to perform a clusterization of 
the available RT-NNRTIs complexes. In particular, the orientation of Y181, 
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Y188, Y183 and primer grip 12-13 hairpin were considered. A 
representative of each different cluster was picked42 and the 3D structure of 
HIV RT was retrieved from the Protein Data Bank43 (Figure 13b). Hence we 
carried out ensemble docking experiments using seven different crystal 
structures.44 It was observed that NNIBP, when Y181 and Y188 adopt a 
parallel position, communicates with RNAse H allosteric pocket.27, 28 The 
overall shape of this pocket is characterized by a L shape (Figure 14) and 
offers many possibility of binding to small molecules. Two crystals, 1tv6 and 
3lp2, are characterized by this conformation and we have chosen to use 
both since they have co-crystalized compounds in different position: the 
first in the NNIBP and the second in the allosteric RNAse H pocket. 
 
Figure 13. a) Chemical and crystal structures pdb codes of co-crystallized NNRTIs selected 
for the ensemble docking procedure b) Stereoview of the primer grip region and residues 
Y181, Y183 and Y188 of the selected pdb complexes. 
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Figure 14. L shape binding pocket in the polymerase domain of HIV 1. 
 
The docking protocol employed for this project has involved the QM 
(quantum mechanical) polarized Docking45 (see 1.3.1 for more details). The 
protocol has been validated through the redocking of the co-crystallized 
ligands (data not shown). In order to consider the whole enzyme, two grids 
box were considered: one centered in W229 (NNIBP) and one in Q500 
(RNAse domain). The obtained EMAC2005-RT complexes were subjected to 
a post-docking procedure based on energy minimization and successive 
binding free energy calculation. The binding free energies (ΔG(Bind)) were 
obtained applying molecular mechanics and continuum solvation models 
using the molecular mechanics generalized Born/surface area (MM-GBSA) 
method.46 As reported in Table 2, by comparing the ΔG-MMGBSA values, we 
can assert that the most probable binding mode in the NNIBP is obtained by 
docking the compound into the RT conformation model reported in 1tv6 
pdb47 (Table 3 and Figure 15).  
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Table 3. Ensemble docking scores and binding free energies of 
[EMAC2005·RT] complexes 
Docking site and box 
centre 
pdb 
ID 
Co-crystallised 
ligand 
G-
score 
G(MMGBSA) 
Best 
Poses 
NNIBP (centre on W229) 
 
1vrt
48
 Nevirapine -4.18 -30.6  
2zd1
49
 Rilpivirine -8.43 -30.7  
1ep4
50
 Capravirine - 8.26 -38.8  
3qo9
23
 TSAO-T -9.21 -35.0  
1rti
48
 HEPT -11.04 -34.1  
1tv6
47
 CP-94,707 -9.53 -48.0 A 
RNase H allosteric pocket 
(centre on W229) 
3lp2
28
 MK3 -6.19 -38.4 
B 
RNase H domain (centre 
on Q500) 
1tv6  -7.50 -38.6 C 
- EN37
51
 -5.58 -24.6  
 
 
Figure 15 Comparison between a), b) HIV-1 RT co-crystallized ligand CP-94,707 binding 
mode reported in 1tv6 crystal structure and c) d) optimized EMAC2005 best docking pose in 
the same site (Pose A). Yellow spheres show hydrophobic contacts, red arrows: HB 
acceptor, violet circle: aromatic interaction. Binding pocket surface is drawn as solid and 
coloured according to lipophilicity: pale yellow indicates lipophilic residues and light blue 
hydrophilic residues. 
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To assess which binding pocket was responsible for the RNase H 
inhibitory activity, we considered the reported binding pockets: one is 
located in the catalytic domain and the other is an allosteric site described 
by Himmel as hydrazone site28 and already considered in our previous 
studies.30, 41 Furthermore, recently, new RNase H inhibitors have been 
described that bind in a cleft below the RNAse H catalytic site, close to 
Q500.51 Probably, these compounds induce an RNase H domain 
conformation which prevent his function. Hence we have to consider also 
this second allosteric pocket for RNAse H inhibitory activity. 
Biochemical experiment directed to verify the ability of this series of 
compounds to coordinate the metal ions indicated that the chelation 
mechanism can be excluded (Figure 11) so we excluded that our compounds 
bind to the catalytic site. However, we could not ignore the possibility of a 
binding site close to the RNase H catalytic residues as reported by Felts.51 
Hence, in order to include the whole RNase H domain for investigation, in 
our docking experiments the binding site was defined by a regular box of 
97336 Å3, centred on residue Q500. The RT conformations adopted for 
docking experiments were: 1tv6 X-ray and the crystallographic model 
reported by Felts et al. but not available in the PDB yet.51 In Table 3 are 
reported the G of the best poses in the first and second allosteric pocket of 
RNAse H. While, in the following figures the best poses are depicted (Figure 
16 and 17). 
 
63 
 
 
Figure 16. a) b) MK3 binding mode reported into 3lp2 crystal structure and c) d) optimized 
EMAC2005 best docking pose (Pose B). Interactions and rendering according to previous Figure 
15 
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Figure17. a), b) EN37 binding mode reported by Felts et al. and c), d) optimized EMAC2005 
best docking pose into 1tv6 crystal structure (Pose C). Interactions and rendering according 
to previous Figure 15 
 
It can be noticed that the predicted G of the two complexes which 
consider the two allosteric RNAse H sites are comparable (Pose B and C). 
Hence a better evaluation of the energy of the complexes may help to 
discriminate between the two binding modes. Therefore we decided to 
perform molecular dynamic simulations considering the best scored poses 
after post-docking protocol: EMAC2005 bound in the NNIBP (A); EMAC2005 
bound in the two RNAse H allosteric pockets described by Himmel (B) and by 
Felts (C). Spatially we have that the most favourable poses occupy the L 
pocket of the palm subdomain (Figure 14 and Figure 18): pose A and B 
(pocket 1); while the pose C is located below the RNAse H catalytic site 
(pocket 2) close to the interface between p66 and p51. 
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Figure 18. Binding sites individuated after docking experiments on the wt HIV-1RT 
structure. 
 
We run the molecular dynamic (MD) simulations up to 6 ns using 
Desmond Molecular Dynamics System ver. 2.4,52 keeping the whole enzyme 
free to move into explicit solvent water environment. 
Docking and MD simulation were carried out also on the mutated 
enzyme complexes containing single point mutation Y181C and K103N. (see 
Table 2 for IC50). We applied the same computational protocol described for 
wt RT: docking, energy minimization, ΔG-MMGBSA calculation and MD 
simulations. 
The interaction energy values of [EMAC2005-RT] complexes are 
reported in Table 4, while their variations, sampled at regular intervals 
during the simulations over the entire MD trajectory, are illustrated in 
Figures 19-21. In particular the analysis of the Root-Mean-Square Deviation 
(RMSD) for wt and mutated enzymes during the MD, shows that the system 
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is structurally stable during the simulation. The effect of mutation was 
analysed for both poses A and B which are close to mutated residues and 
may be affected strongly by the mutations. 
 
 
Table 4 EMAC2005 docking GScoreXP, G_MMGBSA and Total Interaction 
Energy (IE) variation after MD simulation. Terms expressed in kcal/mol per 
complex. 
Pocket Docking site 
and box 
centre 
Enzyme 
G-
score 
G_MMGBSA Total-IE 
Pocket 1 NNIBP 
(centre on 
W229) 
 
wt -9.53 -48.00 -52.01 
Y181C -9.90 -44.30 -48.03 
K103N -9.59 -45.50 -50.78 
RNase H 
allosteric 
pocket 
(centre on 
W229) 
wt -6.19 -38.40 -40.37 
Y181C -5.40 -37.10 -38.79 
K103N -6.06 -36.40 -39.06 
Pocket 2 RNase H 
domain 
(centre on 
Q500) 
wt -7.50 -38.60 -42.40 
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Figure 19. MD Analysis of EMAC2005 bound in NNIBP of RT (pocket 1). Plots depict RMSD, 
calculated considering the RT heavy atoms, and total interaction energy variation a) b) 
[EMAC2005-wt-RT], c) d) [EMAC2005-Y181C-RT], e) f) [EMAC2005-K103N RT] complexes, 
values were sampled at regular intervals during the simulation over the entire MD 
trajectory. 
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Figure 20. MD Analysis of EMAC2005 bound in RNAse H allosteric site of RT (pocket1). Plots 
depict RMSD, calculated considering the RT heavy atoms, and total interaction energy 
variation a) b) [EMAC2005-wt-RT], c) d) [EMAC2005-Y181C-RT], e) f) [EMAC2005-K103N RT] 
complexes, values were sampled at regular intervals during the simulation over the entire 
MD trajectory. 
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Figure 21. MD Analysis of EMAC2005 bound in RNAse H allosteric site of RT (pocket2). Plots 
depict RMSD, calculated considering the RT heavy atoms, and total interaction energy 
variation a) b) [EMAC2005·RT] values were sampled at regular intervals during the 
simulation over the entire MD trajectory. 
 
Considering the MD results reported in Table 4 the binding in the 
allosteric pocket of RNAse H close to NNIBP cannot explain the loss of 
EMAC2005 inhibitory activity toward RNase H. In fact when Y181 is mutated 
in cysteine and K103 is mutated in asparagine, we could not observe any 
significant variation of the energy of the complex. While a significant loss of 
activity was observed experimentally. Consequently we can conclude that 
the binding of EMAC2005 in this pocket is not the most favourite. 
Hence we can suppose that the polymerase inhibition is due to the 
binding of EMAC2005 into the NNIBP (Figure 19). This hypothesis is also 
supported by the similar behaviour of EMAC2005 and CP-94,707 when 
tested in the mutated enzymes. In fact, also CP-94,707 acts in the same 
manner and both compounds interestingly retain RDDP activity.47 
Differently, both biochemical and modelling studies seem to confirm that 
the binding into an allosteric site close to RNase H catalytic residues is 
responsible for RNase H inhibitory activity (Pocket2, Figure 17). Both binding 
modes are retained during MD (Figure 22).  
To further corroborate this hypothesis we evaluated the activity of 
EMAC2005 on A502F RT, a residue close to the RNase H allosteric pocket.53 
As we expected, this mutation does not affect the activity towards the RDDP 
activity. On the contrary, the activity of compound EMAC2005 on the RNase 
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H function is fivefold lower, with respect to the wt RT, indicating that 
residue A502 is close to the EMAC 2005 allosteric binding pocket. 
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Figure 22. Superimposed structures of 6 ns MD simulations frames of [EMAC2005-RT] 
complex: initial, final along with intermediate structures snapshots. a) Overall structure of 
the HIV-1 RT heterodimer with the NNIBP occupied; b) Close-up of the binding cavity; d) 
Overall structure of the HIV-1 RT heterodimer with the Site Q500 occupied; e) close-up of 
the binding cavity. c) f) Residues involved in the complex stabilization sorted by number of 
contacts between ligand and receptor. Interacting and catalytic residues are represented in 
sticks. 
 
Still it remained to be understood why the EMAC2005 inhibitory 
activity towards RNase H is modified in the mutated enzymes. In this regard 
there is a considerable evidence that the binding of NNRTIs as well as the 
mutations in the allosteric pocket in the RT DNA polymerase domain affect 
the activity of the spatially remote RNase H domain. The mechanisms 
involved in this long-range alteration of RNase H activity are not entirely 
understood, but likely involve changes in the positioning of the RNA/DNA 
duplex nucleic acid.54, 55 Therefore we examined long-range effects of both 
mutations by checking the fluctuations of the residues (RMSF) during MDs 
of the wt and mutated enzymes (Figure 23a). We noticed that while wt-RT 
does not show relevant fluctuations in the site Q500 involved in the binding 
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of EMAC2005, some residues in the mutated RTs showed a huge fluctuation 
which may disturb the binding of EMAC2005 (Figure 23b).  
 
Figure 23. RMSF of subunit p66 during MD a) Entire wt and mutated RT. b) Close up of site 
Q500 residues. 
 
Finally we have evaluated the stability of the ternary complex enzyme-
EMAC2005 bound in the two allosteric sites (Figure 24). 
Plots for potential energy and RMSD ﬂuctuations, related to the 
complex, are depicted in Figure 24b,c. The analysis shows that the structure 
reached equilibrium and the low ﬂuctuations support the stability of the 
intermolecular interactions. 
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Figure 24. Superimposed structures of 6 ns MD simulations frames of with EMAC2005-RT 
ternary complex: initial, ﬁnal along with intermediate structures snapshots. a) Overall 
structure of the HIV-1 RT heterodimer; b) potential energy of the complex during the MD 
simulation; c) RMSD ﬂuctuations during trajectory. 
 
2.2.3 Conclusions 
 
In conclusion, with the aim to obtain dual inhibitors of the RT 
associated functions, a small series of 1,3-diarylpropenones was designed, 
synthesised and tested. The activity of some compounds and the profile 
towards mutated enzymes were remarkable and suggestive for further 
modifications and studies. Moreover, investigating the possible mechanism 
of action of the most promising compound EMAC2005, we found that its 
inhibitory activity could be addressed to the binding at two different enzyme 
clefts: the NNIBP and an allosteric site close to the RNase H catalytic DEDD 
motif (close to Q500). We highlighted that the compound is accommodated 
in a pocket with Y181 and Y188 in close conformation (PDB code 1tv6) 
better than in open conformation as most of NNRTIs. This facilitates the 
enzyme recognition when common mutations, such as Y181C and K103N, 
occur and therefore RDDP activity is not impaired. The EMAC2005 binding 
mode confirms the known key role of W229 and Y188 in the stabilization of 
the complex. Other interacting residues, L100, P225, L234, Y318, V106, 
P236, highlighted the importance of hydrophobic contacts. Instead, most 
likely, the loss and decrease of RNase H inhibitory potency is due to the 
improbable entrance of EMAC2005 into the second pocket (close to residue 
Q500) when Y181C and K103N mutations occur. This hypothesis is further 
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confirmed by single point mutation experiment on A502 residue. It was 
found that while the inhibition potency of compound EMAC2005 towards 
the RDDP function of HIV-1 RT A502F is almost not modified (IC50 increased 
by 1.5 folds), the inhibition of the RNase function is remarkably affected 
with a 5 fold reduction of the potency. Thus compound EMAC2005 behaves, 
most likely, as a dual site dual function inhibitor. 
 
2.3 INDOLINONES DERIVATIVES AS DUAL INHIBITORS OF 
HIV-1 RT 
 
The second class of compounds studied was derived directly from the 
most active compound 46 identified with the VS (Figure 8).30 Indeed it is 
important after VS to validate the scaffold in order to see if also derivatives 
retain the same activity. Therefore a small library of indolinones compounds 
with different substituents on the aromatic portion has been synthesised 
(Scheme1, Figure 25).56 
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Scheme 2. Synthesis of (Z)-3-(2-(4-arylthiazol-2-yl)hydrazono)indolin-2-one derivatives 
EMAC 2072-2083. Reagents and solvents: (i) 2-propanol, AcOH; (ii) 2-propanol, room 
temperature (r.t). 
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Figure 25. Structures of compounds with the indolinone scaffold. 
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2.3.1 Biochemical studies 
 
The activity of these compounds was tested toward both RT activities 
(Table 5) and the most active compound was the derivative bearing the 
Cyano group on the para position aromatic portion ((Z)-4-(2-(2-(2-
oxoindolin-3-ylidene)hydrazinyl)thiazol-4-yl)benzonitrile (EMAC2077) with 
an IC50 against RNAse H of 1.3 ± 0.3 μM and against RDDP of 9.8± 1.4 μM. 
 
Table 5. EMAC2072-2083 derivatives effects on the HIV-1 RT-associated functions. 
H
N
O
N
H
N
S
N
Ar  
Compound Ar 
RNase H  
a
IC50 (µM) 
DP  
b
IC50 (µM) 
c
SpI 
EMAC2072 
Cl  
10.6 ± 0.8 20.0 ± 6.0 0.53 
EMAC2073 
F  
6.4 ± 1.5 23.9 ± 5.7 0.26 
EMAC2074 
Br  
14.9 ± 2.8 81.0 ± 15 0.18 
EMAC2075 
NO2  
2.9 ± 0.8 34.0 ± 5 0.08 
EMAC2076 
 
2.5 ± 0.4 22.0 ± 1 0.11 
EMAC2077 
CN 
1.3 ± 0.3  9.8± 1.4 0.13 
EMAC2078 
F F  
2.6 ± 0.5 18.5 ± 2.5 0.14 
EMAC2079 
NO2
 
2.8 ± 0.8 13.0 ± 5 0.21 
EMAC2080 
CH3  
9.0 ± 0.9 45.0 ± 2.5 0.20 
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EMAC2081 
 OCH3  
4.7 ± 0.5 26.0 ± 5 0.18 
EMAC2082 
 
100 71.6 ± 16 1.3 
EMAC2083 
Cl Cl  
3.9 ± 1.5 19.5 ± 2.5 0.20 
Efavirenz  ND
d
 0.023 ± 0.006  
RDS1643  10.1 ± 2.2 ND  
a
Compound concentration required to reduce the HIV-1 RT-associated RNase H activity by 
50%; 
b
Compound concentration required to reduce the HIV-1 RT-associated RNA-dependent 
DNA polymerase activity by 50%; 
c
Specificity Index: ratio between compound concentration required to reduce the HIV-1 
RT-associated RNase H activity by 50% and compound concentration required to reduce 
the HIV-1 RT-associated DP activity by 50% (IC50 RNase H/IC50 DP); 
d
ND, not done. 
 
As we did for diarylpropenones, we wanted to verify if this dual 
activity was due to the binding to a single site or to two different sites.  
Knowing that most of the RNAse H inhibitors act by chelating the Mg2+ 
in the active site38 we firstly analyzed chelating potential of EMAC2077 by 
measuring its UV spectra in the absence and in the presence of magnesium. 
Results showed that EMAC2077 maximum of absorbance did not shift in the 
presence of 6 mM MgCl2, excluding the involvement of chelation in the 
mechanism of action (Figure 26). Therefore, the RNAse H activity of 
EMAC2077 is not due to its binding in the catalytic site, as we previously 
have seen with EMAC2005.  
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Figure 26. Effect of MgCl2 on the spectrum of absorbance of RHIs. Chelation of Mg
2+
 by 
RDS1643 (panel A), Compound 46 (panel B) and EMAC2077 (panel C). UV–vis spectrum was 
measured with compound alone (unbroken line) or in the presence of 6 mM MgCl2 (dotted 
line). 
 
RNase H inhibitors such as vynologous ureas (VUs) are known to 
destabilize the RT heterodimer by binding to an allosteric pocket in the 
RNase H domain at the interface between p66 and p51 subunits. Docking 
studies suggested that the residue C280 in helix αI of p51 subunit was 
particularly important for ligands binding.57 Therefore, we examined 
alterations in HIV-1 RT thermal stability by differential scanning 
fluorimetry58 in the presence of increasing concentrations of EMAC2077 as 
well as known inhibitors such as the NNRTI efavirenz (EFV), the RNase H 
active-site inhibitor hydroxytropolone β-thujaplicinol (BTP) and the allosteric 
RNase H inhibitor 2-(3,4-dihydroxyphenyl)-5,6-dimethylthieno[2,3-
d]pyrimidin-4(3H)-one (VU).59 In agreement with previous studies,57,60 the 
RNase H active-site inhibitor BTP, that has been shown to stabilize the RT 
against thermal denaturation,60 causing a Tm increase of > 2.0 °C in the 
presence of Mg2+, while the interface inhibitor VU, that has been shown to 
destabilize the HIV-1 RT57 decreasing the Tm by 5.5 °C (Figure 27). In 
contrast, EMAC2077 did not affect significantly RT thermal stability, showing 
behavior similar to EFV and suggesting that EMAC2077 may have an 
allosteric binding mode different from VU but possibly similar to the one 
shown by EFV (Figure 27).  
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Figure 27. Effect of RT inhibitors on the thermal stability of p66/p51 HIV-1 RT. a) The 
melting temperature of HIV-1 RT was measured by differential scanning fluorimetry in 
presence of increasing concentrations of different inhibitors: (▼) EFV,(○) BTP, (Δ) VU 
and(●) EMAC2077. b) Maximum HIV-1 RT thermal shift (ΔTm) observedin the presence of 
50µM concentration of compounds. ΔTm values are the average of triplicate analysis, 
standard deviations are indicated as bars. 
 
To investigate the EMAC2077 mode of action with respect to EFV, we 
performed a Yonetani-Theorell analysis40 on the combined effects of 
EMAC2077 and EFV on RDDP function. Such an analysis reveals whether 
simultaneous binding (or inhibition) of two compounds is possible or not. 
Results (Figure 28) showed that EMAC2077 and EFV inhibition are not 
mutually exclusive. However, it is worth to note that the calculated 
interaction constant α had the value of 1.2, suggesting a negative 
interference between the two compounds (i.e. EFV binding has a negative 
influence on EMAC2077 binding, and vice versa) suggesting a close binding 
site. 
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Figure 28. Yonetani–Theorell plot of the combination of EMAC2077 and EFV on the HIV-1 
RT RNA-dependent DNA polymerase activity. HIV-1 RT was incubated in the presence of 
EMAC2077 alone (●) or in presence different concentrations of EFV: 4nM (Δ),  8 nM(■), 
16nM (). 
 
Furthermore, we tested EMAC2077 against several mutants conferring 
resistance to NNRTIs such as K103N, Y181C and Y188L, and against the HIV-1 
group O RT which shows natural resistance to NNRTIs61 due to the presence 
of the amino acid substitutions A98G, V179E and Y181C (Figure 29). 
The DNA polymerase activity of HIV-1 group O RT as well as the one of 
wild-type and mutant of HIV-1 group M subtype B RTs were all susceptible 
to EMAC2077 in RDDP assays (IC50 values in the range 5.4-20.1 µM, for a 
maximum 2 fold increases in the IC50 values relative to the wild type HIV-1 
group M subtype B RT). In contrast, HIV-1 group O RT and mutants K103N 
and Y188L showed decreased susceptibility to EFV (of 7.7- to 9.2-fold 
increases in the IC50 values) (Table 6). These observations suggest different 
modes of action for EMAC2077 and EFV. 
Interestingly, the HIV-1 group O RT was also inhibited by BTP and 
EMAC2077 in RNase H activity assays, although IC50 values were 5 to 6.5 
times higher than those obtained with the prototypic wild-type HIV-1 group 
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M subtype B RT. These effects could be addressed to differences that affect 
the overall structure of the RNase H domain in both enzymes. Previous 
studies showed that HIV-2 RT was about 3.7 times less susceptible to BTP 
than the HIV-1 enzyme,62 while the crystal structure of BTP bound to HIV-1 
group M subtype B RT revealed that major interactions involved in inhibitor 
binding affected RNase H active site residues.28 However, RNase H active 
site residues are conserved in all HIV-1 and HIV-2 clades. Outside the active 
site, the most significant differences between group M subtype B and group 
O HIV-1 RTs are found around positions 460-471, 482-492, and 502-511 
(Figure 29). 
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Figure 29. Clustal O alignment
63
 of the Group M and Group O sequences. In yellow are 
marked mutated residues located in EMAC2077 putative binding sites. An * (asterisk) 
indicates positions which have a single, fully conserved residue. A : (colon) indicates 
conservation between groups of strongly similar properties; A . (period) indicates 
conservation between groups of weakly similar properties 
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Table 6. Susceptibility to EMAC2077 of wt and NNRTI-resistant HIV-1 RTs 
measured in RNase H and RDDP activity assays. 
 EMAC2077 BTP EFV 
RT RNase H RDDP RNase H RDDP 
 IC50 
(µM)
a
 
IC50 
(µM)
b
 
IC50 (µM)
a
 IC50 
(nM)
b
 
wt 1.3 ± 0.3 9.8 ± 
1.4 
0.19 ± 
0.03 
23 ± 2.7
 
K103N 2.3 ± 0.1 13.6 ± 
1.0 
0.22 ± 
0.08 
176 ± 
25 
Y181C 2.1 ± 0.6 5.4 ± 
0.3 
0.23 ± 
0.05 
49.7 ± 
9.1 
Y188L 1.6 ± 0.5 16.5 ± 
3.7 
0.08 ± 
0.05 
198 ± 
60 
Group O 8.5 ± 2.6 20.1 ± 
7.4 
0.91 ± 
0.01 
212 ± 
46 
a
Compound concentration required to reduce the HIV-1 RT-associated RNase H 
activity by 50%; 
b
Compound concentration required to reduce the HIV-1 RT-associated RNA-
dependent DNA polymerase activity by 50. 
 
2.3.2 Computational studies 
 
To achieve further insights into the EMAC2077 binding mode, we 
performed blind docking studies on the wt HIV-1 group M subtype B RT 
heterodimer and EMAC2077, by using the QM-polarized ligand docking 
protocol (QMPLD).64  
As we did for the diarylpropenones, we carried out ensemble docking 
experiments, due to the flexibility of the target and different shapes of 
known inhibitors (Figure 13).36 The major conformational changes in the 
NNRTIs binding pocket were taken into account to cluster the available RT 
complexes. In particular, the orientation of amino acid residues Y181, Y188, 
Y183 and primer grip β12-β13 hairpin were considered.42 A representative 
of each different cluster was picked and the three-dimensional structure of 
HIV RT was retrieved from the Protein Data Bank. The obtained 
[EMAC2077•RT] complexes were then subjected to a post-docking 
procedure, based on energy minimization and successive binding free 
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energies calculation. The binding free energies (ΔG(Bind)) were obtained by 
applying molecular mechanics and continuum solvation models using the 
molecular mechanics generalized Born/surface area (MM-GBSA) method.46 
Blind docking calculations indicated the presence of two energetically 
favored binding pockets sites (Figure 18) for indolinone derivative 
EMAC2077 (Table 7). 
 
 
Table 7. Ensemble docking results: binding free energies of [RMNC•RT] 
complexes. The most likely binding poses are indicated in bold. 
RT Xray  
(pdb code) 
Pocket G_MMGBSA 
(Kcal*mol) 
Best Poses 
1ep4 1 -41.23  
1ep4 2 -36.22  
3lp2 1 -44.85 A 
3lp2 2 -42.58  
1rti 1 -33.26  
1rti 2 -40.49  
1tv6 1 -51 B 
1tv6 2 -48.74 C 
1vrt 1 -35.9  
1vrt 2 -32.44  
2zd1 1 -41.96  
2zd1 2 -32.06  
3q09 1 -39.25  
3q09 2 -38.48  
 
Pocket 1 is located close to the DNA polymerase catalytic center and is 
contiguous to the NNRTIs binding pocket, having an “L shape” (Figure 14). 
According to the first orientation (pose A) (Figure 30a, b), the compound is 
accommodated in a pocket located between polymerase catalytic domain 
and NNRTIs binding pocket. This pocket was recently described as allosteric 
pocket of HIV-1 RNase H function.27-29 However the most stable pose (Figure 
30 c, d) involves amino acids L100, K103, V106, V108, Y183, Y188, L234, 
W229 and Y318 (Pose B). According to both putative binding modes (A and 
B), different residues of the hairpin constituted by the β12 and β13 sheet47 
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are involved with EMAC2077 binding and for this reason were subjected to 
alanine scanning mutagenesis (see below paragraph 2.3.3). 
 
 
Figure 30. Putative binding modes of EMAC2077 and critical residues individuated for 
EMAC2077 binding in the pocket 1: a) binding mode A; b) 2D depiction of EMAC2077 and 
its respective interactions with RT residues. c) binding mode B pale yellow sphere indicates 
hydrophobic interactions with lipophilic residues. Red arrow indicates an hydrogen bond 
(HB) acceptor interaction, green HB donor, while the violet sphere represents the aromatic 
 stacking interaction. 
 
The second putative binding pocket (pocket 2) is located in the RNase 
H domain, between the RNase H active site and the primer grip region, close 
to the p66/p51 interface. This pocket is the same pocket found during 
docking calculations of compound EMAC2005 and discussed before.36 
Docking experiments suggest that, in this site, EMAC2077 could be partially 
sandwiched between different secondary structural units, such as namely 
β21 strand and the αH helix in p51, and the αB helix in p66 (residues 500-
508) (Figure 31).  
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Figure 31. a) Putative binding mode of EMAC2077 and interacting residues in pocket 2.b) 
2D depiction of EMAC2077 and its respective interactions with RT residues. 
 
Overall, such in silico analysis support alternative modes of action for 
EMAC2077, since the compound could bind (i) preferentially only to one of 
the two pockets and have both short- and long-range effects; or (ii) to both 
sites and act by short-range effects on the two functions. According to the 
first mode of action, EMAC2077 would inhibit RDDP and RNase H activities 
through binding into the sole pocket 1, by having a short-range inhibitory 
effect on RDDP activity and a long-range inhibitory effect on RNase H 
activity binding in the RNase H allosteric site (pose A, Figure 30 a,b). Hence, 
it would act differently from classical NNRTIs such as nevirapine and EFV 
that were shown to destabilize the 3’-end of the DNA primer in the DNA 
polymerase active site and promote RT-mediated polymerase-independent 
RNase H cleavages.65  
Alternatively, according to the first mode of action, EMAC2077 could 
bind to the sole pocket 2 and it would have a short-range inhibitory effect 
on RNase H activity and a long-range effect on the RDDP activity.  
Differently, according to the second mode of action EMAC2077 would 
bind to both individual pockets and its activity would be due to short-range 
inhibition effects, so that its binding to each site would be responsible for 
the inhibition of one function. 
To dissect this diverse scenario of possibilities we performed site-
directed mutagenesis studies. 
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2.3.3 Single point site directed mutagenesis in pocket 1 
 
Considering the size of pocket 1, its surface was explored in detail by 
site-directed mutagenesis. Since the hairpin comprising strands β12 and β13 
was identified as potentially involved in EMAC2077 binding alanine-scanning 
mutagenesis was performed for amino acids 224-231. Mutants V108A and 
V106A were also obtained since Val108 and Val106 were identified as 
potentially important for inhibitors binding (pose A and pose B, Figure 30). 
The susceptibility of mutant RTs to EMAC2077 was also tested in RNase H 
and RDDP activity assays, using BTP and EFV as positive controls (Table 8). 
Interestingly, the E224A RT showed a 6-fold reduced susceptibility to 
EMAC2077 in RNase H assays, while mutant enzymes such as V108A and 
V106A showed IC50 values 4 and 10 times higher, respectively, in comparison 
with the wt RT. In contrast, we did not observed major differences in the 
IC50 values obtained with other mutant RTs (Table 8). When the RDDP 
function of mutant RTs was assayed, a similar pattern emerged, even 
though the extent of the reduction in the IC50 values was lower (1.4, 3.3 and 
2.5  for E224A, V106A and V108A RTs, respectively). 
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Table 8. Effects of selected amino acid substitutions in pocket 1 of HIV-1 RT 
in the susceptibility to EMAC2077 in RNase H and RDDP activity assays 
 EMAC2077 BTP EFV 
RT RNase H RDDP RNase H RDDP 
 IC50 (µM)
a
 IC50 (µM)
b
 IC50 (µM)
a
 IC50 (nM)
b
 
V106A 5.3 ± 0.6 (4.1)
c
 25.1 ± 2.3 
(2.5) 
0.16 ± 0.03 (0.8) 35.4 ± 2.2 (1.5) 
V108A 13.1 ± 2.5 (10) 33.0 ± 5.2 
(3.4) 
0.18 ± 0.04 (0.9) 21.3 ± 3.6 (0.9) 
Y188A 3.3 ± 1.5 (2.5) 20.9 ± 4.0 
(2.1) 
0.19 ± 0.08 (1.0) 28.3 ± 7.4 (1.2) 
E224A 7.9 ± 1.1 (6.1) 13.8 ± 4.2 
(1.4) 
0.15 ± 0.03 (0.8) 24.9 ± 0.7 (1.1) 
P225A 1.7 ± 0.2 (1.3) 3.1 ± 0.3 (0.3) 0.13± 0.06 (0.7) 19.5 ± 2.9 (0.8) 
P226A 1.9 ± 0.1 (1.5) 18.9± 0.7 (1.9) 0.29 ± 0.08 (1.5) 18.9 ± 2.4 (0.9) 
F227A 0.7 ± 0.1 (0.5) 15.2 ± 0.9 
(1.5) 
0.22 ± 0.04 (1.2) 61.5 ± 1.4 (2.7) 
L228A 1.5 ± 0.1 (1.1) 13.1 ±1.9 (1.3) 0.10 ± 0.06 (0.5) 21.8 ± 3.8 (1.0) 
W229A 1.9 ± 0.5 (1.5) 15.4 ± 2.8 
(1.6) 
0.15 ± 0.08 (0.8) 22.9 ± 5.2 (1.1) 
M230A 0.5 ± 0.1 (0.4) 15.0 ± 3.5 
(1.5) 
0.14 ± 0.04 (0.7) 29.1 ± 2.2 (1.3) 
G231A 1.7 ± 0.4 (1.3) 10.8 ± 2.4 
(1.1) 
0.25 ± 0.03 (1.3) 67.7 ±3.5 (2.9) 
a
Concentration required to inhibit HIV-1 RT-associated RNase H activity by 50% obtained by 
three independent experiments  (reported as average ± standard deviation). 
b
Concentration required to inhibit HIV-1 RT-associated RDDP activity by 50% obtained by 
three independent experiments  (reported as average ± standard deviation). 
c
Fold of increase with respect to wt RT. 
 
Hence, the results of the assays with the mutant RTs did not provide 
incontrovertible evidence of EMAC2077 binding in one position. Instead the 
results could not exclude the EMAC2077 binding to pocket 1 in two different 
ways. In fact, given the amplitude of the pocket and the high RT flexibility, 
the very limited IC50 reduction towards RDDP function observed could be 
determined by a different orientation of EMAC2077 while accommodating 
in pocket 1, as a response to the introduced amino acid changes. It is worth 
noting that the kinetic analysis of the interaction between EMAC2077 and 
EFV, showed a negative interference between the two compounds, even if 
they are not kinetically mutually exclusive, supporting the possibility that 
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EMAC2077 could accommodate in the large pocket 1 even in the presence 
of EFV. Hence these mutagenesis experiments seem to confirm the binding 
modes predicted by docking studies. 
 
2.3.4 Single point site directed mutagenesis in pocket 2 
 
Pocket 2, located in the RNase H domain, was already predicted51 and 
investigated in the contest of hydrazone derivatives binding studies 53,66 and 
diarylpropenones described above (paragraph 2.2).36 According to our 
modeling results, when bound to this site, EMAC2077 might nudge the 
RNase H domain to a position in which the active site might no longer be 
able to catalyze hydrolysis cleavage of the RNA strand in the of RNA:DNA 
duplex. To investigate possible EMAC2077 binding into this pocket, we 
mutated residues Ala502 to Phe and Ala508 to Val in an attempt to reduce 
the space available for EMAC2077 accommodation. Hence, we tested 
EMAC2077 effects on both RNase H and RDDP functions of mutant RTs, 
using BTP and EFV as positive controls (Table 9). The RNase H function of 
mutant RTs A502F and A508V showed 4- to 10-fold reduced susceptibility to 
EMAC2077 in RNase H assays. 
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Table 9. Effects of selected amino acid substitutions in pocket 2 of HIV-1 RT 
in the susceptibility to EMAC2077 in RNase H and RDDP activity assays 
RT 
EMAC2077 BTP EFV 
RNase H RDDP RNase H RDDP 
IC50 (µM)
a
 IC50 (µM)
b
 IC50 (µM)
a
 IC50 (nM)
b
 
A502F 13.0 ± 0.7 (10.0) 17.1± 2.1 (1.8) 0.17 ± 0.03 (0.9) 22.3 ± 1.5 (1.6) 
A508V 6.5 ± 0.7 (5.0) 19.3 ± 2.8 (2.0) 0.16 ± 0.05 (0.8) 24.7 ± 2.4 (1.8) 
a
Concentration required to inhibit HIV-1 RT-associated RNase H activity by 50% obtained by 
three independent experiments (reported as average ± standard deviation). 
bConcentration required to inhibit HIV-1 RT-associated RDDP activity by 50% obtained by 
three independent experiments (reported as average ± standard deviation). 
c
Fold of increase with respect to wt RT. 
 
These results strongly support the hypothesis that EMAC2077 
interacts with pocket 2 and that this binding is responsible for short-range 
inhibition of the RNase H function. 
With respect to pocket 2, the sequence alignment of HIV-1 RTs of 
group O and group M subtype67, 68 revealed many differences (Figure 29). 
Thus, comparing the pocket 2 residues of prototypic group M subtype B 
enzyme versus HIV-1 group O RT we have the following differences: E404D, 
A502V, A508S and D511T. The 6.5 folds reduction in EMAC2077 
susceptibility obtained with HIV-1 group O RT in RNase H activity assays 
(Table 6) is consistent with the effects observed with single-mutants A502F 
or A508V (Table 9), since amino acid substitutions found in the HIV-1 group 
O RT would also contribute to reducing the size of the putative EMAC2077 
binding pocket in the RNase H domain. In addition, the NNRTI binding 
pocket of the HIV-1 group M subtype B RT differs from that of the group O 
enzyme mainly at the 181 position (Cys in HIV-1 group O RT and Tyr in HIV-1 
group M subtype B RT), but this does not affect the inhibitory efficiency of 
EMAC2077. Taken together, our data reveal a relevant role for pocket 2 in 
EMAC2077 binding. 
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2.3.5 Conclusions 
 
In conclusion, our study demonstrates that EMAC2077 is a novel dual 
function RT inhibitor that has an allosteric binding mode, different from that 
shown by known NNRTIs. Our results support the hypothesis that 
EMAC2077 binds two different sites in HIV-1 RT. This double-site binding 
mode seems to confirm that it could be possible to target both RT-
associated functions by a single molecule, retaining full potency of inhibition 
on drug-resistant mutant RTs. RNase H inhibition by EMAC2077 seems to be 
mainly, but not exclusively, due to its interaction with pocket 2, close to the 
RNase H active site. The long-range effects on RNase H inhibition produced 
by EMAC2077, and observed when amino acids in the polymerase domain 
were mutated, are probably due to an alteration of the substrate binding 
pocket in the RNase H domain that, in turn, alters EMAC2077 binding or 
efficacy. On the contrary, HIV-1 RT-associated RDDP inhibition by EMAC2077 
seems to be related to its binding in the polymerase domain in the NNRTI 
binding pocket. However, the size of the pocket and the plasticity of the 
enzyme may be responsible for  the conservation of the RDDP inhibition of 
the compound on mutant RTs. 
 
2.4 SUMMARY 
 
Although this target has been studied since more than 30 year for drug 
development, it is still actual and offers new opportunity to design inhibitors 
with new mechanism of action. Its flexibility, the presence of two catalytic 
functions make this enzyme hard to examine with both biochemical and 
computational methods. Nevertheless, considering both series synthesised 
and studied in this project we can assert that the overall, the dual site-dual 
RT-functions inhibition by these compounds is an attractive possibility to 
strongly reduce drug resistance occurrence. Furthermore, since pocket 2 is 
specific for HIV RT, compounds that target this site will not interfere with 
human RNase H1. This pocket was deeply investigated in the past, but 
seems to be promising. These results prompt us to undergo further studies 
to better define the compounds interactions within these two pockets in 
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order to perform a rational drug design of dual inhibitors acting on both 
binding sites. 
 
2.5 EXPERIMENTAL PART 
2.5.1 Synthesis and characterization 
 
Material and General methods. Starting materials and reagents were 
obtained from commercial suppliers and were used without purification. All 
melting points were determined by the capillary method on a Büchi-540 
capillary melting points apparatus and are uncorrected. Electron ionization 
mass spectra were obtained by a Fisons QMD 1000 mass spectrometer (70 
eV, 200 mA, ion source temperature 200°C). Samples were directly 
introduced into the ion source. Found mass values are in agreement with 
theoretical ones. 
For the first series all samples were measured in CDCl3 at 278.1 K 
temperature on a Varian Unity 300 spectrometer. In the signal assignments 
the proton chemical shifts are referred to the solvent (1H:  = 7.24 ppm,). 
For the second all samples were measured in DMF-d7 or DMSO-d6 
solvent at 278.1 K temperature on a Bruker AVANCE III 500 MHz 
spectrometer. Chemical shifts are reported relative to TMS (δ = 0) and/or 
referenced to the solvent in which they were measured. (In the 15N chemical 
shift assignments we applied the spectrometer’s digital reference which is 
calibrated to liq. NH3  = 0 ppm.) Coupling constants J are expressed in hertz 
(Hz). 
Both series 13C were recorded on a Varian Unity 500 spectrometer 
using CDCl3 DMF-d7 or DMSO-d6 as a solvent at 278.1 K. 
Elemental analyses were obtained on a Perkin–Elmer 240 B 
microanalyser. Analytical data of the synthesised compounds are in 
agreement within ± 0.4 % of the theoretical values. TLC chromatography 
was performed using silica gel plates (Merck F 254), spots were visualised by 
UV light. 
Synthetic procedures: 1,3-Diarylpropenones were synthesised 
according to a slightly modified Claisen-Shmidt reaction (Scheme 1). NMR 
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analysis supports the “E” configuration, according to the double bond 
protons coupling constants that ranges from 15 to 16 Hz. 
General procedure. 
(E)-1-(4-bromophenyl)-3-(1-methoxynaphthalen-2-yl)prop-2-en-1-one 
(EMAC2000). 0.9 g of 1-(4-bromophenyl)ethanone (4.5 mmol) were 
dissolved in ethanol and a solution of NaOH 10% was added dropwise at r.t. 
The mixture was stirred for 10 min then 1 g of 1-methoxy-2-naphthaldehyde 
(5.4 mmol) in ethanol solution was added. 24 hours later the reaction was 
completed (monitored by TLC, eluent: n-hexane: ethyl acetate 2:1),and a 
pale yellow crystalline solid was filtered, washed with water, crystallised by 
a mixture of water-ethanol, and characterised.  
Yellow crystal, Yield 67%, mp: 110-112°C. 1H-NMR (300 MHz, CDCl3): 
δ= 4.06 (s, 3H, OCH3), 7.3 (d, 1H, J: 9.1, Ar-CH), 7.41 (t, 1H, J: 7.5, Ar-CH), 
7.55 (t, 1H, J: 7.5, Ar-CH), 7.65 (d, 2H, J: 8.3, Ar-CH), 7.82 (d, 1H, J: 7.5, Ar-
CH), 7.85 (d, 1H, J: 15.6, -CH=), 7.9 (d, 1H, J: 9,0 Ar-CH), 7.93 (d, 2H, J: 8.3, 
Ar-CH), 8.25 (d, 1H, J: 8.6, Ar-CH), 8.51 (d, 1H, J: 15.6, -CH=). 13C-NMR (100 
MHz, CDCl3): δ= 56.1 112.7, 117.1, 123.3, 124.1, 126.6, 127.6, 128.7, 129.0, 
130.0, 130.1 (2C), 131.8 (2C), 132.1, 133.1, 137.3, 138.3, 157.2, 190.2. 
According to this general method, the following compounds were 
synthesised: 
(E)-1-(4-fluorophenyl)-3-(1-methoxynaphthalen-2-yl)prop-2-en-1-one 
(EMAC 2001). Yellow crystal, Yield 81%, mp: 93-95°C. 1H-NMR (300 MHz, 
CDCl3): δ= 4.07 (s, 3H, OCH3), 7.11 (t, 1H, J: 8.5, Ar-CH), 7.26 (d, 2H, J: 9.1, Ar-
CH), 7.42 (d, 1H, J: 7.1, Ar-CH), 7.50 (t, 1H, J: 8.5, Ar-CH), 7.57 (d, 1H, J: 7.1, 
Ar-CH), 7.78 (d, 1H, J: 15.9, -CH=), 7.93 (d, 1H, J: 8.6, Ar-CH), 8.09 (t, 2H, JH-H: 
9.1, JH-F: 9.3, Ar-CH), 8.18 (d, 1H, J: 8.5, Ar-CH), 8.43 (d, 1H, J: 15.9, -CH=). 
13C-NMR (100 MHz, CDCl3): δ= 56.5, 112.7, 115.7, 123.3, 124.0, 126.8, 127.6, 
128.6 (2C), 129.0, 130.0 (2C), 131.1, 131.3, 132.0, 133.0, 136.2, 138.3, 157.2, 
190.0. 
(E)-1-(4-methoxyphenyl)-3-(1-methoxynaphthalen-2-ylprop-2-en-1-one 
(EMAC 2002). Yellow crystal, Yield 83%, mp: 137-139°C.1H-NMR (300 MHz, 
CDCl3): δ= 3.9 (s, 3H, OCH3), 4.05 (s, 3H, OCH3), 7.00 (d, 1H, J: 8.9, Ar-CH), 
7.33 (d, 2H, J: 9,0 Ar-CH), 7.70 (t, 1H, J: 8, Ar-CH), 7.47 (d, 1H, J: 16.0, -CH=), 
7.55 (t, 1H, J: 8, Ar-CH), 7.82 (d, 1H, J: 8,0 Ar-CH), 7.89 (d, 1H, J: 9,0 Ar-CH), 
8.08 (d, 1H, J: 9,0 Ar-CH), 8.28 (d, 2H, J: 9.0 Ar-CH), 8.45 (d, 1H, -CH=). 13C-
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NMR (100 MHz, CDCl3): δ= 55.4, 56.5, 112.7, 113.5, 117.7, 123.5, 124.1, 
127.2, 127.6, 128.6, 129.1, 130.9 (2C), 131.5 (2C), 131.7, 133.1, 137.0, 156.9, 
163.3, 189.5. 
(E)-1-(4-chlorophenyl)-3-(1-methoxynaphthalen-2-yl)prop-2-en-1-one 
(EMAC 2003). Yellow crystal, Yield 53%, mp: 108-109°C. 1H-NMR (300 MHz, 
CDCl3): δ= 4.06 (s, 3H, OCH3), 7.33 (d, 1H, J: 9.1, Ar-CH), 7.41 (t, 1H, J: 7.8, Ar-
CH), 7.49 (d, 2H, J: 8.4, Ar-CH), 7.53 (d, 1H, J: 15.6, -CH=), 7.55 (t, 1H, J: 7.8, 
Ar-CH), 7.74 (d, 1H, J: 8.1, Ar-CH), 7.90 (d, 1H, J: 9.6, Ar-CH), 8.01 (d, 2H, J: 
8.3, Ar-CH), 8.25 (d, 1H, J: 8.6, Ar-CH), 8.51 (d, 1H, J: 15.6, -CH=). 13C-NMR 
(500 MHz, CDCl3): δ= 56.3, 112.7, 117,1, 123.3, 124.0, 126.7, 127.6, 128.6, 
128.8 (2C), 129.0, 130.0 (2C), 132.1, 133.1, 136.9, 138.3, 139.0, 157.2, 190.0. 
(E)-1-(3-nitrophenyl)-3-(1-methoxynaphthalen-2-yl)prop-2-en-1-one 
(EMAC 2004). Pale orange crystal, Yield 64%, mp: 143-145°C. 1H-NMR (300 
MHz, CDCl3): δ= 4.10 (s, 3H, OCH3), 7.35 (d, 1H, J: 8.9, Ar-CH), 7.42 (t, 1H, J: 
7.8, Ar-CH), 7.58 (t, 1H, J: 8.5, Ar-CH), 7.72 (t, 1H, J: 7.8, Ar-CH), 7.83 (d, 1H, 
J: 8.0, Ar-CH), 7.93 (d, 1H, J:8.5, Ar-CH), 7.94 (d, 1H, J: 15.6, -CH=), 8.25 (d, 
1H, J: 8.5, Ar-CH), 8.39 (d, 1H, J: 8.5, Ar-CH), 8.44 (d, 1H, J: 8.0, Ar-CH), 8.60 
(d, 1H, J: 15.6, -CH=), 8.89 (s, 1H, Ar-CH). 13C-NMR (500 MHz, CDCl3): δ= 56.3, 
112.6, 116.6, 123.1, 123.4, 124.1, 125.7, 126.8, 127.8, 128.8, 129.0, 129.8, 
132.7, 133.1, 134.1, 139.5, 140.0, 148.3, 157.6, 189.0. 
(E)-1-(4-biphenyl)-3-(1-methoxynaphthalen-2-yl)prop-2-en-1-one 
(EMAC 2005).Yellow crystal, Yield 87%, mp: 104-105°C. 1H-NMR (300 MHz, 
CDCl3): δ= 4.07 (s, 3H, OCH3), 7.34- 7.50 (m, 2H, Ar-CH), 7.56 (t, 1H, J: 8.1, Ar-
CH), 7.69 (d, 2H, J: 7.8, Ar-CH), 7.75 (d, 2H, J: 7.8, Ar-CH), 7.83(d, 1H, J: 8.8, 
Ar-CH), 7.88 (d, 1H, J: 8.0, Ar-CH), 7.91 (d, 2H, J: 8.2, Ar-CH), 7.95 (d, 1H, J: 
15.9, -CH=), 8.04 (d, 2H, J: 8.2, Ar-CH), 8.19 (d, 1H, J: 8.8, Ar-CH), 8.29 (d, 1H, 
J: 8.1, Ar-CH), 8.54 (d, 1H, J: 15.9, -CH=). 13C-NMR (100 MHz, CDCl3): δ= 56.4, 
112.8, 117.4, 123.5, 124.0, 127.2 (3C), 127.3 (3C), 127.5, 128.1, 128.6, 128.9 
(2C), 129.1, 129.2 (2C), 131.8, 137.3, 137.7, 140.1, 145.3, 157.1, 190.7. 
 
Synthetic procedures: Indolinones were synthesised according to the 
following procedure. NMR analysis supports the “Z” configuration: This was 
based on the selective NOE experiment, where we observed NOE 
interaction between the indole NH and CH protons, while no correlation was 
seen between the indole CH and =N-NH- hydrogens. 
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Synthesis of compound EMAC 2072 (Z)-3-(2-(4-(4-
chlorophenyl)thiazol-2-yl)hydrazono)indolin-2-one (general procedure) 
The synthesis is accomplished by a two steps procedure (Scheme 2) 
a) Synthesis of 2-(2-oxoindolin-3-ylidene)-
hydrazinecarbothioamide 
0,5g (3.8 mmol) of indolinone-2,3-dione and 0,35g (3.8 mmol) of 
thiosemicarbazide were introduced in a three necked flask and dissolved 
with 25 mL of 2-propanol at 50°C. 5 drops of CH3COOH were added to the 
mixture reaction as catalyst. After a few minutes the formation of an 
abundant yellow precipitate is observe. The reaction was monitored with 
TLC (eluent ethylacetate: exane 7:2). After 24 hours the reaction is 
completed and the solid filtered. The desired compound is a yellow solid. 
R.f.: 0.33 (eluent ethylacetate: exane 7:2); M.P.: >250°C; Yield: 97% 
1H NMR (DMF-d7) δ(ppm): 12.72 (s; 1H); 11.34 (s; 1H); 9.21 (s; 1H); 
9.05 (s; 1H); 7.66-7.64 (m; 1H); 7.42-7.34 (m; 1H); 7.17-7.10 (m; 1H); 7.06-
7.02 (m; 1H).13C NMR (DMF) δ(ppm): 180.1; 163.3; 143.1; 132.4; 131.6; 
122.8; 121.1; 120.7; 111.5.15N NMR (DMF) δ(ppm): 170.0; 135;6; 110.4 
b) Synthesis of (Z)-3-(2-(4-(4-chlorophenyl)thiazol-2-
yl)hydrazono)indolin-2-one EMAC 2072 
0.5g (2.3 mmol) of (Z)-1-(2-oxoindolin-3-ylidene)thiosemicarbazide 
and 0.54g (2.3 mol) of 2-bromo-4’-chloroacetophenone were stirred at r.t. in 
30 ml of 2-propanol. After few minutes the formation of an abundant light 
yellow-orange precipitate was observed. The reaction was monitored by TLC 
(eluent exane: ethylacetate 7:2) and after 24 hours it was completed. The 
desired compound is a yellow-orange solid. R.f.:0.85 (eluent 
exane:ethylacetate 7:2); M 
NMR Final Compounds characterisation indolinones series:  
(Z)-3-(2-(4-(4-chlorophenyl)thiazol-2-yl)hydrazono)indolin-2-one 
(EMAC2072). Yellow-orange solid, Yield 73%, mp: >250°.1H NMR (DMF-d7) 
δ(ppm): 13.55 (s, 1H); 11.43 (s; 1H); 8.07-8.02 (m; 2H); 7.82 (s; 1H); 7.63 
(dm; J=7.6 Hz; 1H); 7.58-7.53 (m; 2H); 7.41 (td; J=7.6 Hz; 1.1 Hz; 1H); 7.16 
(td; J=7.6 Hz; 1.0 Hz; 1H); 7.10 (dm; J=7.6 Hz; 1H).13C NMR (DMF-d7) δ(ppm): 
166.9; 164.0; 150.6; 142.1; 133.6; 133.1; 132.7; 130.9; 129.2; 127.9; 122.8; 
120.5; 120.3; 111.5; 107.7.15N NMR (DMF-d7) δ(ppm): 156.2; 135.7 
97 
 
(Z)-3-(2-(4-(4-fluorophenyl)thiazol-2-yl)hydrazono)indolin-2-one 
(EMAC2073). Yellow-orange solid, Yield 57%, mp: >250°. 1H NMR (DMSO-d6) 
δ(ppm): 13.33 (s; 1H); 11.25 (s; 1H); 7.97-7.90 (m; 2H); 7.60 (s; 1H); 7.53 
(dm; J= 7.5 Hz; 1H); 7.34 (tm; J= 7.5 Hz; 1H); 7.29-7.17 (m; 2H); 7.09 (tm; J= 
7.5 Hz; 1H); 6.99-6.92 (m; 1H).13C NMR (DMSO-d6) δ(ppm): 166.4; 163.2; 
161.9 (d; J= 244.6 Hz); 150.0; 141.3; 132.2; 130.6; 130.5; 127.8 (d; J= 8.3 Hz) 
122.4; 119.9; 119.8; 115.6 (d; J= 21.6 Hz); 111.1; 106.6.15N NMR (DMSO-d6) 
δ(ppm): 137.1 
(Z)-3-(2-(4-(4-bromophenyl)thiazol-2-yl)hydrazono)indolin-2-one 
(EMAC2074). Yellow-orange solid, Yield 95%, mp: >250°.  1H NMR (DMF-d7) 
δ(ppm): 13.53 (s; 1H); 11.42 (s; 1H); 7.99-7.93 (m; 2H); 7.82 (s; 1H); 7.71-
7.65 (m; 2H); 7.61 (dm; J= 7.6 Hz; 1H); 7.39 (tm; J= 7.6 Hz; 1H); 7.14 (tm; J= 
7.6 Hz; 1H); 7.08 (dm; J= 7.6 Hz; 1H).13C NMR (DMF-d7) δ(ppm): 167.0; 
164.0; 150.7; 142.1; 133.9; 132.7; 132.1; 130.9; 128.1; 122.8; 121.6; 120.5; 
120.3; 111.5; 107.8.15N NMR (DMF-d7) δ(ppm): 156.1; 135.7. 
(Z)-3-(2-(4-(4-nitrophenyl)thiazol-2-yl)hydrazono)indolin-2-one 
(EMAC2075). Yellow-orange solid, Yield 84%, mp: >250°.  
1H NMR (DMF-d7) δ(ppm): 13.55 (s; 1H); 11.42 (s;1H); 8.38-8.32 (m; 
2H); 8.30-8.24 (m; 2H); 8.12 (s; 1H); 7.62 (dm; J= 7.7 Hz; 1H); 7.40 (td; J= 7.7 
Hz; 1.2 Hz; 1H); 7.15 (td; J= 7.7 Hz; 0.7 Hz; 1H); 7.08 (dm; J= 7.7 Hz; 1H).13C 
NMR (DMF-d7) δ(ppm): 167.3; 163.9; 149.7; 147.2; 142.2; 140.7; 133.1; 
131.1; 127.0; 124.5; 122.9; 120.4; 120.3; 111.6; 111.6.15N NMR (DMF-d7) 
δ(ppm): 155.8; 135.7. 
(Z)-3-{2-[4-(4-biphenyl)- thiazol-2-yl)hydrazono)indolin-2-one 
(EMAC2076). Yellow-orange solid, Yield 96%, mp: >250°.1H NMR (DMF-d7) 
δ(ppm): 13.56 (s; 1H); 11.41 (s; 1H); 8.13-8.08 (m; 2H); 7.85-7.75 (m; 5H); 
7.63 (d; J= 7.6 Hz; 1H); 7.55-7.49 (m; 2H); 7.44-7.36 (m; 2H); 7.15 (tm; J= 7.6 
Hz; 1H); 7.08 (dm; J= 7.6 Hz; 1H).13C NMR (DMF-d7) δ(ppm): 166.8; 164.0; 
151.6; 142.1; 140.4; 140.3; 133.8; 132.6; 130.9; 129.4; 127.9; 127.4; 127.0; 
126.7; 122.8; 120.5; 120.2; 111.5; 107.1.15N NMR (DMF-d7) δ(ppm): 156.5; 
135.7 
(Z)-3-(2-(4-(4-bromophenyl)thiazol-2-yl)hydrazono)indolin-2-one 
(EMAC2077). Yellow-orange solid, Yield 99%, mp: >250°. 
1H NMR (DMF-d7) δ(ppm): 13.54 (s; 1H); 11.42 (s; 1H); 8.23-8.17 (m; 
2H); 8.04 (s; 1H); 7.97-7.93 (m; 2H); 7.62 (d; J: 7.6 Hz; 1H); 7.40 (tm; J: 7.6 
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Hz; 1H); 7.15 (tm; J: 7.6 Hz; 1H); 7.08 (d; J: 7.6 Hz; 1H).13C NMR (DMF) 
δ(ppm): 167.2; 163.9; 150.1; 142.2; 138.8; 133.2; 133.0; 131.0; 126.8; 122.9; 
120.4; 120.3; 119.3; 111.6; 110.8; 110.6. 15N NMR (DMF) δ(ppm): 155.9; 
135.6. 
(Z)-3-(2-(4-(2,4-difluorophenyl)thiazol-2-yl)hydrazono)indolin-2-one 
(EMAC2078). Yellow-orange solid, Yield 66%, mp: >250°.1H NMR (DMF-d7) 
δ(ppm): 13.52 (s; 1H); 11.39 (s; 1H); 8.23-8.14 (m; 1H); 7.62 (d; J= 7.6 Hz; 
1H); 7.58(d; J= 2.4 Hz; 1H); 7.45-7.36 (m; 2H); 7.25 (td; J= 8.5 Hz; 2.5 Hz; 1H); 
7.15 (td; J= 7.6 Hz; 0.7 Hz; 1H); 7.07 (dm; J= 7.6 Hz; 1H). 13C NMR (DMF-d7) 
δ(ppm): 166.4; 164.0; 162.3 (dd; J= 248.0 Hz; 12.4 Hz); 160.4 (dd; J= 251.9 
Hz; 12.3 Hz); 144.7 (dd; J= 2.6 Hz; 0.9 Hz); 142.1; 132.8; 131.2 (dd; J= 9.6Hz; 
4.8 Hz); 131.0; 122.9; 120.5; 120.3; 119.1 (dd; J= 11.3Hz; 3.7 Hz); 112.3 (dd; 
J= 21.4Hz; 3.4 Hz); 111.5; 111.2 (d; J= 15.0 Hz); 104.9 (t; J= 26.5 Hz). 15N NMR 
(DMF-d7) δ(ppm): 155.9; 135.5 
(Z)-3-(2-(4-(3-nitrophenyl)thiazol-2-yl)hydrazono)indolin-2-one 
(EMAC2079). Yellow-orange solid, Yield 86%, mp: >250°.1H NMR (DMF-d7) 
δ(ppm): 13.57 (s; 1H); 11.41 (s; 1H); 8.84-8.76 (m; 1H); 8.46 (dm; J= 8.1 Hz; 
1H); 8.26 (dm; J= 8.1 Hz; 1H); 8.09 (s; 1H); 7.80 (t; J= 8.1 Hz; 1H); 7.63 (d; J= 
7.6 Hz; 1H); 7.41 (tm; J= 7.6 Hz; 1H); 7.15 (tm; J= 7.6 Hz; 1H); 7.08 (dm; J= 7.6 
Hz; 1H). 13C NMR (DMF-d7) δ(ppm): 167.3; 164.0; 149.5; 149.0; 142.2; 136.3; 
133.0; 132.2; 131.0; 130.7; 122.9; 122.9; 120.6; 120.4; 120.3; 111.5; 109.6. 
15N NMR (DMF-d7) δ(ppm): 155.9; 135.5. 
(Z)-3-(2-(4-p-tolylthiazol-2-yl)hydrazono)indolin-2-one (EMAC2080). 
Yellow-orange solid, Yield 72%, mp: >250°. 
1H NMR (DMF-d7) δ(ppm): 13.53 (s; 1H); 11.38 (s; 1H); 7.91-7.86 (m; 
2H); 7.66 (s; 1H); 7.62 (d; J= 7.6 Hz; 1H); 7.39 (td; J= 7.6 Hz; 1.2 Hz; 1H); 7.30-
7.25 (m; 2H); 7.15 (td; J= 7.6 Hz; 0.8 Hz; 1H); 7.07 (dm; J= 7.6 Hz; 1H); 2.35 
(s; 3H). 13C NMR (DMF-d7) δ(ppm): 166.6; 164.0; 152.0; 142.0; 138.0; 132.4; 
132.1; 130.8; 129.7; 126.1; 122.8; 120.5; 120.2; 111.5; 106.0; 20.8. 15N NMR 
(DMF-d7) δ(ppm): 156.4; 135.5. 
(Z)-3-(2-(4-(4-methoxyphenyl)thiazol-2-yl)hydrazono)indolin-2-one 
(EMAC2081). Yellow-orange solid, Yield 84%, mp: >250°.1H NMR (DMF-d7) 
δ(ppm): 13.53 (s; 1H); 11.40 (s; 1H); 7.95-7.91 (m; 2H); 7.63-7.59 (dm; J= 7.7 
Hz; 1H); 7.56 (s; 1H); 7.39 (td; J= 7.7 Hz; 1.1 Hz; 1H); 7.15 (td; J= 7.7 Hz; 1.0 
Hz; 1H); 7.08 (dm; J= 7.7 Hz; 1H); 7.06-7.02 (m, 2H); 3.85 (s; 3H). 13C NMR 
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(DMF-d7) δ(ppm): 166.6; 164.0; 159.9; 151.8; 142.0; 132.4; 130.8; 127.5; 
127.5; 122.8; 120.5; 120.2; 114.3; 111.5; 104.7; 55.3. 15N NMR (DMF-d7) 
δ(ppm): 156.6; 135.6. 
(Z)-3-(2-(4-phenylthiazol-2-yl)hydrazono)indolin-2-one (EMAC2082). 
Yellow-orange solid, Yield 92%, mp: >250°. 
1H NMR (DMF-d7) δ(ppm): 13.54 (s; 1H); 11.41 (s; 1H); 8.01-7.97 (m; 
2H); 7.74 (s; 1H); 7.62 (dm; J= 7.7 Hz; 1H); 7.49-7.44 (m; 2H); 7.42-7.34 (m; 
2H); 7.17-7.10 (m; 1H); 7.08 (dm; J= 7.7 Hz; 1H). 13C NMR (DMF-d7) δ(ppm): 
166.8; 164.0; 151.9; 142.1; 134.7; 132.6; 130.9; 129.1; 128.3; 126.1; 122.8; 
120.5; 120.2; 111.5; 106.9. 15N NMR (DMF-d7) δ(ppm): 156.2; 135.6. 
(Z)-3-(2-(4-(2,4-dichlorophenyl)thiazol-2-yl)hydrazono)indolin-2-one 
(EMAC2083). Yellow-orange solid, Yield 90%, mp: >250°.1H NMR (DMF-d7) 
δ(ppm): 13.51 (s; 1H); 11.39 (s; 1H); 8.05 (d; J= 8.5 Hz; 1H); 7.85 (s; 1H); 7.75 
(d; J= 2.2 Hz; 1H); 7.63 (dm; J= 7.6 Hz; 1H); 7.58 (dd; J= 8.5 Hz; 2.2 Hz; 1H); 
7.40 (td; J= 7.6 Hz; 1.2 Hz; 1H); 7.15 (td; J= 7.6 Hz; 1.0 Hz; 1H); 7.07 (dm; J= 
7.6 Hz; 1H). 13C NMR (DMF-d7) δ(ppm): 166.1; 164.0; 147.1; 142.1; 133.6; 
132.6; 132.9; 132.2; 132.1; 131.0; 130.4; 128.1; 122.9; 120.5; 120.3; 112.9; 
111.5. 15N NMR (DMF-d7) δ(ppm): 155.6; 135.5 
 
2.5.2 Protein expression and purification.  
 
HIV-1 RT group M subtype B. The recombinant HIV-1 RT protein, 
whose coding gene was subcloned in the p6HRT_prot plasmid, was 
expressed in E. coli strain M15.69, 70 The bacteria cells were grown up to an 
OD600 of 0.8 and induced with 1.7 mM IPTG for 5 hrs. HIV-1 RT purification 
was carried out as described.71 Briefly, cell pellets were resuspended in 
Lyses Buffer (20 mM Hepes pH 7.5, 0.5 M NaCl, 5 mM β-mercaptoethanol, 5 
mM imidazole, 0.4 mg/mL lysozime), incubated on ice for 20 min, sonicated 
and centrifuged at 30,000 x g for 1 hr. The supernatant was applied to a His-
binding resin column and washed thoroughly with wash buffer (20 mM 
Hepes pH 7.5, 0.3 M NaCl, 5 mM β-mercaptoethanol, 60 mM imidazole, 10% 
glycerol). RT was eluted by imidazole gradient and the enzyme-containing 
fractions were pooled, dialyzed and aliquots were stored at –80 °C.  
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Recombinant HIV-1 group O RT was expressed and purified as 
previously described72, 73. 
It was obtained as a heterodimer composed of subunits of 66 and 51 
kDa, with a polyhistidine tag at the C-terminus of p66. For this purpose, the 
RT p66 subunit encoded within a p66RTB expression vector was co-
expressed with the HIV-1 protease in E. coli XL-1 Blue, and the obtained 
heterodimers were then purified by ionic exchange followed by 
chromatography on Ni2+-nitriloacetic acid agarose. The enzyme was 
quantified by active site titration before biochemical studies. 
Site directed mutagenesis. Aminoacid substitutions were introduced 
into the p66 HIV-1 RT subunit coded in a p6HRT-prot plasmid using the 
QuikChange mutagenesis kit by following the manufacturer’s instructions 
(Agilent Technologies Inc., Santa Clara, CA). 
 
2.5.3 Biochemical assays. 
 
RNase H polymerase-independent cleavage assay. The HIV-1 RT 
associated RNase H activity was measured as described74 in 100 µL reaction 
volume containing 50 mM Tris HCl pH 7.8, 6 mM MgCl2, 1 mM dithiothreitol 
(DTT), 80 mM KCl, hybrid RNA/DNA (5’-GTTTTCTTTTCCCCCCTGA C-3’-
Fluorescein, 5’-CAAAAGAAAAGG GGGGACUG-3’-Dabcyl) and increasing 
concentrations of inhibitors, whose dilution were made in water, and 
different amounts of enzymes according to a linear range of dose-response 
curve: 6 ng wt RT; 30 ng K103N RT; 12 ng V106ART; 19 ng V108A RT; 1.51.5 
ng Y181C RT; 45 ng Y188A RT; 15 ng Y188L RT; 30 ng E224A RT; 15 ng P225A 
RT; 18 ng P226A RT; 23 ng F227A RT; 15 ng L228A RT; 30 ng W229A RT; 30 
ng M230A RT; 15 ng G231A RT; 15 ng A502F RT; 19 ng A508V RT; 38 ng HIV-
1 group O RT. After enzyme addition, the reaction mixture was incubated for 
30 min at 37 °C and the stopped by addition of EDTA. Reaction products 
were detected by picogreen addition and measured with a multilabel 
counter plate reader Victor 3 (Perkin Elmer model 1420-051) equipped with 
filters for 502/523 nm (excitation/emission wavelength). 
DNA polymerase assay. the HIV-1 RT associated (RDDP) activity was 
measured using Invitrogen EnzCheck Reverse Transcriptase Assay Kit, in 50 
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µL volume containing 60 mM Tris‐HCl pH 8.1, 8 mM MgCl2, 60 mM KCl, 13 
mM Dithiothreitol, 100 µM dTTP, and poly(A)-oligo(dT) and increasing 
concentrations of inhibitors, whose dilution were made in water, and 
different amount of enzyme according to a linear range of dose-response 
curve: 20 ng of WT RT; 60 ng K103N RT; 37.5 ng V106A RT; 75 ng V108A RT;  
5 ng Y181C RT; 50 ng Y188A RT; 30 ng Y188L RT; 100 ng E224A RT; 37.5 ng 
P225A RT; 20 ng P226A RT; 18 ng F227A RT; 30 ng L228A RT; 30 ng W229A 
RT;  10 ng M230A RT; 30 ng G231A RT; 100 ng A502F RT; 37.5 ng A508V RT; 
38 ng HIV-1 group O RT. The reaction mixture was incubated for 1 h at 37 °C, 
stopped by addition of EDTA and products were measured with a multilabel 
counter plate reader Victor 3 (Perkin Elmer model 1420-051) equipped with 
filters for 490/528 nm (excitation/emission wavelength). 
The Yonetani-Theorell analysis. The Yonetani-Theorell analysis was 
performed according to the official protocol 75 
The calculation of the interaction constant α, allows to estimate the 
degree of interference of the two inhibitors for the binding, was performed 
according to the following equation, assuming that KEEFV  = IC50 for non-
competitive inhibitors in accordance with Prusoff–Cheng equation 76 and 
equal to 12 nM in our system. 
 
slope with EFV
slope without EFV
= 1 +
[nM EFV]
α KEEFV
 
 
Detection of protein inhibitor interactions by Differential Scanning 
Fluorimetry. 
Thermal stability assays were performed according to Nettleship et 
al.77. In a LightCycler 480 96-well plate (Roche) we incubated 10 μM 
inhibitor, in 50 μl of reaction buffer containing 20 mM HEPES, pH 7.5, 10 
mM MgCl2, 100 mM NaCl, 300 nM of HIV-1 RT and a 1:1000 dilution of Sypro 
Orange dye (Invitrogen). 
The mixture was heated from 30 to 90 °C in increments of 0.2 °C. 
Fluorescence intensity was measured using excitation and emission 
wavelengths of 483 and 568 nm, respectively. Changes in protein thermal 
stability (ΔTm) upon inhibitor binding were analyzed by using the LightCycler 
480 software. All assays were performed in triplicate. 
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Cell lines and virus. The human embryonic c kidney cells 293T and the 
human T-lymphoid Jurkat cell line (clone E6-1) were from the American Type 
Culture Collection and maintained in DMEM or RPMI medium (Invitrogen), 
respectively, containing 10% fetal bovine serum (Invitrogen), at 37 °C in a 
humidified 5% CO2 atmosphere. Recombinant viral stock was produced by 
transient transfection of 293T cells as previously described78 and used to 
transduce Jurkat cells. In this context, an env-defective provirus encoding 
the bacterial chloramphenicol acetyltransferase (CAT) gene was 
complemented in trans by the envelope glycoprotein derived from the 
laboratory-adapted T-cell-tropic strain HXBc2. The level of CAT expression in 
the infected cells reflects the efficiency of a single round of the retroviral 
infection cycle.  
Cytotoxicity assay. For cytotoxicity assays, cell lines were seeded in 
96-well plates (Falcon) at an initial density of 105 cells/100 µL in medium 
containing 10% FBS, in the absence or presence of serial dilutions of test 
compounds. Plates were incubated for 72 hrs at 37 °C in a humidified 5% 
CO2 atmosphere. Cell viability was determined by using Cell Proliferation Kit 
I (MTT) (Roche). 
 
2.5.4 Molecular modeling 
 
Ligand preparation. Theoretical 3D models of the compounds were 
built by means of Maestro.79 Starting conformations were optimized by 
means of an energy minimization carried out using the MMFFs force field,80 
the GB/SA81 water implicit solvation model and the Polak-Ribier Coniugate 
Gradient (PRCG) method, converging on gradient with a threshold of 0.05 
kJ(mol*Å)-1. 
Protein preparation. The coordinates for reverse transcriptase 
enzymes were taken from the RCSB Protein Data Bank43 (PDB codes 1vrt48, 
2zd149, 1ep450, 3qo923, 1rti48, 1tv647, 3lp228). The proteins were prepared by 
using the Maestro Protein Preparation Wizard protocol. Original water 
molecules were removed and termini were capped. The bond orders and 
formal charges were added for hetero groups, and all the hydrogen atoms 
were added in the structure. Missing atoms and residues were included. 
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After preparation, the structures were refined in order to optimize the 
hydrogen bond network using OPLS_200582 force field. The minimization 
was terminated when the energy converged or the RMSD reached a 
maximum cut-off of 0.30 Å.  
Docking protocol. Molecular docking studies were performed using 
QMPL workflow protocol.45 Grids were defined around the refined structure 
by centering on the residue indicated in the text (i.e W229 and Q500) and 
fixing the box volume at 97336 Å3. The extra precision (XP) docking 
algorithm was applied for scoring theoretical poses. The other settings were 
left as default. The same protocol was applied for all docking simulations. 
Post-docking protocol. 10.000 steps of the Polak-Ribier conjugate 
gradient (PRCG) minimization method were conducted on the top ranked 
theoretical complexes using OPLS_2005 force field. The optimization process 
was performed up to the derivative convergence criterion equal to 0.01 
kJ/(mol*Å)-1.The binding free energies (ΔG(Bind)) were computed applying 
molecular mechanics and continuum solvation models with the molecular 
mechanics generalized Born/surface area (MM-GBSA) method.46 
Furthermore for EMAC2005 mechanism investigation, best docking 
complexes were submitted to 6 ns of MD by using Desmond ver. 2.4.52 The 
complexes were solvated with a TIP3P (Transferable Intermolecular 
Potential 3-Point)83 box of water and counter ions were added to neutralize 
the system net charge. The solvated models were optimised, and 
subsequently the MTK_NPT (Martyna-Tobias-Klein with constant Number of 
particles, Pressure and Temperature) ensemble was employed.84 The default 
stages in the relaxation process for the NPT ensemble include two energy 
minimizations and four simulation steps. During the energy minimizations, 
two runs of 2000 iteration were processed using the steepest descent 
method: during the first run, the protein structure was fixed by a force 
restraint constant of 50 kcal/(molÅ) and in the second all restraints were 
removed. With the first simulation, at NVT (constant Number of particles, 
Volume, and Temperature) ensemble, the system reached a temperature of 
10 K. In the following three simulations in the NPT ensemble, the system 
was heated up to 300 K and the pressure was kept constant at 1 bar using 
the Berendsen thermostat–barostat. During the production phase, 
temperature and pressure were kept constant using the Nosè-Hoover 
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thermostat–barostat. The energy and trajectory were recorded every 1.2 ps 
and 4.8 ps, respectively. For multiple time step integration, RESPA 
(REversible reference System Propagator Algorithm)85 was applied to 
integrate the equation of motion with Fourier-space electrostatics 
computed every 6 fs, and all remaining interactions computed every 2 fs. All 
chemical bond lengths involving hydrogen atoms were fixed with SHAKE.86 
Short range cut-off was set to 9 Å and the smooth particle mesh Ewald 
method (PME)87 was used for long range electrostatic interaction. The 
resulting seven trajectories were analyzed in terms of interaction energies 
and geometries. 
The same protocol was applied for the EMAC2005-RT ternary 
complex. 
Molecular modeling figures were depicted by LigandScout88, 89, VMD 
ver. 1.8.7.90 and Maestro.79 
 
2.5.5 In vitro membrane permeation study 
 
HPLC determination of EMAC2005. Sensitive HPLC method with UV 
detection was developed for the quantitative determination of EMAC2005. 
The chromatographic system was a HPLC Jasco mod. PU-1580 (Tokyo, Japan) 
with a 20 µl loop injection valve. The chromatographic system was equipped 
with a Jasco MD 1510 diode array detector, which was set at λmax 296 for 
EMAC2005. The separation was performed using a C18 reverse-phase 
Phenomenex column (Jupiter 250 × 4.60 mm, 5 m particle size), which was 
maintained at room temperature. The mobile phase was pH 9 water (eluent 
A) and acetonitrile (eluent B) and it was delivered at a flow rate of 1 ml/min. 
Solvents were degassed by sonication for 15 min. A gradient elution method 
was applied for the determination of EMAC2005. The gradient was set as 
follow, eluent A/eluent B 70:30 0-7 min, linear increase of eluent B to 60% 
7-9 min, linear increase of eluent B to 70 % 9-12 min, eluent A/eluent B 
30:70 was maintained for 7 min (12-19 min), linear decrease of eluent B to 
50 % 19-21 min and then the system was linearly returned to original 
conditions 21-25 min (see supplementary materials for further details). 
 HPLC data were processed using the Borwin chromatography 
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software (Version 1.5) from Jasco. A pure ethanol solutions of the 
compound EMAC2005 was prepared (1 mg/ml) and used as a stock solution 
for the calibration curve. EMAC2005 quantification was carried using a 
calibration curve in a linear concentration interval ranging from 0.1 to100 
µg/ml, according to the following equation: 
Eq. 1   AUC = 0.5598x - 1.94010 
where AUC is the area under the curve (mAu × min) and x is the drug 
concentration (µg/ml). 
In vitro trans-membrane permeation. A model of biological 
membrane was prepared as elsewhere reported.91 Briefly, a polycarbonate 
membrane (50 nm pore size) was pre-soaked in pH 7.4 isotonic phosphate 
buffer for 3 h and layered on a synthetic cellulose nitrate membrane 
(molecular weight cut-off 10,000 Da), which was previously impregnated 
with a liquid paraffin-lauryl alcohol (2.1:10 w/w) mixture up to the doubling 
of the weight.  Flow Franz diffusion cells were used for the trans-membrane 
permeation of EMAC2005 and they were characterized by a surface area of 
0.75 cm2 and a nominal receiving volume of 4.75 ml. The model of biological 
membrane was placed horizontally between the donor and receptor 
compartments. An ethanol/water mixture (50/50 v/v) was used to fill the 
receptor compartment. The same mixture (200 μl) was used to suspend the 
drug. This suspension was placed into the donor compartments. The 
receptor fluid was constantly stirred at 600 rpm during experiments by 
means of a magnetic anchor and warmed (GR 150 thermostat, Grant 
Instruments Ltd, Cambridge, UK) to 37 °C. These conditions were maintained 
throughout the experiments. At predetermined times, 400 µl of the receptor 
compartment were withdrawn using a Minipuls 3 peristaltic pump (Gilson 
Italia S.r.l., Cinisello Balsamo (MI), Italy) connected to a FC 204 fraction 
collector (Gilson Italia S.r.l., Cinisello Balsamo (MI), Italy) and immediately 
replaced with the same volume of fresh solution. The amount of EMAC2005, 
which permeated through the membranes, was immediately analyzed by 
HPLC. Experiments were carried out in triplicate and results were the mean 
of five different experiments ± standard deviations. 
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3   CHAPTER  
3.1  INTRODUCTION TO MONOAMINO OXIDASE B 
 
In this third chapter I will discuss about the study conducted on a class 
of new oxadiazoles synthesised and tested on Monoamine Oxidase enzymes 
(MAO). But firstly, a brief introduction of these target is necessary, in order 
to understand their role in the human organism. 
MAO are ubiquitous enzymes that contain a flavin adenine 
dinucleotide cofactor (FAD) and play a key role in the degradation of 
exogenous and endogenous amines.  
MAO catalyzes the oxidative deamination with this simple reaction: 
 
RCH2NH2 + MAO  → RCHO + NH3 + MAO−reduced 
MAO−reduced + O2 →MAO + H2O2 
 
The mammalian family of MAOs consists of two isozymes, namely 
MAO-A and MAO-B, differing in their selectivity versus substrates and 
inhibitors, serotonin (5HT) and norepinephrine (NE) are preferentially 
deaminated by the A isoform, whereas 2-phenylethylamine and 
benzylamine are MAO-B substrates. Both isoforms act on dopamine (DA) 
and tryptamine.1 These enzymes are tightly bound to the mitochondrial 
outer membrane. Although MAOs are widely distributed in various organs, 
most of the studies concerning their functional properties and involvement 
in pathological processes have been mainly focused on the central nervous 
system. In the periphery, MAO-A and MAO-B are differently expressed in a 
variety of tissues: MAO-A is predominant in heart, adipose tissue, and skin 
fibroblasts, MAO-B is the major form found in platelets and lymphocytes, 
whereas both isoenzymes are expressed in kidney and liver.2, 3 
From an historical point of view, the application of MAO inhibitors in 
therapy showed a fluctuating trend: After the first enthusiastic interest on 
their use as antidepressants, the incidence of side effects and hypertensive 
crisis, due to the interference with metabolism of dietary amines (known as 
cheese effect), slowly let these drugs disappear from clinical practice. These 
severe side effects are due to the irreversible and unselective inhibition of 
MAO first generation drugs. Then the research on this target has led to 
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focusing efforts on finding first, selective inhibitors (second generation), and 
successively selective and reversible compounds for the two enzyme 
isoforms (third generation).4-6 
Reversible inhibitors of monoamine oxidase A (RIMA) led to 
reexamination of MAOIs in psychiatry and they represent the first choice 
drugs in the treatment of atypical depression, anxiety and panic disorders. 
In fact, such inhibitors can be displaced by high concentration of xenobiotic 
amines allowing their deamination by the enzyme. 
Instead selective irreversible human MAO-B inhibitors (hMAO-BIs) are 
used alone or in combination with other drugs, in the treatment of both 
Parkinson’s (PD) 7, 8 and Alzheimer’s (AD) diseases.9-12  
In fact, increased levels of MAO-B were observed in both PD patients 
and elderly population13, 14 which lead to an increased production of 
hydrogen peroxide and other reactive oxygen species. These substances are 
responsible for neuron degeneration in the central nervous system (CNS) 
and in particular in the “substantia nigra”.15-18 MAO-A expression, 
differently from MAO-B, does not increase with age, suggesting that a 
totally independent mechanism regulates the expression of the two 
enzymatic isoforms.19, 20  
 
 
Figure 1. Irreversible (I), reversible (R), and/or selective hMAO-A and hMAO-B inhibitors. 
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An increase of the DA levels as well as a neuroprotective effect can be 
observed following the inhibition of MAO-B.2, 3, 6, 21, 22 
Although the two isoforms share a high sequence similarity, they differ 
in shape and volume of the catalytic site allowing to discover selective 
binders. In fact, structural studies reported the presence of a single cavity of 
about 550 Å3 for MAO-A (Figure 2a,b), whereas MAO-B has a tight and 
longer dipartite cleft, named entrance and substrate cavities. These two 
pockets can merge into a single cavity of ~700 Å3 (Figure 2c,d). 23 
The availability of crystal structures of MAO played a central role in 
galvanizing researchers to synthesise new inhibitors. In the last decade 
several crystallographic models have been published in the Protein Data 
Bank24 (Table 1). Apart from revealing the differences in volume and shape 
of the binding pocket of the two isoforms, crystallographic and mutagenesis 
studies showed which residues are pivotal in catalysis and inhibition. All 
structural studies converge on considering the residues Ile199 and Tyr326, 
which separate the “access” from “substrate” cavity of MAO-B, as 
determinants of enzyme specificity and selectivity. 25,26,27 In some complexes 
with reversible MAO-BIs it has been highlighted that the residue Ile199 is in 
“open” conformation behaving as “gate” between the two cavities. 28, 29 
The access of substrates or inhibitors is modulated also by the loop 99-
112.30 Recent mutagenesis studies followed by crystallographic studies 
corroborated the fundamental role of the “aromatic cage” on the 
deamination mechanism.31 This explains why the aromatic pair of tyrosine 
involved in the “cage” is conserved in homologues and related enzymes, 
such as polyamine oxidase (PAO). The achievement of high-resolution 
crystal structures of several protein-ligand complexes made structure-based 
computational studies possible. 
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Figure 2. Main differences between the a) MAO-A  and b) MAO-B active site. 
 
The structural information helped to understand the reason of 
selectivity of potent cavity-spanning MAO-BIs such as safinamide (Figure 
3),32, 33 coumarin derivatives,29 farnesol,34 caffeine derivatives35, 36 and the 
anti-diabetes drug pioglitazone.37 
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Figure 3.Safinamide-MAO-B complex. 
 
Table 1. PDB models MAO B and MAO A. 
Isofor
m 
PDB Res. 
Mutatio
n 
Ligand 
Bindin
g 
Year Ref. 
hMAO
-B 
1GO
S 
3 
 
pargyline Cov 2002 
38
 
1OJ
9 
2.3 
 
1,4-diphenyl-2-butene 
Non 
Cov 
2003 
39
 
1OJ
A 
1.7 
 
isatin 
Non 
Cov 
2XF
U 
2.2 
 
tranylcypromine Cov 
1OJ
C 
2.4 
 
N-(2-amminoethyl)-p-
clorobenzamide 
Cov 
1OJ
D 
3.1 
 
lauryl-N,N-dimethylamine-
N-oxyde (detergent) 
Non 
Cov 
1S2
Q 
2.1 
 
rasagiline Cov 
2004 
40
 
1S2
Y 
2.1 
 
N-propargyl-1(S)-
aminoindan 
Cov 
1S3
B 
1.7 
 
N-methyl-N-propargyl-1(R)-
aminoindan 
Cov 
1S3
E 
1.6 
 
6-hydroxy-N-propargyl-1(R)-
aminoindan 
Cov 
2BK
3 
1.8 
 
farnesol 
Non 
Cov 
2005 
34
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2BK
4 
1.9 I199F rasagiline Cov 
2BK
5 
1.8 I199F isatin 
Non 
Cov 
2BY
B 
2.2 
 
selegiline Cov 2005 
41
 
2C6
4 
2.2 
 
6-hydroxy-N-methyl-N-
propargyl-1(R)-aminoinda 
Cov 
2005 
34
 
2C6
5 
1.7 
 
4-(N-methyl-N-ethyl-
carbamoyloxy)-N-methyl 
-N-propargyl-1(R)-
aminoindan 
Cov 
2C6
6 
2.5 
 
4-hydroxy-N-propargyl-1(R)-
aminoindan 
Cov 
2C6
7 
1.7 
 
N-methyl-1(R)-aminoindan 
Non 
Cov 
2C7
0 
2.1 
 
p-nitrophenylmethylamine 
(substrate) 
Cov 
2006 
42
 
2C7
2 
2 Y435H rasagiline Cov 
2C7
3 
2.2 Y435F rasagiline Cov 
2C7
5 
1.7 Y435L rasagiline Cov 
2C7
6 
1.7 Y435W rasagiline Cov 
2V5
Z 
1.6 
 
safinamide 
Non 
Cov 
2007 
29
 
2V6
0 
2 
 
7-[(3-chlorobenzyl)oxy]-2-
oxo-2H-chromene-4-
carbaldehyde 
Non 
Cov 
2V6
1 
1.7 
 
7-[(3-chlorobenzyl)oxy]-4-
[(methylamino) 
methyl]-2H-chromen-2-one 
Non 
Cov 
2VR
L 
2.4 
 
benzylhydrazine Cov 
2008 
43
 
2VR
M 
2.3 
 
phenyletylhydrazine Cov 
2VZ
2 
2.3 
 
mofegiline Cov 2008 
44
 
2XF
N 
1.6 
 
2-(1-benzofran)imidazole 
Non 
Cov 
2010 
45
 
2XC
G 
1.9 
 
tranylcypromine & 2-(1-
benzofran)imidazole 
Cov 
2XF
P 
1.7 
 
isatin & 2-(1-
benzofran)imidazole 
Non 
Cov 
2XF 2.2 
 
rasagiline & 2-(1- Cov 
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Q benzofran)imidazole 
2XF
O 
2.1 I199A 
tranylcypromine & 2-(1-
benzofran)imidazole 
Cov 
3PO
7 
1.8 
 
zonsinamide 
Non 
Cov 
2011 
46
 
2ZY
X 
2.2 
I199A 
I326A 
methylen blue 
Non 
Cov 
2011 
47
 
 
4A7
9 
1.89  pioglitazone 
Non-
Cov 
2011 
37
 
4CR
T 
1.8  Ass234 Cov 2014 
48
 
Isofor
m 
PDB Res. 
Mutatio
n 
Ligand 
Bindin
g 
Year Ref. 
hMAO
-A 
2BX
R 
3 
 
clorgyline 
Cov 2005 
41
 
2BX
S 
3.2 
 
clorgyline 
2Z5
X 
2.2 
 
harmine 
Non 
Cov 
2008 
27
 
2Z5
Y 
2.2 G110A harmine 
Non 
Cov 
rMAO-
A 
1O5
W 
3.2 
 
clorgyiline Cov 2004 
49
 
 
Many scaffolds have been proposed for MAO-BIs both from nature50, 
51 or obtained by synthesis: chalcones,52-54 chromanones,55-58, pyridines,59 
benzoxathiolones,60 pyrroles,61, 62 indanones,63 pyridazinones,63 and many 
others.  
An interesting prospective in the field of neurodegenerative diseases 
therapy is the application of MAO-BIs with multi-target activity.6, 35, 64 
The introduction of a carbamate group or the presence of substituted 
or unsubstituted thiocarbamoil, acetyl group often leads also to the 
acetylcholinesterase inhibition.65-68 This could be advantageous for possible 
application on AD therapy.69, 70 Also the presence of  moieties able to 
chelate iron ions seems to be promising: It was found that iron dramatically 
increases in patients with PD and produces radical oxygen species involved 
in neurodegeneration.12 Recently, antagonists of the adenosine receptor 
A2A with methylxanthine group or benzimidazole group have been studied 
as MAO-BIs and proposed as new neuroprotective agents dual-target-
directed.36, 71, 72 Finally, several compounds from selegiline and 
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propargilamine derivatives73 to lazabemide,74 quinoline12 and coumarin 
derivatives,75-82 show, besides the MAO-BI activity, antioxidant potential. 
Our group is working in this field since many years and several series 
of compounds have been synthesised.83-87 Recently a first series of 
oxadiazoles was synthesised and tested toward MAO showing a good 
activity and selectivity toward MAO-B.88, 89 
 
 
3.2 NEW OXADIAZOLES AS SELECTIVE INHIBITORS OF MAO-
B 
3.2.1 Design 
 
Starting from previously reported theoretical complexes between 
MAO-B and the 2-(4-chlorophenyl)-3-acetyl-5-(4-chlorophenyl)-2,3-dihydro-
1,3,4-oxadiazole88 we carried out a molecular interaction fields (MIFs) 
analysis: after removing the inhibitor, the interaction capabilities of the 
MAO-B active site were investigated by means of CL probe as implemented 
in the program GRID.90 We subsequently monitored the resulting isocontour 
maps taking into account the two most energy stabilized previously 
reported poses (Pa and Pb) of the inhibitor into the hMAO-B binding cleft.
88 
MIFs indicated a strong interaction between the target and organic 
chlorine suggesting the possibility to include a second chlorine atom on the 
p-chlorophenyl ring substituent located at the position 2 of the 
dihydrooxadiazole ring (Figure 4).  
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Figure 4. Chlorine molecular interaction field (yellow wireframe grids) displayed on previous 
reported a) Pa and b) Pb theoretical complexes of compound 4p-MAO-B.
88
 The FAD cofactor 
is reported in spacefill notation and the ligand in sticks cyan carbon and brown chlorine 
atoms colored. The rest of the enzyme is depicted in transparent violet cartoon. 
 
An important requirement for selectivity is the ability of the inhibitors 
to fit within the elongated bipartite cavity of MAO-B, which is bigger (700 
Å3) and narrower than the single substrate cavity of MAO-A (550 Å3).23 
Therefore the skeleton of the series was maintained because of its ability to 
occupy both cavities. In fact previous series showed good selectivity toward 
MAO-B.88  
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3.2.2 Synthesis 
 
The 4a-j series was synthesised according to a previously described 
procedure88 as illustrated in Scheme 1.  
 
Ar
O
NH
NH2
+
O
H
O
NH
N
1 2 3a-j
N
N
O
H3C
O
 4a-j
i ii
i: CH3COOH (CAT)/ EtOH, reflux; ii: (CH3CO)2O, reflux
Ar Ar
Cl
Cl
Cl
Cl
Cl
Cl
Scheme 1. Synthetic pathway to compounds 4a-j 
 
Briefly, the suspension in acetic anhydride of the appropriate 
benzoylhydrazide was heated under reflux until the formation of a yellow-
orange solution was observed. The reaction mixture was then poured onto 
ice water and vigorously stirred. The obtained precipitate was then washed 
with 10% aqueous NaHCO3 solution, water, and purified by crystallization. 
All of the products were characterised by means of both analytical and 
spectroscopic methods (Experimental section) and tested towards MAO-A 
and MAO-B.  
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3.2.3 Biological activity 
 
The inhibitory activities of compounds 4a-j on human recombinant 
MAO-A and -B isoforms, expressed in baculovirus infected BTI infected cells, 
as IC50, are reported in Table 2.  
Tested compounds demonstrated no interference with the 
measurements, since they were unable to react directly with the Amplex 
Red reagent. The kinetic parameters of hMAO-A and hMAO-B were 
evaluated in the presence of different tyramine concentrations. In our 
experiments, hMAO-A displayed a Michaelis constant (Km) of 514 ± 46.8 M 
and a maximum reaction velocity (Vmax) of 301.4 ± 27.9 nmol/min/mg 
protein, whereas hMAO-B showed a Km of 104.7 ±16.3 M and a Vmax of 28.9 
± 6.3 nmol/min/mg protein (n =5). Active compounds showed reversible 
behaviour according to the method proposed by Cer et al.91 Therefore, 
reported IC50 is a useful tool to determine the relative activity of the 
compounds within the series as well as to determine key substituents in the 
scaffold.  
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Table 2 Inhibitory activities towards hMAO A and hMAO-B of 3-acetyl-2-(3,4-
dichlorophenyl)-5-aryl-2,3-dihydro-1,3,4-oxadiazoles derivatives 4a-j. 
Compound Ar 
hMAO-A 
(IC50) 
hMAO-B 
(IC50) 
4a 
 
** 69.36 ± 3.51 µM 
4b 
 
** *** 
4c 
 
** 217.99 ± 10.62 nM 
4d 
 
** 19.35 ± 0.68 nM 
4e 
 
** 626.82 ± 36.52 nM 
4f 
 
** 9.46 ± 0.57 nM 
4g 
 
** ** 
4h 
 
** 67.69 ± 4.27 nM 
4i 
 
** ** 
4j 
 
** 2.46 ± 0.17 µM 
Clorgyline  4.6 ± 0.3 nM 61.35 ± 1.13 µM 
Deprenyl  67.25 ± 1.02 µM 0.019 ± 8,6*10
-4
 µM 
Iproniazide  6.56 ± 0.76 µM 7.54 ± 0.36 µM 
Moclobemide  3.61 ± 1.94 µM 69.36 ± 3.51 µM 
All IC50 values shown in this table are the mean ± S.E.M. from five experiments. 
* Inactive at 1 mM (highest concentration tested). 
** Inactive at 100 µM (highest concentration tested). At higher concentration the compounds precipitate. 
*** 100 µM inhibits the corresponding MAO activity by approximately 40-45%. At higher concentration the 
compounds precipitate. 
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Half of the tested compounds exhibited inhibitory activity towards 
hMAO-B at nM concentration, with the exception of compound 4b which 
inhibited the corresponding MAO activity by approximately 40-50% at the 
concentration of 100 µM and compounds 4g and 4i that were inactive at 
100 µM. Compounds 4a and 4j were effective in the µM range. Interestingly, 
none of the tested compounds exhibited activity towards the A isoform of 
the enzyme at the tested concentration of 100 µM.  
 
3.2.4 Structure Activity Relationships 
 
Biological tests confirmed our hypothesis, in other words, that the 
introduction of a 3,4-dichlorophenyl moiety in the position 5 of the 
dihydrooxadiazole ring could lead to more effective and selective 
compounds with respect to the previously reported mono-chloro derivatives 
(i.e. the mono-chloro analog of 4f was inactive on MAO-A whereas 
demonstrated a MAO-B IC50 equal to 121.62 ± 9.63 nM).
88 Although an 
excellent remote Hammett correlation (p or p
+) has been found for para 
substitution in the two aryl rings at the positions 2 and 5 of the 
dihydrooxadiazole,89 the electronic effect of the substituent in the para 
position of the phenyl moiety at the position 5 of the dihydrooxadiazole did 
not seem to play a relevant role in determining the potency of the 
inhibitors. On the contrary, just the presence of a substituent in this position 
seemed to be essential for the activity, probably due to the need of bulky 
substituent in this position. This hypothesis was corroborated by the low 
activity exhibited by compound 4a and 4b bearing a pyridyl and a phenyl 
substituent respectively. However either the introduction of a 
dimethylamino moiety or of a cyano as in compound 4g and 4i, led to a 
decrease of the inhibitory activity. It is worth to note that the introduction 
of a methyl substituent in the ortho position, as in compound 4j, led to 
decrease of the inhibitory potency more than 100 fold higher than the 
corresponding para-substituted compound 4d. Hence a complex blend of 
electronic and steric effects should be considered to determine the best 
substitutions for the biological activity. 
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3.2.5 Enantiomeric mixture resolution 
 
All the synthesised compounds have a stereogenic centre at the 
position 2 of the heterocyclic ring. 4d, 4e and 4f were chosen to perform the 
separation of the single enantiomers and to evaluate the influence of 
stereochemistry on their biological properties. Repetitive semipreparative 
HPLC resolutions carried out on the Chiralpak IA chiral stationary phase 
(CSP) using the mixture dichloromethane/DEA 100/0.1 (v/v) as eluent 
enabled us to easily collect tens of mg of enantiopure samples (Table 3). The 
enantiomeric nature of the samples obtained on mg-scale was 
demonstrated by polarimetric (Table 3) and circular dichroism (CD) analysis 
(Figure 5). 
 
Table 3. Chromatographic and polarimetric analysis of the pooled fractions 
containing the first (F1) and second (F2) eluted enantiomers of 4d-f.  
Compound k1
a
 k2
b
 A
c
/V
d
 F1
e
 F2
e
 
 
   
e.e.(%
) 
 20D  e.e.(%
) 
 20D  
4d 0.14 0.46 10/0.1 >99.0 +15 
(c = 0.1, CH2Cl2) 
>99.0 -15 
(c = 0.1, CH2Cl2) 
4e 0.10 0.40 6/0.05 >99.0 +7 
(c = 0.1, CH2Cl2) 
>99.0 -7 
(c = 0.1, CH2Cl2) 
4f 0.10 0.35 5/0.3 >99.0 -35 
(c = 0.1, CH2Cl2) 
99.0 +34 
(c = 0.1, CH2Cl2) 
a
 retention factor for the first eluted enantiomer.
b
 retention factor for the second eluted enantiomer. 
c
amount of sample (in mg) resolved in a single semipreparative run.
d
: volume of sample (in 
mL).
e
enantiomeric purity and polarimetric data for the pooled fractions containing the first (F1) and 
second (F2) eluted enantiomers. 
 
The chiroptical properties of the enantiopure antipodes were perfectly 
specular (Table 3 and Figure 5). The absolute configuration of the 
enantiomers of 4e and 4f was empirically established by CD correlation 
method using the enantiomers of 4d as reference samples. Crystallization of 
the second eluted enantiomer of (-)-4d (in the chromatographic conditions 
reported in Table 3) from ethanol/water afforded single crystals which were 
suitable for X-ray diffraction analysis. An Oak Ridge Thermal Ellipsoid Plot 
Program (ORTEP) view of (S)-(-)- 4d is showed in Figure 6. The replacement 
of the methyl group on the phenyl ring (compound 4d) by a chlorine atom 
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(compound 4e) or a nitro group (compound 4f) did not produce significantly 
alteration in the spectral location of the maximum and minimum of the 
representative CD bands recorded in ethanol solution (Figure 5). 
 
 
Figure 5. CD spectra of the enantiomers of 4d-f recorded in ethanol. 
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Figure 6. An ORTEP view of the molecular structure of (S)-(-)-4d 
 
 
The pure enantiomers of 4e and 4f, respectively the less active and the 
most active compounds in the nM range, were then evaluated for their 
ability to inhibit the two different MAO isoforms. Also in this case no activity 
towards MAO-A at the concentration of 100 mM was observed. The results 
for MAO-B isoform are reported in Table 4: The activity is exclusively (4e) or 
mostly (4f) associated with the (R)- enantiomer. 
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Table 4 Inhibitory activities towards hMAO-B of 3-acetyl-2-(3,4-
dichlorophenyl)-5-aryl-2,3-dihydro-1,3,4-oxadiazoles 4e and 4f as pure 
enantiomers and racemates. Data reported in nM. 
Compound Structure 
hMAO-B (IC50) 
 
(±) 4e 
 
626.82 ± 36.52 
(R)-(+) 4e 203.59 ± 18.61 
(S)-(-) 4e ** 
(±) 4f 
 
9.46 ± 0.57 
(R)-(+) 4f 7.61 ± 0.64 
(S)-(-) 4f 523.46 ± 41.30 
Each IC50 values is the mean ± S.E.M. from five experiments. 
** Inactive at 100000 nM (highest concentration tested). 
 
 
3.2.6 Molecular modeling 
 
In order to rationalize at molecular level the enzyme inhibition of most 
promising compounds, suggesting their putative binding mode, we carried 
out docking and molecular dynamic (MD) simulations, but before that we 
validated both docking and MD protocol.  
Among the crystal structure available (Table 1), we selected crystal structure 
of non-covalent inhibitors complexes, with a resolution < 2.5 Å, Ki < 40 M. 
Then, docking protocol was validated performing self and cross-docking of 
seven crystallized reversible inhibitors (Table 5), into the hMAO-B complex 
crystal structure dwith the best resolution, having the code 2V5Z.29 
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Table 5. PDB crystal structures, of MAO-B in complex with no-covalent 
inhibitors, employed for docking validation. 
PDB 
entry 
Lig. 
abbrev 
Ligand 
X-ray 
res. (Å) 
Ki (μM) 
Gdiss 
(kcal/mol) 
1OJ9
92
 1PB 
1,4-diphenyl-2-butene[(1E)-4-
phenylbut-1-enyl]benzene 
2.3 35
 
6.34 
1OJA
92
 RM1 N-methyl-1(R)-aminoindan 1.7 3 7.87 
2C67
93
 ISN Isatin 1.7 17 6.79 
2BK3
34
 FOH Farnesol 1.8 2.3 8.04 
2V5Z
29
 SAG Safinamide 1.6 
0.45 ± 
0.13 
9.05 
2V60
29
 C17 
7-[(3-chlorobenzyl)oxy]-2-oxo-2H-
chromene- 4-carbaldehyde 
2.0 
0.40 ± 
0.02 
9.12 
2V61
29
 C18 
7-[(3-chlorobenzyl)oxy]-4-
[(methylamino)methyl]- 2H-
chromen-2-one 
1.7 
0.10 ± 
0.02 
9.96 
 
The purpose of this step was to estimate the efficiency of our docking 
protocol in predicting the correct orientation of co-crystallized inhibitors 
into the substrate binding cavity. The biological activity of reference 
compounds varies with a Ki ranging from 35 to 0.10μM. Among the docking 
settings implemented in Glide software (Glide SP,94 Glide XP,95 Quantum 
Mechanics-polarized ligand docking (QMPLD)96, 97 and Induced Fit workflow 
protocol98), QMPLD workflow96, 97 successfully reproduced the 
crystallographic poses of 5 out of 7 compounds within 1.6 Å root-mean-
square deviation (RMSD). However, also the docking pose of farnesol, the 
co-crystallized ligand reported in 2BK3 34 PDB model, in absence of electron 
density maps could be considered good. In fact, farnesol has a plausible 
pose rotated of almost of 180° and the second best pose, is slightly shifted 
compared to experimental data even if with an RMSD value > 2 Å. Finally 
isatin is quite small and could adopt several binding modes inside the 
catalytic pocket (Figure 7) (Table 6)  
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Figure 7. Results of seven self and cross-docking experiments performed using 2V5Z as 
receptor model. Below each docking superimposition is reported the RMSD between co-
crystallized (in ball and sticks) and first pose (in sticks). For 2BK3 ligand is reported also the 
second docking pose. 
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Table 6. Results of 7 (self and cross)-docking experiments performed using 
2V5Z as receptor model without water co-crystallized (2V5Z) and with 
crystallized water (2V5Z-w). Below each setting of docking experiment is 
reported the RMSD between experimental and best 5 docked poses.  
PDB Lig 
2V5Z 2V5Z-w 
SP XP 
Qmp
l 
QmplX
P 
Ifd SP XP 
Qmp
l 
QmplX
P 
Ifd 
1OJ
9 
1PB 
1.57 
1.6
0 
1.40 1.60 8.65 8.40 
8.3
5 
8.42 8.35 1.60 
2.11 
1.6
1 
1.26 1.66 2.96 8.17 
8.2
0 
0.88 8.20  
8.17  1.33 1.67  1.36 
1.3
8 
1.36 1.38  
8.40  1.57 0.89  7.89 
0.9
0 
1.36 0.90  
  8.12 1.37  1.58 
1.6
2 
1.34 1.62  
1OJ
A 
ISN 
4.28 
4.2
7 
4.24 4.24 3.61 2.26 
9.4
1 
2.27 9.41 0.68 
2.07  4.24  4.53 4.69 
4.1
0 
2.25 4.10  
3.19  4.24   3.71 
4.0
3 
2.27 4.03  
3.56  4.24   4.82 
3.7
2 
2.26 3.72  
3.93  4.24   4.99 
3.7
2 
2.21 3.72  
2BK
3 
FO
H 
3.39 
2.2
5 
8.94 2.04 3.36 1.98 
2.7
2 
2.00 2.72  
3.81  3.25 2.00 8.06 2.50 
2.0
4 
2.01 2.04  
2.93  3.29 2.52  1.99 
2.3
0 
2.30 2.30  
2.92  3.24 2.66  1.35 
8.9
0 
2.27 8.90  
3.41  3.29 9.12  2.23  2.14   
2C6
7 
RM
1 
5.08 
5.0
2 
1.35 1.61 1.93 4.83 
3.7
6 
4.82 3.76 
11.2
2 
1.36  1.35 1.74 5.07 
10.8
8 
1.6
1 
4.83 1.61 1.67 
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10.2
0 
 1.11 10.26 1.94 
10.8
2 
3.2
8 
4.83 3.28  
4.78  0.89 3.26 
10.3
4 
10.5
8 
 4.83   
4.75  1.65 9.95  3.27  4.82   
2V5
Z 
SAG 
0.40 
2.0
3 
0.38 2.09 1.95 0.36 
0.4
4 
0.35 0.44 2.53 
1.54  0.38 0.41 2.28 1.66 
0.4
4 
0.35 0.44 2.53 
1.10  0.37 1.76 2.52 1.08 
1.6
8 
0.34 1.68 2.54 
1.61  0.37 2.37 2.42 1.91 
1.6
8 
0.36 1.68  
  1.10  1.87 1.24  0.36   
2V6
0 
C17 
0.47 
3.2
3 
0.43 8.39 2.03 0.49 
1.4
0 
0.44 1.40 3.07 
0.86 
8.3
9 
0.43 3.23 0.84 1.93 
8.3
3 
0.44 8.33 1.41 
2.69  0.42 2.27  0.72 
8.3
1 
0.44 8.31 2.40 
3.25  0.43 8.45  2.05 
2.3
9 
0.50 2.39  
1.89  0.40 3.36    1.93   
2V6
1 
C18 
1.70 
3.7
5 
1.64 3.33 2.04 1.95 
1.8
6 
1.82 1.86 1.98 
2.18  1.64 2.55 1.70 2.58 
1.8
3 
1.84 1.83 1.86 
3.33  1.63 3.77 9.01 8.70 
2.4
8 
1.77 2.48 2.50 
2.74  1.63 3.72  3.35 
2.4
5 
1.86 2.45  
2.81  1.64 3.83    2.65   
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After this validation step, we applied then the best protocol to dock 
the separated enantiomers (R)-4e and (R)-4f. Due to lack of accuracy of 
docking scores, the simple docking experiment alone is not often sufficient 
to rank binding scores with a linear correlation with experimentally 
measured binding affinities of known complexes.99  
Therefore we decided to use a combination of docking and MD. 
Actually, explicit solvent MD, coupled with efficient free-energy sampling 
algorithms, can potentially offer accurate prediction of ligands to proteins 
binding free energies.  
Firstly, as we did for the docking procedure, we validated the 
molecular dynamic simulation considering the 7 crystal taken into account 
for docking validation. We wanted to evaluate the importance of the 
mitochondrial membrane therefore we prepared three different systems 
settings: monomer, dimer and dimer in membrane (Figure 8).  
 
 
Figure 8. Overview of MAO B a) monomer; b) homodimer; c) homodimer embedded in a 
lipid bilayer. 
 
We decided to consider the enzyme embedded into the mitochondrial 
membrane since in literature has been reported its key role in compound 
recognition. In particular, it was reported that the loop 85-112 is involved in 
the substrate catalytic site entrance modulation.100 We observed that the 
estimated interaction energies well correlate with G of dissociation data 
with all three settings (Figure 9). However, the monomer showed the best 
correlation with a r 2 = 0.89 (0.98 if we leave the crystal 1OJA (with co-
crystallized isatin (ISN)) out of the evaluation). 
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Figure 9. MD energy analysis. Inhibitors are arranged from left to right by increasing 
magnitude of ΔG of dissociation. Sum of binding energy components for each inhibitor and 
setting (a) monomer, (c) dimer, (e) membrane. The Total energy (Tot_E) of interaction is 
shown with a line. Besides each histogram: figures (b), (d) and (f), the related linear 
regression plot and r
2
 values for the sum of all interaction energies between each inhibitor 
and MAO B. 
 
According to these data, the presence of the membrane into the 
theoretical models, although relevant in the stage of compound entrance 
and recognition, was found to be not essential for the correct prediction of 
the interaction energy. 
Hence, to better estimate the new ligands-receptor interaction 
energies, the poses, reporting an RMSD > 2 Å within the top five ranked 
docking poses, were submitted to 10 ns of MD simulations (pose 1 and 2, 
Table 7). 
Thanks to the previously performed studies, the monomer MD setting 
was used to run further simulation taking into account two starting poses 
per compound. The best poses results are illustrated in Figure 10. 
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Compound 4e was able to enter deeply in the binding cavity and was 
stabilized by hydrophobic and aromatic interactions (Figure 10a-c). Although 
the dichlorophenyl moiety was able to rotate, still the  interaction with 
Phe343 was conserved. On the contrary, compound 4f was kept between 
the entrance and the catalytic cavity separated by the Ile199 due to the 
interaction of the bulky nitro moiety with residues and waters in this region. 
More in details, compound 4f resulted stabilized within the binding site 
through an array of aromatic (Tyr326, Phe168), hydrophobic (Leu171, 
Ile199, Leu167, Ile198), and H-bond interactions with binding site residues 
(Figure 10d-f and Figure 11).  
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Figure 10. a) d) Superimposed structures of 10 ns MD simulations frames of [4e 4f- MAO-B] 
complex coloured by time-step: initial (red), final (blue) along with intermediate structures 
snapshots. b) e) close-up of the binding cavity; c) f) 2D representing compound and 
interacting residues. 
 
 
Figure 11. MD trajectory analysis. Number of hydrogen bonds between 4f and MAO-B 
 
The H-bond between the 4f carbonyl and the hydroxyl group of the 
important residue Tyr435, which, together with FAD and Tyr398, delimit the 
aromatic cage, pivotal for MAO activity, was monitored and found to be 
stable along the whole MD simulation (Figure 11). In addition, the number 
of good contacts was higher for 4f compared to 4e (Figure 12). 
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Figure 12. Residues involved in the complex stabilization sorted by number of contacts 
between ligand and receptor. a) 4e; b) 4f. 
 
Furthermore, the averaged energy of interaction (Table 7) was in 
accordance with the difference of activity and underlines the higher weight 
of van der Waals interactions contribution. 
 
Table 7 Averaged energies of interaction between new compounds and 
hMAO-B. Tot-E, Coul-E and vdW-E are respectively the total interaction 
energy, its electrostatic and van der Waals terms expressed in kcal/mol. The 
different starting poses are indicated by 1 and 2. 
 
 Tot-E 
(kcal/mol) 
Coul-E 
(kcal/mol) 
vdW-E 
(kcal/mol)  
(R)-4e
1
 -56.76  -5.38  -45.78 
(R)-4e
2
 -56.19 -2.98 -51.79 
(R)-4f
1
 -64.15 -9.26 -50.39 
(R)-4f
2
 -63.75 -6.89 -48.12 
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With the aim to estimate the drug-likeness of the compounds, we 
carried out in silico ADME-tox prediction.101 Since 4f was identified as the 
best inhibitor of our series, we investigated the prediction of its absorption, 
distribution, metabolism, excretion and toxicity (ADMEtox) properties using 
the Qikprop 102 software.  
Such an approach provides molecular properties by means of 
calculation and comparison of the predicted value for the novel compound 
with respect to the 95% of known drugs. The computed molecular 
descriptors are shown in Table 8. 
All properties were within the ranges specified. The predicted IC50 for 
human Ether-à-go-go-Related Gene (HERG) K+ Channel Blockage was 
borderline in its value.  
However, considering the possibility of a limited error of prediction in 
discriminating a safe or not-safe compound, biological experiments are 
needed. Tissue distribution is an important element of the pharmacokinetic 
(PK) profile of a drug united with knowledge of the in vitro activity. The 
activity of this compound should occur in the brain, therefore we paid great 
attention on analysing in silico molecular descriptors that are required for a 
CNS active agent like the polar surface area (PSA) and the logarithm of the 
blood-brain barrier partition (LogBB). The values indicate that newly 
synthesized molecule would cross blood-brain barrier (BBB) with a low rate. 
Hence, we checked if this was an issue of other interesting compounds of 
the series and in particular of 4d, which also has good inhibitory activity 
(19.35 ± 0.68 nM). In this case the prediction of CNS activity was positive. 
Therefore, this compound appears more interesting in this respect. Finally, 
qualitative human oral absorption was predicted with favourable score. In 
conclusion, 4d revealed to have slightly more favourable physicochemical 
properties and therefore seems to be a good candidate for future 
development.  
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Table 8. Summary results ADME/Tox prediction for 4f and 4d solute, in 
brackets are reported the ranges observed in 95% of known drugs. (SASA: 
Solvent accessible surface area; SA: Surface area). 
Descriptors 4f 4d Range 95% of Drug 
Solute Molecular Weight       380.19 349.22 ( 130.0 / 725.0) 
Solute Dipole Moment (D)      9.29 6.01 (   1.0 /  12.5) 
Solute Total SASA      612.26 604.33 ( 300.0 /1000.0) 
Solute Hydrophobic SASA      78.70 166.91 (   0.0 / 750.0) 
Solute Hydrophilic SASA      161.56 64.02 (   7.0 / 330.0) 
Solute Carbon Pi SASA      241.58 243.00 (   0.0 / 450.0) 
Solute Weakly Polar SASA      130.41 130.41 (   0.0 / 175.0) 
Solute Molecular Volume (A^3) 1053.95 1039.37 ( 500.0 /2000.0) 
Solute vdW Polar SA (PSA)     96.57 51.56 (   7.0 / 200.0) 
Solute No. of Rotatable Bonds 0.00 0.00 (   0.0 /  15.0) 
Solute as Donor - Hydrogen Bonds  0.00 0.00 (   0.0 /   6.0) 
Solute as Acceptor - Hydrogen Bonds  5.50 4.50 (   2.0 /  20.0) 
Solute Globularity (Sphere = 1)    0.82 0.82 (  0.75 /  0.95) 
Solute Ionization Potential (eV)     9.55 8.96 (   7.9 /  10.5) 
Solute Electron Affinity    (eV)     1.78 0.75 (  -0.9 /   1.7) 
QP Polarizability (Angstroms^3)        37.690M 37.762M (  13.0 /  70.0) 
QP log P for hexadecane/gas       11.725M 10.907M (   4.0 /  18.0) 
QP log P for octanol/gas          17.318M 15.717M (   8.0 /  35.0) 
QP log P for water/gas            9.177M 7.740M (   4.0 /  45.0) 
QP log P for octanol/water        3.16 4.22 (  -2.0 /   6.5) 
QP log S for aqueous solubility     -5.35 -5.07 (  -6.5 /   0.5) 
QP log S - conformation independent    -5.55 -5.36 (  -6.5 /   0.5) 
QP log K hsa Serum Protein Binding     0.16 0.43 (  -1.5 /   1.5) 
QP log BB for brain/blood          -0.79 0.25 (  -3.0 /   1.2) 
No. of Primary Metabolites             2.00 2.00 (   1.0 /   8.0) 
Predicted CNS Activity (-- to ++)      - + 
 HERG K+ Channel Blockage: log IC50     -5.63 -5.59 (concern below -5) 
Apparent Caco-2 Permeability (nm/sec)  290.00 2448.00 (<25 poor, >500 great) 
Apparent MDCK   Permeability (nm/sec)  674.00 6745.00 (<25 poor, >500 great) 
QP log Kp for skin permeability        -3.55 -1.84 (Kp in cm/hr) 
Jm, max transdermal transport rate     0.00 0.01 (micrograms/cm^2-hr) 
Lipinski Rule of 5 Violations          0.00 0.00 (maximum is 4) 
Jorgensen Rule of 3 Violations         0.00 0.00 (maximum is 3) 
% Human Oral Absorption in GI (+-20%)  90.00 100.00 (<25% is poor) 
Qual. Model for Human Oral Absorption  HIGH HIGH (>80% is high) 
 
149 
 
3.2.7 Conclusions 
 
Given our interest in the development of MAO-BIs as a potential 
therapeutic strategy for neurodegenerative diseases, we developed 
molecules with optimized activity toward B isoform. Starting from the 2-(4-
chlorophenyl)-3-acetyl-5-(4-chlorophenyl)-2,3-dihydro-1,3,4-oxadiazole we 
found out, through Molecular Interaction Field analysis that the introduction 
of a second chlorine atom in the 5-phenyl substituent improved the 
potency. 
Therefore, we synthesised a new series of 2-(3,4-dichlorophenyl)-3-
acetyl-5- aryl-2,3-dihydro-1,3,4-oxadiazoles. We found out that several 
compounds showed inhibition properties in the nM range and a high 
selectivity toward MAO-B. As previously observed for similar compounds, 
the (R)-enantiomer exhibits a higher inhibitory activity compared to both 
the racemic mixture and the (S)-enantiomer.  
In addition we have validated a computational protocol of molecular 
docking and molecular dynamic, obtaining  a good qualitative and 
quantitative accord between experimental and theoretical activities. 
Therefore, the devised workflow will be applied for future studies on MAO-
B. 
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3.3 EXPERIMENTAL PART 
3.3.1 Chemistry and compounds characterization  
 
General methods. Melting points were uncorrected and were 
determined on a Reichert Kofler thermopan apparatus. 1H-NMR spectra 
were recorded on a Varian Unity 500 and on a Bruker 400, using 
tetramethylsilane (TMS) as internal standard (chemical shifts in  values). . 
Electron ionisation (EI) mass spectra were obtained by a Fisons QMD 1000 
mass spectrometer (70 eV, 200 µA, ion source temperature 200 °C). The 
samples were introduced directly into the ion source. TLC analyses were 
performed on silica gel 60 F254 plates. All synthesized compounds were 
purified by crystallization from an appropriate solvent. Elemental analyses 
were obtained on a Perkin Elmer 240 B microanalyser. Analytical data of the 
synthesised compounds are in agreement within ± 0.4 % of the theoretical 
values. 
Synthesis of compounds 4a-j.88 Equal amounts of aromatic aldehyde 
(0.018 mol) and the appropriate arylhydrazide (0.018 mol) were refluxed in 
ethanol (60 mL) under vigorous stirring from 1 to 3 h in presence of acetic 
acid as catalyst (0.5mL). With respect to the different aromatic substituents 
in positions 2 and 5 of the oxadiazole ring, a differently coloured solution is 
obtained. The reaction solution is monitored by TLC (eluent 
dichloromethane: methanol 20:1). After the mixture is cooled at room 
temperature, the precipitated product is filtered off and then washed with 
isopropyl ether. Obtained arylidenearylhydrazides (0.003 mol) are refluxed 
in 6 mL of acetic anhydride under vigorous stirring from 15 min to 2 h. The 
suspension is monitored by TLC (eluent chloroform: methanol 20:1). The 
solution is then poured onto ice-water (100 g) and vigorously stirred. A 
precipitate is formed which is washed with NaHCO3 (10% aqueous solution) 
to remove the acetic acid. The obtained solid is further purified by 
crystallization. 
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2-(3,4-dichlorophenyl)-3-acetyl-5- pyridin-2,3-dihydro-1,3,4-oxadiazole 
(4a) 
C15H11Cl2N3O2. Pink powder, M.p. 117-118°C (isopropyl ether), MS 
(m/z) 294, yield 92%. CHN %: Calc. C, 53.59; H, 3.30; N, 12.50, Found C, 
53.55; H, 3.29; N, 12.46  
1H-NMR (500 MHz, DMSO):  2.39 (s, 3H), 7.24 (s, 1H), 7.50 (d, 1H, J = 
8Hz), 7.73 (m, 3H, J = 8, and 4 Hz), 7.82 (s, 1H), 8.75 (s, 2H). 13C-NMR (100 
MHz, DMSO):  21.38, 91.36, 120.39, 127.23, 129.26, 131.39, 131.71, 
132.94, 137.15, 150.80 (2C), 153.15, 157.01, 166.44, 166.55 
4b: 2-(3,4-dichlorophenyl)-3-acetyl-5- phenyl-2,3-dihydro-1,3,4-
oxadiazole (4b)  
C16H12Cl2N2O2. White crystals, M.p. 99-100°C (ethanol), MS (m/z) 335, 
yield 43%. CHN %: Calc. C, 57.33; H, 3.61; N, 8.36, Found C, 57.36; H, 3.63; N, 
8.37 
1H-NMR (400 MHz, DMSO):  2.27 (s, 3H), 7.22 (s, 1H), 7.48 (dd, 1H, J = 
8.3 and 2.0 Hz), 7.54 (t, 2H, J = 7.6 Hz), 7.61 (t, 1H, J = 7.2 Hz), 7.73 (d, 1H, J = 
8.4 Hz ), 7.95 (d, 1H, J = 2 Hz ), 7.84 (m, 2H). 13C-NMR (100 MHz, DMSO):   
21.39, 90.56, 123.89, 126.83 (2C), 127.03, 129.12, 129.32 (2C), 131.46, 
131.68, 132.24, 132.79, 137.57, 154.80, 167.27.  
2-(3,4-dichlorophenyl)-3-acetyl-5-(4-methoxyphenyl)-2,3-dihydro-
1,3,4-oxadiazole (4c) 
C17H14Cl2N2O3. Pale yellow crystals, M.p. 118-120°C (ethanol), MS 
(m/z) 364, yield 45%. CHN %: Calc. C, 55.91; H, 3.86; N, 7.67, Found C, 55.89; 
H, 3.86; N, 7.65 
1H-NMR (500 MHz, DMSO): 2.25 (s, 3H), 3.82 (s, 3H), 7.07 (d, 2H, J = 
9 Hz), 7.17 (1H, s), 7.45 (dd, 1H, J = 8.5 and 2.0 Hz), 7.71 (d, 1H, J = 8.5 Hz), 
7.75 (d, 1H, J = 2 Hz), 7.77 (d, 2H, J = 8.5 Hz). 13C-NMR (100 MHz, DMSO):   
21.32, 55.66, 90.16, 114.75 (2C), 115.93, 126.89, 128.69 (2C), 128.99, 
131.40, 131.61, 132.67, 137.67, 154.81, 162.29, 167.01. 
2-(3,4-dichlorophenyl)-3-acetyl-5-(4-methylphenyl)-2,3-dihydro-1,3,4-
oxadiazole (4d) 
C17H14Cl2N2O2. Pale yellow crystals, M.p. 120-122°C (isopropyl ether), 
MS (m/z) 348, yield 75%. CHN %: Calc. C, 58.47; H, 4.04; N, 8.02, Found C, 
58.50; H, 4.03; N, 8.05 
152 
 
1H-NMR (400 MHz, DMSO):  2.26 (s, 3H), 2.38 (s, 3H), 7.2 (s, 1H), 7.34 
(d, 2H, J = 8 Hz), 7.46 (dd, 1H, J = 8 and 2 Hz), 7.72 (m, 3H, J = 8, and 2 Hz), 
7.77 (d, 1H, J = 2 Hz). 13C-NMR (100 MHz, DMSO):  21.32, 21.38, 90.37, 
121.06, 126.83 (2C), 126.98, 129.07, 129.87 (2C), 130.17, 131.47, 132.76, 
137.63, 142.44, 154.94, 167.17.  
2-(3,4-dichlorophenyl)-3-acetyl-5-(4-chlorophenyl)-2,3-dihydro-1,3,4-
oxadiazole(4e) 
C16H11Cl3N2O2. Pale yellow crystals, M.p. 119-120°C (ethanol); MS 
(m/z) 367, yield 92%. CHN %: Calc. C, 51.99; H, 3.00; N, 7.58 Found C, 52.02; 
H, 3.02; N, 7.60 
1H-NMR (400 MHz, DMSO):  2.27 (3H, s), 7.22 (1H, s), 7.48 (1H, dd, J = 
8.4 and 2.0 Hz), 7.61 (2H, d, J = 8.8 Hz), 7.72 (1H, d, J = 8.4 Hz), 7.80 (1H, d, J 
= 2.0 Hz), 7.84 (2H, d, J = 8.8 Hz). 13C-NMR (100 MHz, DMSO):  21.39, 
90.88, 122.83, 127.10, 128.63 (2C), 129.17, 129.49 (2C), 131.44, 131.70, 
132.85, 136.88, 137.41, 154.02, 167.34.  
2-(3,4-dichlorophenyl)-3-acetyl-5-(4-nitrophenyl)-2,3-dihydro-1,3,4-
oxadiazole(4f) 
C16H11Cl2N3O4. Yellow crystals , M.p. 165-166°C (ethanol); MS (m/z) 
348, yield 47%. CHN %: Calc. C, 50.55; H, 2.92; N, 11.05 Found C, 50.53; H, 
2.91; N, 11.03 
1H-NMR (500 MHz, DMSO):  2.29 (3H, s), 7.26 (1H, s), 7.51 (1H, dd, J = 
8 and 1.5 Hz), 7.72 (1H, d, J = 8.5 Hz), 7.83 (1H, d, J = 2.0 Hz), 8.07 (2H, d, J = 
8 Hz), 8.35 (2H, d, J = 9 Hz). 
13C-NMR (100 MHz, DMSO):  21.38, 91.46, 122.51, 124.41 (2C), 
127.20, 128.12 (2C), 129.23, 129.83, 131.38, 132.94, 137.14, 149.25, 153.26, 
167.55.  
2-(3,4-dichlorophenyl)-3-acetyl-5-(4-N,N-dimethylaminophenyl)-2,3-
dihydro-1,3,4-oxadiazole(4g) 
C18H17Cl2N3O2. Yellow crystals , M.p. 156-158°C (isopropyl ether); MS 
(m/z) 377, yield 76%. CHN %: Calc. C, 57.16; H, 4.53; N, 11.11 Found C, 
57.18; H, 4.55; N, 11.13 
1H-NMR (400 MHz, DMSO): 2.23 (3H, s), 2.99 (6H, s), 6.77 (2H, d, J = 
8.8 Hz), 7.13 (1H, s), 7.43 (1H, dd, J = 8.4, and 2 Hz), 7.63 (2H, d, J = 9.2 Hz), 
7.72 (2H, m, J = 8.4 Hz). 13C-NMR (100 MHz, DMSO):  21.36, 39.80 (2C), 
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89.55, 109.72, 111.68 (2C), 126.85, 128.20 (2C), 128.94, 131.45, 131.61, 
132.58, 137.99, 152.58, 155.69, 166.68. 
2-(3,4-dichlorophenyl)-3-acetyl-5-(4-bromophenyl)-2,3-dihydro-1,3,4-
oxadiazole(4h) 
C16H11BrCl2N2O2. White cottony solid, M.p. 140-142°C (ethanol); MS 
(m/z) 411, yield 47%. CHN %: Calc. C, 46.41; H, 2.68; N, 6.77 Found C, 46.40; 
H, 2.69; N, 6.78. 
1H-NMR (400 MHz, DMSO): 2.27 (3H, s), 7.22 (1H, s,), 7.48 (1H, dd, J 
= 8.4 and 2.0 Hz), 7.72 (1H, d, J = 8.4 Hz), 7.76 (4H, m, J = 2.0 Hz), 7.79 (1H, d, 
J = 2 Hz). 13C-NMR (100 MHz, DMSO): 21.39, 90.88, 123.17, 125.77, 
127.10, 128.74 (2C), 129.17, 131.44, 131.70, 132.41 (2C), 132.85, 137.40, 
154.13, 167.34. 
2-(3,4-dichlorophenyl)-3-acetyl-5-(4-cyanophenyl)-2,3-dihydro-1,3,4-
oxadiazole (4i) 
C17H11Cl2N3O2. Pale yellow crystals, M.p. 148-150°C 
(ethanol/isopropanol); MS (m/z) 359, yield 86%. CHN %: Calc. C, 56.69; H, 
3.08; N, 11.67; N, 6.77 Found C, 56.68; H, 3.09, N, 11.68 
1H-NMR (400 MHz, DMSO):  2.28 (3H, s), 7.25 (1H, s); 7.50 (1H, dd, J = 
8.4, and 2.0 Hz); 7.72 (1H, d, J = 8 Hz), 7.83 (1H, d, J = 2.0 Hz), 7.99 (4H, m, J 
= 8.6 Hz). 13C-NMR (100 MHz, DMSO): 21.39, 91.34, 114.13, 118.30, 
127.22, 127.48 (2C), 128.23, 128.72, 129.25, 131.41, 131.73, 133.21 (2C), 
137.22, 153.51, 167.54. 
2-(3,4-dichlorophenyl)-3-acetyl-5-(2-methylphenyl)-2,3-dihydro-1,3,4-
oxadiazole (4j) 
C17H14Cl2N2O2. White solid, M.p. 147-150°C (hexane); MS (m/z) 348, 
yield 32%. CHN %: Calc. C, 58.47; H, 4.04; N, 8.02 Found C,58.49; H, 4.06; N, 
8.04 
1H-NMR (400 MHz, DMSO) :  2.43 (3H, s), 2.70 (3H, s), 7.45 (1H, s), 
7.54 (1H, t, CH, J = 7.33 Hz), 7.78 (1H, d, J = 7.6 Hz), 7.88 (1H, dd, J = 8.2 and 
2.2), 8.09 (1H, td, J = 7.6 and 1.5 Hz), 8.14 (3H, m). 13C-NMR (100 MHz, 
DMSO):  20.18, 23.11, 91.37, 126.39, 128.28, 128.39, 128.56, 128.95, 
129.71, 130.58, 131.34, 132.12, 132.98, 133.35, 136.50, 154.70, 157.99 
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3.3.2 Enantioseparation and X-ray crystal 
 
HPLC resolution of 4d-f. The enantioseparations of 4d-f were 
performed by using the stainless-steel Chiralpak IA (250 mm x 4.6 mm i.d. 
and 250 x 10 mm i.d.) (Chiral Technologies Europe, Illkirch, France) columns. 
All chemicals and solvents for HPLC were purchased from Aldrich (Italy) and 
used without further purification.The analytical HPLC apparatus consisted of 
a Perkin-Elmer (Norwalk, CT, USA) 200 lc pump equipped with a Rheodyne 
(Cotati, CA, USA) injector, a 20-l sample loop, a HPLC Dionex CC-100 oven 
(Sunnyvale, CA, USA) and a Jasco (Jasco, Tokyo, Japan) Model CD 2095 Plus 
UV/CD detector. For semipreparative separations a Perkin-Elmer 200 LC 
pump equipped with a Rheodyne injector, a 1 mL sample loop, a Perkin-
Elmer LC 101 oven and Waters 484 detector (Waters Corporation, Milford, 
MA, USA) were used. The signal was acquired and processed by Clarity 
software (DataApex, Prague, The Czech Republic). 
Circular dichroism. The CD spectra were measured in ethanol solution 
by using a Jasco Model J-700 spectropolarimeter. The concentration was 0.2 
mg/mL.  The optical path and temperature were set at 0.1 mm and 20°C, 
respectively. The spectra were average computed over three instrumental 
scans and the intensities were presented in terms of ellipticity values 
(mdeg). 
Polarimetry. Specific rotations were measured at 589 nm by a 
PerkinElmer polarimeter model 241 equipped with a Na/Hg lamp. The 
volume of the cell was 1 cm3 and the optical path was 10 cm. The system 
was set at 20 °C. 
Crystal structure determination for compound 4d. C17H14Cl2N2O2 
M=349.21, Monoclinic, space group P 21, a=9.095(1), b=6.552(1), 
c=13.870(1)Å, β=95.982(4), V=822.0(2)Å3, Z=2  Dc=1.415, =3.643mm-1, 
F(000)= 362. 3040 reflections were collected with a 4.8969.78 range 
with a completeness to theta 95.7%; 2307 were unique, the parameters 
were 213 and the final R index was 0.0446 for reflections having I and 
0.0689 for all data. A colourless prismatic shaped crystal (0.08x0.06x0.02) 
was used for data collection. Hydrogen atoms were assigned in calculated 
positions, except H2 (on asymmetric C2) which was found in the F.D map. 
RX-analysis was carried out with a Goniometer Oxford Diffraction KM4 
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Xcalibur2 at room temperature. Cu/K radiation (40mA/-40KV), 
monochromated by an Oxford Diffraction Enhance ULTRA assembly, and an 
Oxford Diffraction Excalibur PX Ultra CCD were used for cells parameters 
determination and data collection. The integrated intensities, measured 
using the ω scan mode, were corrected for Lorentz and polarization 
effects.102 Direct methods of SIR2004103 were used in solving the structures 
and they were refined using the full-matrix least squares on F2 provided by 
SHELXL97.104 Multi-scan symmetry-related measurement was used as 
experimental absorption correction type. The non-hydrogen atoms were 
refined anisotropically whereas hydrogen atoms were refined as isotropic. 
The X-ray CIF file for this structure has been deposited at the Cambridge 
Crystallographic Data Center and allocated with the deposition number 
CCDC 1030508. Copies of the data can be obtained, free of charge, from 
CCDC, 12 Union Road, Cambridge, CB2 1EZ UK (e-mail: 
deposit@ccdc.cam.ac.uk; http://www.ccdc.cam.ac.uk). 
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3.3.3 Enzymatic assay  
 
MAO inhibition measurements were evaluated following the general 
procedure previously described by us 86. Briefly, test drugs and adequate 
amounts of recombinant hMAO-A or hMAO-B (Sigma-Aldrich Quıímica S.A., 
Alcobendas, Spain) required and adjusted to oxidize 165 pmol of p-
tyramine/min in the control group, were incubated for 15 min at 37 °C in a 
flat-black-bottom 96-well microtest plate (BD Biosciences, Franklin Lakes, 
NJ) placed in the dark fluorimeter chamber. The reaction was started by 
adding 200 μM Amplex Red reagent (Molecular Probes, Inc., Eugene, OR), 1 
U/mL horseradish peroxidase, and 1 mM p-tyramine and the production of 
resorufin, was quantified at 37 °C in a multidetection microplate 
fluorescence reader (FLX800, Bio-Tek Instruments, Inc., Winooski, VT) based 
on the fluorescence generated (excitation, 545 nm; emission, 590 nm). The 
specific fluorescence emission was calculated after subtraction of the 
background activity, which was determined from vials containing all 
components except the hMAO isoforms, which were replaced by a sodium 
phosphate buffer solution. 
 
3.3.4 Molecular modelling 
 
MAO-B active site characterization. The previous reported1 
theoretical complex between the PDB MAO-B and the most active 
compound 2-(4-chlorophenyl)-3-acetyl-5-(4-chlorophenyl)-2,3-dihydro-
1,3,4-oxadiazole was considered for the active site characterization. The 
binding cleft was defined by means of a regular box of 1000 Å3 centred onto 
the ligand position. After removing the inhibitor, GRID90 software was 
applied for mapping the target previous defined using CL probe. Default 
software directives were taken into account except for the number of planes 
per Angstrom (NPLA) that was increased till 3 corresponding to a grid 
spacing equal to 0.333 Å. Computed isocontour maps were displayed using 
VMD ver. 1.9.1 105 and graphical inspected considering an energy threshold 
equal to -5.5 kcal/mol. 
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Docking protocol. Three-dimensional coordinates of the receptor29 
were obtained from the Protein Data Bank (PDB). The protein was processed 
and the internal hydrogen bonding network of the receptor was optimized 
using the algorithm implemented in Protein Preparation wizard.106 In order 
to compare energetic analysis it has been necessary to complete the 
transmembrane portion considering the aminoacid sequence and helix 
packing reported in literature.30,49 The mitochondrial bilayer membrane was 
simulated with an Dipalmitoylphosphatidylcholine (DPPC) bilayer.107 Three-
dimensional ligand structures for all docking experiments were built using 
Maestro GUI. Structures were optimized by means of energy minimization 
carried out using the Merck Molecular Force Field (MMFFs)108, the 
Generalized Born/Surface Area (GB/SA)109 water implicit solvation model 
and the Polak-Ribier Coniugate Gradient (PRCG) method, converging on 
gradient with a threshold of 0.05 kJ (molÅ)-1 as implemented in 
Macromodel. Molecular docking studies were performed using Glide SP,94 
Glide XP,95 QMPLD96, 97 and Induced Fit workflow protocol.98 Grids were 
defined around the refined structure by centring on co-crystallized ligand 
reported into the PDB entry 2V5Z.29  
Molecular dynamics. The docking resulting complexes were solvated 
with a box of TIP3P (Transferable Intermolecular Potential 3-Point) water110 
and counter ions were added creating an overall neutral system simulating 
approximately 0.15 M NaCl. The ions were equally distributed in a water 
box. The final system was subjected to a MD simulation up to 10 ns using 
Desmond.111 Restraint force of 50 kcal/(molÅ) was added to monomer and 
dimer transmembrane portion whereas the dimer in membrane was left 
without any restraint. The solvated models were optimized, and 
subsequently the MTK_NPT (Martyna-Tobias-Klein with constant Number of 
particles, Pressure and Temperature) ensemble was employed112. The 
default stages in the relaxation process for the NPT ensemble included two 
energy minimizations and four simulation steps. During the energy 
minimizations, two runs of 2000 iteration were processed using the steepest 
descent method: during the first run, the protein structure was fixed by a 
force restraint constant of 50 kcal/(molÅ) and in the second all restraints 
were removed. With the first simulation, at NVT (constant Number of 
particles, Volume, and Temperature) ensemble, the system reached a 
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temperature of 10 K. In the following three simulations in the NPT 
ensemble, the system was heated up to 325 K and the pressure was kept 
constant at 1 bar using the Berendsen thermostat–barostat. During the 
production phase, temperature and pressure were kept constant using the 
Nosè-Hoover thermostat–barostat. The energy and trajectory were 
recorded every 1.2 ps and 4.8 ps, respectively. For multiple time step 
integration, RESPA (REversible reference System Propagator Algorithm)113 
was applied to integrate the equation of motion with Fourier-space 
electrostatics computed every 6 fs, and all remaining interactions computed 
every 2 fs. All chemical bond lengths involving hydrogen atoms were fixed 
with SHAKE.114 Short range cut-off was set to 9 Å and the smooth particles 
mesh Ewald method (PME)115 were used for long range electrostatic 
interaction. The MD trajectories were analysed in terms of interaction 
energies and geometries. 
ADME-Tox prediction. The energy minimized ligands structures were 
evaluated for their drug-like properties using Qikprop102 which predicts 
physically significant descriptors and pharmaceutically relevant properties of 
organic molecules.116, 117  
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4 CHAPTER  
4.1 INTRODUCTION TO VP35 OF EBOLA VIRUS 
 
EBOV was first discovered in 1976 near the Ebola river in Zaire (now 
Democratic Republic of the Congo) and has re-emerged in the last decade 
with an increase of incidence and geographical extension of human 
outbreaks. In March 2014, largest and most complex outbreak was 
registered in several countries of West Africa with more than 28000 cases 
and 11000 deaths as of November 2015.1  
Ebola virus disease (EVD) is a severe, often fatal illness in humans 
caused by infection with negative-sense ssRNA viruses of the family 
Filoviridae, genus Ebolavirus.2, 3 This disease causes haemorrhagic fever in 
humans and non-humans primates. 
Five Ebolavirus species have been identified so far, four of which are 
known to be pathogenic to humans: Zaire ebolavirus (EBOV, formerly 
ZEBOV), Sudan ebolavirus (SUDV, formerly SEBOV), Taï Forest ebolavirus 
(TAFV, formerly Cote d’Ivoire ebolavirus, CIEBOV) and Bundibugyo ebolavirus 
(BDBV, formerly BEBOV). The fifth species, Reston ebolavirus (RESTV, 
formerly REBOV), has caused disease in non-human primates but not in 
humans.4 
 
 
Figure 1. Electron microscope image showing ultrastructural morphology assumed by 
filamentous virion ZEBOV (F.E. Murphy, CDC). 
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Death from EBOV infection is associated with markedly impaired 
coagulation and innate immunity cascades, increased production of pro-
inflammatory cytokines, profound immune suppression resulting in 
peripheral T lymphocyte apoptosis and a lack of adaptive immunity.5 The 
success of EBOV replication is dependent on viral inhibition of initial innate 
immune responses to infection. Disarming innate immune responses is a 
common mechanism employed by highly pathogenic human viruses,6 and 
EBOV is one of the most successful in evading innate immune interference. 
EBOV is introduced into the human population through close contact 
with the blood, secretions, organs or other bodily fluids of infected animals 
such as chimpanzees, gorillas, fruit bats, monkeys, followed by subsequent 
human-to-human transmission.7 In response to the 2014 EVD outbreak, a 
human trial campaign has been prompted and is currently underway for 
several vaccine platforms.8-11 There is as yet no licensed treatment proven 
to neutralise the virus but a range of blood, immunological and drug 
therapies are under development. These include a monoclonal antibody 
cocktail known as ZMapp, small interfering RNA molecules and 
phosphorodiamidate morpholino oligomers such as the TKM-Ebola and the 
AVI-7537 respectively, or nucleotide/nucleoside analogues like Favipiravir 
and BCX-4430, as well as other small-molecule inhibitors such as 
Brincidofovir.12 
In humans, EBOV haemorrhagic fever often results in very high 
mortality rates, reaching 90% for the most lethal species such as Zaire 
ebolavirus (ZEBOV). Early events in EBOV infection influence the patient’s 
ability to develop an effective immune response. In fact, survivors to EBOVs 
infection seem to develop an effective immune response.13, 14 This suggests 
that events early in the EBOV infection may influence the patients’ ability to 
activate an effective immune response.15,16 Hence, the development drug 
targeting EBOV specific enzymes would be advantageous. 
EBOV genome is about 19 kb long and includes 7 genes arranged in 
tandem 9 coding for viral proteins , including 7 structural and 2 non-
structural. 
Starting at the 3' to the 5' of the genome we can find the NP gene, 
coding for the nucleoprotein of the same name; VP35 (Viral Protein 35), 
encoding for the homonymous polymerase cofactor; VP30, whose gene 
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product is a transcriptional cofactor; GP , coding for the only surface 
glycoprotein and, through a process of RNA editing for 2 glycoproteins 
soluble SGP and ssGP; VP24 and VP40, encoding for the two matrix proteins; 
L, coding for the catalytic subunit of the complex-RNA-dependent RNA 
polymerase (RdRp). The 7 genes are separated by intergenic regions 
transcribed and untranslated, and two regulatory regions leader and trailer 
which appear respectively at the end of the genome in the 3 'and 5'.17, 18 
 
 
Figure 2. VP35 genome organization. 
 
Once inside the cytoplasm of the host cell, the EBOV suppresses the 
host innate immune system via VP35 and VP24 proteins.15 
VP35 is a multifunctional protein that is indispensable for EBOVs 
replication. In fact, VP35 is an essential cofactor of the EBOV RNA 
polymerase complex,19-21 it serves as a nucleocapsid viral assembly 
factor,22,23 it is a RNAi suppressor in mammalian cells.24,25 
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Furthermore, VP35 is directly involved in neutralizing the host innate 
immune response by blocking, at many different steps, the production of 
IFNs-a/b. For the latter, VP35 acts, at least in part by sequestering viral 
dsRNA from recognition by a set of cellular helicases termed RIG-I-like 
receptors (RLRs)(Figure 3).26 
 
 
Figure 3. Schematic representation of the inhibition of Interferon induced by VP35: VP35 
inhibits the binding of ds-RNA to RIG-I and by doing this, it prevents the induction of 
Interferon and consequently the immune response.  
 
In fact, since cytoplasmic dsRNA has no homologues within cellular 
nucleic acids, RLRs recognize it as a signature of non-self, promptly 
activating a signalling cascade that culminates in the production of IFN-α/β.6 
However, sequestration of dsRNA by EBOV VP35 acts upstream by 
subverting the RLRs signalling pathway and ultimately suppressing host IFN-
α/β production, and consequently immune system activation.26,6 
Basic and hydrophobic amino acid residues involved in such 
interactions are highly conserved among all EBOVs and form a positively 
charged pocket at the VP35-dsRNA interface. Mutation into alanine of 
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critical residues within this domain, such as R312 and K339, resulted in the 
loss of VP35 dsRNA binding activity and loss of EBOV IFN suppression 
capabilities in cellular assays.26 EBOV variants bearing these amino acid 
mutations failed to inhibit IFN-α/β production and exhibited no virulence in 
infected animals, further demonstrating the importance of VP35 dsRNA 
binding-mediated IFN-antagonism for EBOV pathogenesis.26 Therefore, VP35 
is a validated and attractive target for the development of strategies to 
counter EBOV diseases. 
Hence, in order to define their impact on dsRNA end-capping and IFN-
antagonism function, we performed here a structure-based alanine scanning 
mutagenesis of VP35 residues involved in this interaction. Data collected, 
together with computational studies, allowed the identification of a defined 
site important for prospective drug design against immune suppression 
function of EBOV VP35. 
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Figure 4. Project workflow. 
 
4.2 DEFINITION KEY RESIDUES IN dsRNA RECOGNITION OF 
VP35 
 
4.2.1 dsRNA binding property of Ebola VP35 end-capping mutants 
 
The analysis of the primary and secondary structure of VP35 has 
allowed to identify the existence of at least two different regions, an N-
terminal region and a C-terminal region. 
The N-terminal region comprises amino acids 1-221 and contains a 
domino coiled-coil involved in the process of homo-oligomerization of the 
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protein. It is important for viral replication and for the formation of the 
nucleocapsid (Figure 5a). 
The C-terminal region corresponds instead to approximately one third 
of the entire amino acid sequence (residues 221-340) and is of great 
importance as it is responsible for the interaction with the protein NP and 
with dsRNA. 
 
Figure 5. EBOV VP35 structure a) schematic representation of VP35 domains; b) VP35 
RBD/IID crystal structure (pdb code 3FKE
27
) and asymmetric dimer of VP35 RBD/IID-dsRNA 
(pdb code 3L25
28
). 
The crystallographic structures of EBOV and RESTV VP35 RBD/IID 
bound to blunt-ended dsRNA show a dimeric complex of two RBD/IID 
arranged to interact with the nucleic acid through asymmetric dimer with 
surfaces that describe a backbone-binding monomer and an end-capping 
one.29,26, 28 A recent work described the kinetics in which dsRNA binding by 
the end-capping RBD/IID monomer constitutes the earliest binding event, to 
which attachment of backbone-binding RBD/IID monomers all along the 
dsRNA helix follows.30 Within this picture, a small area interacting with 
dsRNA terminal bases in the concave surface of the end-capping RBD/IID 
monomer represents the most suitable target for small molecule inhibitors 
design. In fact, selected residues laying in this area, like F239, or surrounding 
it, such as R312, K319, R322 and K339 were found critical for RBD/IID dsRNA 
binding and IFN inhibition, as their mutation into alanine resulted in a 
decrease, or even a total loss, of those functions.26, 28, 31-37 
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In our previous efforts to characterize a bacterially-expressed full 
length EBOV rVP35 (recombinant VP35),38 we also investigated the impact of 
rVP35 mutants at residues involved in dsRNA backbone interactions, namely 
R305A, K309A and R312A, on dsRNA binding ability.37 Here, we wanted to 
explore the role, relevance and potential effect of the residues involved in 
dsRNA end-capping and, to this aim, we performed alanine-scanning in vitro 
site-directed mutagenesis of rVP35 residues L277, I278, I280 (hydrophobic), 
S272, Q279, T281 (polar uncharged), K282 (polar charged) together with the 
previously studied F239, Q274, K319, R322, K319/R322 and K339 residues.26, 
28, 31-37 
 
 
Figure 6. In vitro site-directed mutagenesis: mutated residues are indicated in different 
colors: orange: end-capping residues monomer B, pale orange: corresponding backbone 
residues in monomer A; blue: charged residues interacting with last portion of dsRNA in 
monomer B; light blue: corresponding residues in monomer A involved in backbone binding 
; yellow and pale yellow alpha helix cleft which include residues I278 and K282 that are 
involved in end capping interactions (L277-K282) respectively in monomer B and A. 
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Once all rVP35 mutants were expressed and purified as previously 
described,38 to assess their proper folding and exclude that any difference in 
dsRNA binding might have been imputable to major structural 
perturbations, we performed a differential scanning fluorimetry (DSF) 
analysis comparing the thermal stability of full length wt and mutants rVP35. 
Interestingly, all rVP35 mutants showed melting temperature (Tm) values 
comparable to wt rVP35 (59.4 ± 0.6 °C), which suggests maintenance of 
proper folding and no structural perturbations beyond minimal local 
changes (Table 1).  
Secondly, by using a previously described magnetic pull down assay,37 
we assessed the dsRNA binding activity of rVP35 mutants through an 
homologous-competition binding curve titration with an in vitro transcribed 
(IVT) 500 bp dsRNA as ligand. Results showed that EBOV rVP35 end-capping 
mutants were impaired in dsRNA binding function, having no measurable Kd 
values or even poorly detectable activity with percentages ranging from 
0.8% to 6% of bound dsRNA with respect to wt rVP35 (Figure 8).  
 
 
Figure 7. Thermal stability of wt and mutants rVP35. 
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Table 1. Thermal stability of wt and mutants rVP35. Tm values obtained by 
DSF analysis on rVP35 wt and mutants. Data shown are the mean ± SD of 
three independent experiments performed in triplicate samples. 
VP35 protein Tm [°C] 
wt 59.4 ± 0.6 
F239A 59.7 ± 0.2 
S272A 59.0 ± 0.4 
Q274A 60.6 ± 0.6 
L277A 58.8 ± 0.5 
I278A 61.3 ± 1.2 
Q279A 60.0 ± 0.6 
I280A 56.5 ± 0.9 
T281A 58.3 ± 0.6 
K282A 59.4 ± 0.3 
K319A 58.2 ± 0.6 
R322A 60.3 ± 1.0 
K319A/R322A 58.0 ± 0.4 
K339A 59.2 ± 0.5 
 
Figure 8. dsRNA binding ability of EBOV rVP35 backbone and end-capping mutants. 
Relative dsRNA binding activity of rVP35 backbone (white dotted) and end-capping (black 
dotted) mutants expressed as percentage of the total amount of dsRNA bound by wt rVP35 
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Only exceptions were, Q274A, R322A and K319A/R322A rVP35 
mutants, which were able to bind the IVT 500 bp dsRNA even though with 
lower affinity (increased Kd values) with respect to wt rVP35. In particular, Kd 
values for wt, Q274A, R322A and K319A/R322A rVP35 mutants were 2.6 ± 
0.3 nM, 5.23 ± 1.8 nM, 9.13 ± 1.5 nM and 15.62 ± 2.0 nM, respectively. 
According to these data, rVP35 dsRNA binding activity was highly 
compromised by the change of a single amino acid residue in the end-
capping binding surface. 
Utilizing for the first time a full-length VP35 protein, binding 
experiments performed with the magnetic pull down assay, they showed 
that minimal changes on the surface electrostatic charge in the protein 
pocket that houses the dsRNA terminus – such as those that may come from 
the alanine substitution of residues that interact with terminal bases or 
phosphate groups – may result in significant decrease, if not in total loss, of 
dsRNA binding activity in biochemical assay. In fact, while Q274 rVP35 
mutant showed a 2-fold decreased binding affinity with respect to wt rVP35, 
for most of the tested end-capping mutants, including F239A, I278A, Q279A, 
I280A, T281A, K319A and K339A rVP35, the amount of bound dsRNA was 
barely detectable. Interestingly, and in substantial agreement with what was 
observed for the backbone binding R312A mutant, the absence of dsRNA 
binding activity previously reported for the R322A and K319A/R322A VP35 
RBD26,39 was partially restored in our full length rVP35 proteins that bear the 
same mutations, even though with affinities that were respectively 3-fold 
and 5-fold lower when compared to wt rVP35. Possibly, this greater 
efficiency in dsRNA binding displayed by full length VP35s with respect to 
the RBD alone may reflect the critical contribution of regions lacking in the 
sole RBD that might have a role in stabilizing or strengthening other 
domains of the protein during exertion of their function. Previous 
crystallographic studies on VP35 RBD mutants focused on the effects of 
mutations in charged residues, showing that the loss of affinity for dsRNA in 
these mutants is due to changes in the electrostatic surface potential.26  
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4.2.2 Molecular modeling   
 
In order to achieve a deeper understanding of the molecular basis of 
our observations, we integrated the dsRNA binding data with a 
computational study with the purpose of identifying a VP35 region suitable 
as a site for drug design. In particular we wanted to investigate the 
contribution of these mutations on the two VP35 monomeric binding 
surfaces (i.e backbone and capping), to select key residues involved in the 
EBOV VP35 dsRNA binding function. In fact VP35 dimer is asymmetric. 
Hence the question arisen is if it is possible to weight the importance of 
mutated residues in end-capping vs backbone ones. This enquiry could not 
be answered by the biochemical assay. 
In recent years, molecular dynamic (MD) simulations combined with 
binding free energy calculations have been applied successfully to 
understand the behaviour of protein complex structures in solution 
(protein-ligand, protein-protein, protein-RNA interactions) and guide the 
drug design.40 
In light of this, we performed computational studies to understand the 
molecular basis of the effects of selected VP35 amino acid mutations. 
Firstly, we investigated the effect of 5’-ppp portion by adding the 
triphosphate moiety to the crystallographic model.26 Once minimized, the 
complex VP35-dsRNA was subjected to MD simulation, finding the 
formation of a more stable complex as compared to the original one without 
5’-ppp portion (-197 kcal/mol vs -175 kcal/mol). These results are in 
agreement with previous experimental studies that revealed the importance 
of 5’-ppp.6 In fact, in the MD simulation the 5’-ppp appears to be stabilized 
by an array of hydrophobic, hydrogen  bonds and ionic interactions. Once 
validated this modified model to properly assess EBOV VP35 selectivity for 
5’-ppp-dsRNA versus dsRNA, we used it as starting point for all successive 
MD simulations where single amino acids (except double mutated 
K319A/R322A) have been mutated in alanine.  
During MD simulations, the trajectories were monitored from the 
convergence of the Root-Mean Square deviation (RMSD) of all atoms in the 
EBOV VP35-dsRNA complex. All systems resulted stable during MD 
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simulation (Figure 9), with an overall RMSD fluctuating in the range of 0.5 
nm, indicating that the system is indeed equilibrated.  
 
 
Figure 9. MD simulations. Root-Mean Square Deviation (RMSD) of VP35–dsRNA complexes 
during MD simulations. All systems resulted stable during MD simulation. 
 
All mutants maintained the backbone conformation of wt EBOV VP35, 
free and in complex with dsRNA. This confirms the observations done by 
crystallographic experiments reported in PDB [R312A, PDB: 3L27; K339A, 
PDB:3L28, 26 K319A/R322A, PDB:3L2939]. For all VP35 mutants, MD analysis 
showed a decreased stability of the complexes, given the increased energy 
with respect to wt (Table 2).  
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Table 2. Energetic stability of wt and mutants EBOV VP35-dsRNA 
complexes. All mutations showed a decreased energetic stability of the 
complexes, given the energy increase with respect to wt. 
 ΔE (kcal/mol) 
ΔE
mut
-ΔE
wt
 
Wild-type -197,20  
I278A -195,79 -1,41 
L277A -193,87 -3,32 
T281A -190,23 -6,96 
R312A -190,22 -6,98 
K319A -188,56 -8,64 
S272A -182,84 -14,36 
F239A -170,47 -26,73 
K339 -168,92 -28,28 
K319A/R332A -167,48 -29,72 
Q274A -164,11 -33,09 
R305A -163,68 -33,52 
R322A -157,58 -39,62 
I280A -155,31 -41,89 
K309A -148,88 -48,32 
K282A -143,18 -54,02 
Q279A -140,81 -56,39 
 
Decomposing the total energy interaction (Etot) into major 
components we found that electrostatic factor provides the main driving 
force of binding affinity (Figure 10). This could be easily interpreted since 
many of the mutated important residues have electrically charged or polar 
side chains. The only exceptions were F239, L277, I278A, I280A and T281A. 
These mutants were not associated to particular electrostatic changes and 
MD simulations showed only subtle differences in the complex side chain 
conformations. 
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Figure 10. Calculated averages of ΔE and its major components (ΔEvdw and ΔEele) expressed 
in kcal/mol of the wild type(3L25) and mutated VP35–dsRNA complexes, based on the 
frames of MD trajectories. 
 
Therefore their importance should probably be attributed to the loss 
of contacts with dsRNA. Hence, we investigated i) the loss of contacts 
between the mutant VP35s and the whole dsRNA (Figure 11a), ii) the loss of 
contacts between the single mutated amino acid in both backbone binding 
monomer (chain A) and end-capping monomer (chain B) together (Figure 
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11b) and iii) for single chain A (Figure 11c) and chain B separately (Figure 
11d). The analysis of the overall loss of contacts showed that all mutations 
are associated with fewer contacts between VP35 and the whole dsRNA 
(Figure 11a).  
The decomposition analysis of contacts loss of backbone vs end-
capping binding monomers did not show a univocal behaviour for all 
residues. However, for K282A and R322A VP35 mutants the loss of affinity 
for dsRNA is due exclusively to the contacts loss between these two residues 
in the end-capping binding monomer and dsRNA (Figure 11d), for other 
residues the loss of contacts is higher for end-capping monomer B: Q279A, 
R305A, F239A, S272A, I278A.  
In addition, MD analysis showed that some residues that impaired 
VP35 affinity for dsRNA such as K319, I280 and T281 were not involved 
directly with interactions with dsRNA. However, their localization in chain B 
is closer to dsRNA with respect to chain A, therefore their mutations in the 
end-capping position appear to be more important than that in backbone-
binding. Overall, we conclude that the effects of mutation of the B-chain 
residues involved in end-capping binding is more important than the effect 
of the same residues when they are involved in backbone binding. 
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Figure 11. Number of contacts loss between the mutated enzyme and dsRNA. a) Loss of 
good contacts between VP35 RBD and the whole dsRNA; b) Loss of good contacts between 
the mutated residue (both chains A and B) and dsRNA; c) VP35 RBD loss of good contacts 
between specific residues mutated in chain A (backbone-binding) and dsRNA; d) VP35 RBD 
loss of good contacts between specific residues mutated in chain B (end-capping-binding 
backbone-binding). 
 
To summarize computational results, firstly we have confirmed the 
possibility of modeling the VP35 interaction with dsRNA by showing the 
importance of 5’-ppp portion for a more stable VP35:dsRNA complex 
compared to the crystal (without 5’-ppp) and, secondly, we have shown that 
- investigating the contacts loss between the mutant VP35s and the whole 
dsRNA - the effect upon mutation on the monomer involved in end-capping 
binding seems to be more important than the one involved in backbone 
binding monomer. Moreover, it was determined that the electrostatic 
component provides the main driving force of binding affinity. In fact, most 
of the important mutated residues have electrically charged or polar side 
chains. We can then define a region that could be targeted by small 
molecules delimited by hot spots (determinant) amino acids. But first we 
investigated the effect of mutants in RIG-I-mediated signaling cascade 
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measuring the IFN-B inhibition to confirm the key residues also with cellular 
assay. 
4.2.3 IFN-β inhibition property of EBOV VP35 mutants 
 
EBOV VP35 interferes at various levels the RIG-I-mediated signaling 
cascade that leads to the type I IFN production, ultimately allowing 
uncontrolled viral replication.32 To assess the effect of end-capping 
mutations on the ability of EBOV VP35 to suppress type I IFN induction in 
cellular systems, a reporter gene assay was carried out that uses Influenza A 
virus (IAV) dsRNA transfection as a stimulus for RIG-I signaling pathway 
culminating in the activation of the IFN-β promoter.41 When A549 cells were 
co-transfected with IFN-β reporter vector and increasing amounts of 
plasmid expressing EBOV VP35 wt or mutants, we observed a dose-
dependent inhibition of the dsRNA-stimulated, RIG-I-mediated IFN-β 
production by EBOV VP35 wt (Figure 12). Hence, we tested the IFN-
antagonism ability of EBOV VP35 end-capping mutants transfecting the 
VP35 carrying plasmids at different concentration to assess the relative 
impairment of the mutant VP35s IFN-antagonism function. Since the assay 
herein used is different from those previously described, we firstly assayed 
VP35 mutants R305A, K309A and R312A to properly compare our results 
with those previously reported.32,34,35,27  
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Figure 12. The dose dependent inhibition of the vRNA RIG-I pathway activation by EBOV 
VP35 wild type. A549 cells were co-transfected with 250 ng of pGL IFN-β luc and various 
amount (1.6, 8, 40, 200 and 1000 ng) of pcDNA3-ZEBOV-VP35 wild type. 24 hours post 
transfection cells were additionally transfected with 250 ng of IAV RNA and after additional 
6 hours cells were lysed and luciferase activity was measured. Inhibition of luciferase 
expression was indicated as percentage of induced control. The error bars indicate standard 
deviation from three independent experiments. 
 
The obtained results on these three mutants showed that K309A have 
a moderate and R312A a significant reduction in IFN-antagonist activity, 
while R305A does not affect this function, confirming previous reports 
(Figure 13).32,35 Secondly, we tested all other VP35 mutants showing that 
F239A, S272A, Q274A, L277A and Q279A VP35 mutants substantially 
maintained an IFN-antagonist ability comparable to the one showed by wt 
VP35 (Figure 13). Differently, I278A, I280A, T281A, K319A, K339A mutants 
exhibited a strong reduction in IFN-antagonism ability. The reduction was 
statistically significant at lower VP35 mutant plasmid concentrations, 
suggesting that these VP35 mutants can compensate dsRNA binding affinity 
reduction at higher protein concentrations. Most relevantly, similarly to 
R312A VP35, K282A and R322A VP35s showed the strongest reduction in 
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VP35 IFN-antagonist ability, statistically significant even at the highest 
tested VP35 plasmid concentration (Figure 13).  
 
 
Figure 13. Luciferase reporter RIG-I-mediated IFN-β activation gene assay inhibition of 
EBOV VP35 wild type and mutants. A549 cells were co-transfected with 250 ng of pGL IFN-
β luc and 1000 (black), 200 (black dotted), 100 (grey dotted) and 40 ng (white dotted) of 
pcDNA3-ZEBOV-VP35 wild type and end-capping mutants. 24 hours post transfection cells 
were additionally transfected with 250 ng of IAV RNA and after additional 6 hours cells 
were lysed and luciferase activity was measured. Inhibition of luciferase expression was 
indicated as percentage of induced control. Data are average of three independent 
experiments, with error bars representing standard deviation (* p value < 0.05). 
 
An exception case is the one of K319A/R322A VP35 mutant that 
showed a reduction of the IFN-antagonist ability only at the intermediate 
plasmid concentrations. The dose dependent inhibition of the vRNA RIG-I 
pathway activation allowed to determine the plasmid concentration 
required to reduce the IFN-β promoter induction by 50% (ICp50) value, for all 
tested VP35s. Compared to the wt VP35 ICp50 value of 110 ± 4.9 ng, I278A, 
I280A, T281A, K319A, and K339A VP35s exhibited a significant increase in 
their ICp50 values comprised in the range of 150-170 ng (p < 0.05), while 
R312A, K282A and R322A mutants exhibited higher ICp50 values (517 ± 28.2 
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ng, 584 ± 49.4 ng and 663 ± 60.3 ng, respectively, with p < 0.05), 
demonstrating the criticality of these three single amino acid mutations for 
the inhibitory activity of the protein (Table 3). It is worth to note that 2 out 
of 3 VP35 mutants that showed the strongest reduction in IFN-antagonist 
efficacy in cell-based assays, R312A and R322A, maintained an although 
reduced capability of binding dsRNA in biochemical assays (Figure 8). 
 
Table 3. Wt and mutant EBOV VP35s IFN-β promoter induction inhibition 
VP35 protein 
a
ICp50 [ng] 
wt  110 ± 4,9  
R305A  88 ± 15,5  
K309A  146 ± 4,8  
R312A  517 ± 28,2  
F239A  143 ± 1,9  
S272A  59 ± 8,1  
Q274A  89 ± 1,8  
L277A  85 ± 9,4  
I278A  151 ± 0,5  
Q279A  100 ± 8,2  
I280A  157 ± 11,4  
T281A  166 ± 6,2  
K282A  584 ± 49,4  
K319A  169 ± 6,3  
R322A  663 ± 60,3  
K319A/R322A  177 ± 16,8  
K339A  173 ± 17,3  
 
In contrast, other VP35 mutants such as F239A, S272A, Q274A, L277A, 
I278A, I280A, T281A, K319A, and K339A that showed no or limited reduction 
of their IFN-antagonist efficacy in cell-based assays almost completely lost 
their dsRNA binding ability in biochemical assays (Figure 8). A number of 
reasons could be involved to explain these observations: i) some of the 
mutated VP35 amino acid residues, such as F239, Q274, I278 and K339, 
participate in both end-capping and backbone-binding VP35 monomers; ii) it 
is not clear at the moment if the magnetic binding assay with rVP35 involves 
monomeric, dimeric, multimeric (or a mixture of them) VP35 forms, and 
whether these forms have different responses to alanine scanning 
mutagenesis; iii) some of the mutated VP35 amino acid residues participate 
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in both protein–RNA and protein–protein interactions with cellular proteins 
involved in the RIG-I pathway and the loss of one of the two functions is not 
sufficient to impair the VP35 inhibition. 
Comparing the biochemical and cellular data, it is clear that the loss of 
dsRNA binding capacity by some mutants is not necessarily manifested in a 
loss of VP35 IFN-antagonism. In fact, it is known that VP35 also interacts 
with PACT (PKR activator), leading to the inhibition of PACT-induced RIG-I 
ATPase activity,42 it interacts with the TBK-1/IKK-ε kinases complex 
suppressing the activation of IRF-3,43 and it was reported that, when the 
IFN-β production is activated by a dsRNA-independent mechanism, the 
mutated R312A, R322A and K339A VP35 showed reduced suppression of 
IFN-β production.32,26 On the contrary, the mutated F239A VP35, which lost 
the dsRNA-binding function, preserved the dsRNA-independent IFN-
inhibitory property.26 These results suggest that the loss of the dsRNA 
binding ability by some amino acid substitutions may not impair the protein-
protein interactions among others components of RIG-I signalling pathway, 
which explains the discrepancy between our biochemical and cellular data. 
Overall, therefore, we can classify these VP35 mutants in 3 categories:  
i) VP35 mutants that show a reduced dsRNA binding ability in 
biochemical assay but retain IFN-antagonism in cell culture 
assay such as F239A, S272A, Q274A, L277A and Q279A, 
probably retaining a dsRNA-binding independent inhibition 
mechanism;  
ii) VP35 mutants that show a reduced dsRNA binding ability in 
biochemical assay as well as a reduced IFN-antagonism in cell 
culture assay at lower level of protein expression but they 
retain IFN-antagonism functions at higher level of protein 
expression, such as I278A, I280A, T281A, K309A, K319A, 
K319A/R322A and K339A, suggesting that they can 
compensate dsRNA binding affinity reduction at higher protein 
concentrations;  
iii) VP35 mutants that show a reduced dsRNA binding ability in 
biochemical assay and show a reduced IFN-antagonism in cell 
culture assay even at higher level of protein expression such 
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as R312A, K282A and R322A, proving to be involved also in 
dsRNA-binding independent inhibition mechanism. 
In any case, the overall biochemical and cellular analysis of the results 
showed that a number of the selected VP35 amino acid residues such as 
I278A, I280A, T281A, K319A, K319A/R322A and K339A, and in particular 
R312A, K282A and R322A, significantly reduced VP35 ability to inhibit vRNA 
induced RIG-I pathway activation. 
4.2.4 Conclusions 
 
The multifunctional viral protein EBOV VP35 is a validate drug target 
since it is one of the most potent weapons that EBOV uses to evade the 
innate immune antiviral response.44 In the context of EBOV infection, loss of 
VP35 dsRNA binding and IFN-antagonist functions results in severely 
impaired virus replication in cells capable of mounting an IFN-α/β response 
and also fully attenuates the virus in vivo.33,39 Moreover, point mutations in 
VP35 that impaired dsRNA binding abolished VP35–PACT interaction and 
VP35 became unable to disrupt PACT–RIG-I interaction. This generated a 
loss of VP35 inhibition of PACT-facilitated activation of RIG-I.44,42 
Previous studies reported that some residues comprised in the end-
capping domain have critical roles in dsRNA binding wt EBOV VP3526,27 and 
mutational studies have confirmed their implication in loss of dsRNA binding 
ability32,27,26,36,37 as well as in suppression of IFN-β induction. 32,33,34,26,27,36  
Overall, the set of data obtained with mutational studies with the three 
methods (biochemical, computational and cellular) allowed us to highlight 
the importance of some residues involved in end-capping binding and are 
localized in a delimitated area (Figure 14), where the most important 
residues appear to be the R312, K282 and R322. Noteworthy, the overall 
data analysis suggests that this site could be involved not only in VP35 
dsRNA binding but also in VP35 interaction with other cellular proteins 
involved in the RIG-I pathway. Therefore, this site seems to be an attractive 
target to develop drugs that can impede the VP35 impairment of the IFN 
activation and could be used in future studies in order to find small 
molecules able to inhibit EBOV VP35. 
 
199 
 
 
Figure 14. Hot spots of VP35 surface. Residues are coloured in order of importance: red 
(R312, K282 and R322) > orange (I278, I280, T281, and K339) > yellow (K309 and K319) > 
green (R305, F239, S272, Q274, L277 and Q279) according to p value. It is possible to 
highlight a binding site useful for drug design delimited by yellow circle. 
 
4.3 VIRTUAL SCREENING 
 
VP35 is a validate drug target and we have already remarked the 
strategic role in evading the innate immune antiviral response.44 Thus the 
inhibition of VP35 could lead to restore the ability of human immunity 
system to fight against EVD. Probably this would also means to reduce the 
mortality caused by EBOV infection. 
Hence there is an urgent need of weapons to win against this target. 
Therefore we carried out a Virtual screening aiming at finding drug 
candidates able to inhibit VP35 and in particular the formation of the 
complex with dsRNA. 
Recently, another group published a virtual screening targeting VP35 
but the protein-protein interaction with NP protein. In this work some 
compounds were found to inhibit VP35–NP interaction with affinities (Kd ) 
<100 μM.45, 46 
Our strategy was different. Previous studies highlighted that end-
capping RBD/IID monomer constitutes the earliest binding event, to which 
attachment of backbone-binding RBD/IID monomer follows.30 Furthermore 
in the previous paragraph we have studied several mutations and, with the 
support of computational studies, we have demonstrated the importance of 
end-capping residues (Figure 14). 
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The emergence of the outbreak registered in several countries of West 
Africa last year obligates a rapid response, thus we decided to screen the 
FDA approved drugs Database.47 Drug repositioning is an interesting 
approach with more and more success stories available in literature.48 In 
fact, the finding that many drugs interact with more than one target 
provided the rationale behind the selective optimization of side activities 
(SOSA) approach recently developed.49, 50 
First we applied a pharmacophore filter by means of LigandScout 
program.51, 52 This approach, as it was highlighted in the first chapter offers 
several advantages and it is a fast tool useful to perform rapid and reliable 
VS.53, 54 Furthermore in literature there are plenty of success stories were 
structure-based pharmacophore was applied alone or in combination.55-61 
Since we aim to find molecules that bind the end-capping region to avoid 
the dsRNA binding, structure-based pharmacophore was generated 
considering the terminal portion of dsRNA as “core molecule”. In particular 
the lowest energetic frame of MD simulation of wt 5’-pppVP35-dsRNA 
complex was selected as starting structure. The pharmacophore was applied 
to screen the prepared FDA Database containing all the approved drugs 
available in the market. Selected compounds were then minimized and 
docked considering three different protocols: GlideXP,62 QMPLD63, 64 and 
Autodock.65, 66 Best pose of each compound was then subjected to a post-
docking procedure considering eMBrAcE.67 In this way we have rescored the 
docking poses obtained with different docking programs using the same 
procedure. eMBrAcE applies multiple minimizations, during which each of 
the specified pre-positioned ligand is minimized with the receptor. By 
calculating a consensus score we ranked the compounds and selected 9 hits. 
These were purchased and tested in cells assay for their ability to inhibit 
VP35.  
Preliminary data show that two of the compounds are active in the 
low micromolar range. 
Due to the novelty of this target and the importance of the results 
obtained we cannot show their structures. In fact, up to now, these 
compounds are the only ones acting with this mechanism and showing to 
inhibit VP35 at low concentration. For the same reason the virtual screening 
is not described in details.  
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Figure 15. VS workflow 
 
4.3.1 Conclusions 
 
In conclusion we have demonstrated the ability of the combination of 
two structure-based approaches in selecting good hits. We are going to 
perform other biological tests to confirm the activity and the mechanism. 
We will then perform a further selection of similar compounds to 
confirm the importance of the scaffolds and to derive structure activity 
relationships to guide the optimization process. Starting from approved 
drugs the process for their development should be easier and less 
expensive. 
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4.4 EXPERIMENTAL PART 
 
4.4.1 EBOV VP35 wt and mutant plasmids 
 
Cloning of the EBOV VP35 gene into pET45b(+) vector (Novagen) to 
obtain the pET45b-ZEBOV-VP35 plasmid was previously described.38 The 
QuickChange II Site-Directed Mutagenesis kit (Agilent technologies) was 
used to obtain corresponding mutant plasmids by introducing in the EBOV 
cDNA VP35 gene sequence previously described single point mutations 
R305A, K309A, R312A37 and new mutations F239A, S272A, Q274A, L277A, 
I278A, Q279A, I280A, T281A, K282A, K319A, R322A, K319A/R322A and 
K339A. 
 
4.4.2 EBOV VP35 wt and mutants mammalian expression plasmid  
 
To introduce its sequence into a mammalian expression vector, we 
amplified cDNA of the EBOV VP35 gene (GenBank: NC) previously cloned in 
the pET45b-ZEBOV-VP35 vector38 (Zinzula et al., 2009), by polymerase chain 
reaction (PCR). Primers were designed to amplify the gene and subclone it 
into the pcDNA3 mammalian expression plasmid (Invitrogen) by BamHI and 
NotI restriction enzymes. Primer sequences were: 5’-
TCAGCAGAGGATCCGATAATGCATCACCACCACCATCAC-3’ and 5’-
GTACTAATATGCGGCCGCTCAAATTTTGAGTCCAAGTGT-3’. PCR reaction was 
carried out in a mixture containing: pET45b-ZEBOV-VP35 plasmid (100 ng), 
each primer (400 μM), MgCl2 (1.5 mM), each dNTP (0.2 mM) and 0.025 μl 
FideliTaq™ DNA Polymerase (Usb). PCR mixtures were filled with nuclease-
free water to a final volume of 50 μL and PCR cycle consisted of: an initial 
denaturation at 94 °C for 2 min, 35 cycles of denaturation at 94 °C for 30 
sec, annealing at 55 °C for 30 sec, extension at 68 °C for 2 min, and a final 
extension at 68 °C for 5 min. The amplified EBOV VP35 gene and the 
pcDNA3 plasmid (Invitrogen) were digested by BamHI and NotI restriction 
enzymes (New England BioLabs), linear pcDNA3 plasmid was 
dephosphorylated with Antarctic Phosphatase (New England BioLabs) and 
fragments (50 ng of linear pcDNA3 and 20 ng of EBOV VP35 insert) were 
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ligated by T4 DNA ligase (New England BioLabs) to obtain the pcDNA3-
EBOV-VP35 plasmid, which was used to transform E. coli TOP 10 cells 
(Invitrogen) by standard heat shock protocol at 42 °C for 90 sec. Plasmid was 
extracted and sequenced for control. The same procedure was used to 
produce the mutants pcDNA3-EBOV-VP35/R305A, pcDNA3-EBOV-
VP35/K309A, pcDNA3-EBOV-VP35/R312A, pcDNA3-EBOV-
VP35/K319A/R322A, pcDNA3-EBOV-VP35/S272A, pcDNA3-EBOV-
VP35/Q274A, pcDNA3-EBOV-VP35/F239A, pcDNA3-EBOV-VP35/L277A, 
pcDNA3-EBOV-VP35/I280A, pcDNA3-EBOV-VP35/I278A, pcDNA3-EBOV-
VP35/Q279A, pcDNA3-EBOV-VP35/T281A, pcDNA3-EBOV-VP35/K282A, 
pcDNA3-EBOV-VP35/K319A, pcDNA3-EBOV-VP35/R322A and pcDNA3-
EBOV-VP35/K339A. 
 
4.4.3 Expression and purification of full-length wt and mutants 
EBOV rVP35 
 
Full-length, wt and mutants, bacterially-expressed rVP35s were 
obtained as previously described.38 Briefly, protein expression was carried 
out on transformed E. coli BL21AI (Invitrogen) cultured in LB media at 37 °C 
and induced at an optical density of 0.6 OD at 600 nm with 0.4% L-arabinose 
(Sigma-Aldrich). rVP35s were IMAC purified with Ni-Sepharose High 
Performance (GE Healthcare) beads by using a BioLogic LP FPLC system 
(Biorad), and dialyzed in desalting buffer (50 mM sodium phosphate pH 7.5, 
300 mM NaCl, 10% glycerol, 0.014% β-mercaptoethanol). As previously 
published,38 rVP35 full-length proteins were purified at ≈95% homogeneity, 
their integrity was assessed by PAGE analysis and their concentration was 
calculated using the Protein Quantification kit-Rapid (Fluka). 
 
4.4.4 Differential scanning fluorimetry analysis 
 
Differential scanning fluorimetry (DSF) analysis was carried out in a 
MiniOpticon real-time PCR instrument (BioRad) by using the Protein 
Thermal Shift Dye kit (Life technologies) according to manufacturer’s 
instructions. Measurements were performed using excitation λ = 470-505 
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nm and emission λ = 540-700 nm and data were acquired on a temperature 
gradient from 25 °C to 95 °C with increments of 0.5 °C. Samples contained 2 
μg rVP35 protein, 1X SYPRO Orange (Life technologies), 50 mM sodium 
phosphate pH 7.5, 150 mM NaCl and 20 mM MgCl2 in a 20 μl final volume. 
Fluorescence data were analysed, and the derivative of the curve 
representing melting temperature (Tm) of wild type and mutants rVP35 was 
obtained by using the CFX manager software v.2.1 (BioRad) tool for protein 
thermal shift assays protocols. 
 
4.4.5 Magnetic pull down assay 
 
Heterologous 500 bp dsRNA and 500 bp radio-labeled dsRNA 
production was previously described.37 The rVP35-dsRNA complex 
formation was assessed exploiting the properties of the TALON 
paramagnetic Dynabeads (Invitrogen). Firstly, 1 μg of rVP35 was conjugated 
to 50 μL TALON beads in a volume of 700 μL of binding/washing buffer (50 
mM sodium phosphate pH 7.5, 150 mM NaCl, 0.05% Tween-20) for 15 min 
at 23 °C under gentle rotating agitation (20 rpm). Unconjugated rVP35 was 
removed by magnetic field application, supernatant removal and further 
washing with binding/washing buffer. Pellets with conjugated rVP35 were 
re-suspended in a 100 μl volume of binding/washing buffer containing 20 
mM MgCl2 and 1.5 nM 500 bp 
3H-dsRNA (0.1 Ci/mmoles), then incubated for 
60 min at 37 °C (20 rpm). Unbound 3H-dsRNA was separated by the 
conjugated rVP35-dsRNA complex by magnetic field application and 
supernatant removal. A further washing step was performed to completely 
remove unbound 3H-dsRNA. Elution of VP35-dsRNA elution was performed 
by incubation of the beads pellet in 300 μl elution buffer (binding/washing 
buffer plus 1 M imidazole pH 7.5) for 10 min at 23 °C (20 rpm), subsequent 
magnetic field application and supernatant removal. The supernatant was 
transferred to vials and radioactivity was determined with a Beckman LS 
6500 beta-counter (Beckman-Coulter). 
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4.4.6 Molecular modeling 
 
Complex preparation. The coordinates of VP35-dsRNA homodimer 
structure were taken from the RCSB Protein Data Bank (PDB ID: 3L25).26 The 
protein was prepared by using the Maestro GUI Protein Preparation Wizard 
module (Schrödinger LLC. 2014. Maestro GUI, New York, NY, USA). Bond 
orders and formal charges were added for hetero groups, and all the 
hydrogen atoms were added in the structure. After preparation, the 
structures were refined to optimize the hydrogen-bond network by using 
OPLS2005 force field.68 The minimization was terminated once the energy 
converged or the RMSD reached a maximum cut off of 0.30Å. The wt model 
was generated introducing 5’-ppp dsRNA as terminal portion using build 
module in Maestro GUI available in Schroedinger Suite 2014 (Schrödinger 
LLC. 2014. Maestro GUI, New York, NY, USA). The protein was then 
minimized with the Polak-Ribiere conjugate gradient minimization allowing 
10000 iterations and a convergence threshold of 0.01 in GB/SA implicit 
water.69 Since the model misses the coil-coil tail portion and dsRNA is likely 
to be open during the simulation, force constraints were applied around 
residue Asp218 and dsRNA terminal bases (C1-G8). The rest of the complex 
was left free to move. Minimized complex was then used as initial structure 
for MD simulation, where the same constraints were maintained. Mutants 
were generated based on wt structure by mutating the corresponding 
residues. 
Molecular dynamic simulations and MMGBSA calculations. 
MacroModel of Schrödinger Suite Software70 was applied to carry out 
molecular dynamic simulations (3ns) including the energy minimization and 
equilibration protocols (200ps). The production phase runs 3ns. The binding 
free energy calculations were performed by MM/GBSA71 method using 
extracted frames from equilibrated trajectories. Binding free energy was 
computed: ΔGbind = Gcomplex –Gprotein -GRNA. The free energy G, can be 
calculated using the scheme as follows: ΔG = ΔEMM + ΔGsol -TΔS, ΔGsol and ΔS 
are considered approximately similar for all similar complex therefore ΔG is 
proportional to ΔE: ΔEMM = ΔEint + ΔEele + ΔEvdw. The average energies of MD 
simulation are listed in Table 4 while Figure 10 shows ΔE and the most 
important contributions to the energy of binding: electrostatic (ΔEele) and 
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van der Walls (ΔEvdw). The resulting complexes were considered for the 
binding modes graphical analysis with Maestro (Schrödinger LLC. 2014. 
Maestro GUI, New York, NY, USA) and Pymol.72 
 
VIRTUAL SCREENING 
Pharmacophore generation. The frame with the lowest energy of wt 
3P-VP35 coming from the MD was considered for pharmacophore 
generation. Only end capping interacting monomer was selected. The two 
terminal bases and the triphosphate portion were considered as core 
molecule and the pharmacophore was automatically generated by 
Ligandscout. This original pharmacophore was modified with the 
introduction of hydrophobic feature in correspondence of Guanine aromatic 
portion and used to screen the database allowing 2 omitting features. 
Database preparation. FDA Drugs .sdf file was downloaded from IPMC 
(Institut de Pharmacologie Moléculaire et Cellulaire).47 This file contains one 
conformer for each drug with indication of chiral centres or list of possible 
diastereoisomers if the drug possess more than one chiral center  and it is 
given as a mixture. 
Compounds were prepared with Ligprep using the right ionization at 
7.4 and allowing possible tautomers.73, 74 This file was then converted in a 
multiconformer .ldb database with ldbgen by LIgandScout and screened 
with the pharmacophore. 
Docking. Selected compounds were then minimized and docked 
considering 3 docking protocols: GlideXP,62 QMPL63 and Autodock.65, 66 
Grid was centred considering the residue F239 located in the middle of 
end-capping surface and it was wide enough to contain the whole monomer 
(36 x36 x36)Å. For Glide and QPLD, extra-precision (XP) mode was selected. 
All the other settings were left as default as well as for Autodock, where the 
files were generated with Raccoon.75 
The best poses of each compound were then subjected to a post-dock 
eMBrAcE protocol.67 For each ligand, the protein-ligand complex, the free 
protein, and the free ligand were all subjected to energy minimization in 
implicit solvent (generalized Born).76 It uses a traditional molecular 
mechanics (MM) method to calculate ligand–receptor interaction energies, 
with a Gaussian smooth dielectric constant function method for 
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electrostatic part of solvation energy and solvent-accessible surface for the 
nonpolar part of solvation energy. A conjugate gradient minimization 
protocol was used in all the performed minimizations. The compounds with 
the best consensus scoring were then analysed by visual inspection. 9 
compounds were purchased. 
 
4.4.7 Cell line 
 
A549 cells were grown in Dulbecco’s modified Eagle’s medium 
(DMEM) (Gibco) supplemented with 10% fetal bovine serum (FBS) (Gibco), 
1% Penicillin-Streptomycin (Pen/Strept) (EuroClone). Cells were incubated at 
37 °C in a humidified 5% CO2 atmosphere 
 
4.4.8 EBOV VP35 luciferase reporter gene inhibition assay 
 
A549 cells (5 x 104 per well) were co-transfected in 48-well plates with 
T-Pro P-Fect Transfection Reagent (T-Pro Biotechnology) with the pGL IFN-β 
luc plasmid, kindly provided by Prof. Stephan Ludwig (Institute of Molecular 
Virology, Münster, Germany), and the pcDNA3-ZEBOV-VP35. Twenty-four 
hours after transfection cells were additionally transfected with Influenza A 
Virus/Puerto-Rico/8/34 viral RNA (IAV PR8 vRNA) and incubated for further 
6 hours at 37 °C with 5% CO2. Cells were harvested with lysis buffer (50 mM 
Na-MES pH 7.8, 50 mM Tris-HCl pH 7.8, 1 mM dithiothreitol, 0.2% Triton X-
100). The crude cell lysates were cleared by centrifugation and 50 µL of 
cleared lysates were added to 50 µL of luciferase assay buffer (125 mM Na-
MES pH 7.8, 125 mM Tris- HCl pH 7.8, 25 mM magnesium acetate, 2.5 
mg/ml ATP) in a white 96-well plate. Immediately after addition of 50 µL 1 
mM D-luciferin (Gold Biotechnology) into each well luminescence was 
measured in a Victor3 luminometer (Perkin Elmer). The relative light units 
(RLU) were normalized as the fold activity of the unstimulated control. 
Inhibition of luciferase expression was indicated as percentage of induced 
control; each assay was carried out in triplicate. 
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5  CHAPTER  
5.1 INTRODUCTION TO COVALENT DOCKING WITH 
AUTODOCK 
 
The aim of this work was to apply and compare these two methods of 
covalent docking developed in Olson’s laboratory at the Scripps Research 
Institute, in order to find the best procedure to be implemented in Autodock 
platform.  
There has recently been a resurgence of interest in inhibitors that bind 
covalently to their biomolecular targets.1-3 These compounds have the 
advantage of very tight binding, allowing to design of compounds with small 
molecular mass but with high potency. Potential problems with selectivity 
have been a concern for development of covalent inhibitors. However one 
third of currently-approved drugs act through covalent mechanisms. The 
major approach to reducing toxicity is to improve the selectivity of the 
compounds, both by optimizing the non-covalent interactions within the 
binding site and by tailoring the chemistry of reaction with a specific site of 
alkylation. 
Computational docking provides an effective way to evaluate the 
interaction of a trial compound with a target. With the recent increased 
interest in covalent inhibitors, a variety of methods have been reported for 
using computational docking to predict the binding of covalently-bound 
compounds.4-7 In general, these methods search the conformations 
available to the ligand in its covalently-attached state, and evaluate the 
energetics of interaction with the target binding site. More detailed 
methods, such as quantum mechanical analysis, complement these docking 
analyses to address the chemical reactivity of the compound. 
AutoDock is an automated procedure for predicting the interactions of 
ligands with macromolecular targets. It is a two steps process where first the 
maps and the interactions of each atom type of the ligand and the receptor 
are pre-calculated in a grid surrounding the binding region. Then the docking 
simulation takes place, in which grid interactions energies are used as look-
up table to speed ligand energy evaluation. Autodock uses a Lamarckian 
genetic algorithm where a population of trial conformations is created, and 
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then in successive generations these individuals mutate, exchange 
conformational parameters, and compete in a manner analogous to 
biological evolution, ultimately selecting individuals with lowest binding 
energy.8, 9 
We have studied two different covalent methods to modify the 
distributed version of AutoDock9 to evaluate covalent complexes, by 
extending its standard functionality with custom potentials and new atom 
types. The specification and architecture of AutoDock was designed to allow 
this type of user modification for specialized systems, and has been used 
previously to model protein flexibility,10 flexible rings in ligands,11 zinc 
interaction,12 and selective hydration.13  
The need to compute automated docking for covalent complexes led 
to the development of two methods: the double point attractor method and 
the flexible sidechain method.9 In this regard, Autodock has proven to be 
extremely flexible and reliable. These two methods differ in the way the 
ligand is modeled (Figure 1). With the two-point attractor method, the 
alkylating molecule is modeled as a free ligand, and a custom potential is 
used to bring together the covalently-bound portions of ligand and alkylated 
residue. 
With the flexible sidechain method, the ligand is joined in an arbitrary 
conformation with the target, and the attached ligand is modeled as a fully 
flexible side chain in the AutoDock simulation, in a similar fashion as other 
docking programs (GOLD14 and FlexX15). Previously reported results suggest 
that AutoDock flexible residue method outperformed GOLD in a dataset of 
76 complexes.4 
With both methods, it is possible to model the most frequently 
covalently modified residues, such as cysteine, lysine, threonine, and serine. 
These two methods were tested on a set of 20 diverse systems in 
order to compare their relative performance and identify pros and cons of 
each. 
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Figure 1. Schematic diagram of the two covalent docking approaches, with the protein in 
gray and the ligand in black. a) The two-point attractor method calculates two energetically-
attractive maps (shown schematically with circles) at the site of covalent attachment on the 
protein, and uses two dummy atom types (X and Z) to target the ligand to the site. b) The 
flexible sidechain method overlaps the ligand, then uses AutoDock to optimize the 
conformation. 
 
5.2 METHODS 
5.2.1 Two point attractor method 
 
The two-point attractor method uses modified interaction maps and 
modified atom types. The target residue side chain is clipped to remove two 
terminal atoms (i.e. C and O for serine). These two atoms are attached to 
the alkylating ligand at the appropriate location with ideal chemical 
geometry, and assigned two special atom types (X and Z). Two specialized 
interaction maps are created for these atom types, with a Gaussian 
potential (termed here the Z-potential) centered on the location of the 
original atoms in the receptor structure, with a negative value close to the 
desired location and rising to zero at distant locations. The Z-potential 
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penalizes poses where Z or X atoms are outside their covalently-attached 
location, pulling the ligand in the proper pose (see Figure 1a).  
The Gaussian Z-potential is defined with two parameters: width (, 
unit: Å) and amplitude (, unit: Kcal/Mol). Optimal values for these 
parameters need to provide a good compromise between atom placement 
accuracy and search accessibility. The combination of large  and small  
results in a narrow and deep potential, whose energetic minimum will be 
accurately located on the atom position, but will be much harder to be 
found by the search algorithm. Conversely, small  and large  would be 
easier to be reached during the search, but it would provide lower precision 
in reproducing the covalent geometry.  
Prior to performing dockings on the whole dataset with the two-point 
attractor method, we identified the optimal the values of Gaussian potential 
coefficients  and  using the complex of a DD-peptidase with penicillin G 
(PDB entry 1pwc16) which was also used as test case for the first 
implementation of the method.9 We tested a range of values (0.5-100 Å for 
 and 10-50 kcal/mol for  Table 1). Most values provided satisfying results, 
with several combinations achieving RMSD below 1.0 Å. As expected, 
extreme value pairs (i.e. high-/low, low-/high-) corresponded to the 
worst results with higher deviations from the experimental poses. To 
identify the optimal values, the following criteria were adopted: a) the 
largest  was chosen that still provides proper atom placement, to improve 
the search effectiveness; b) the smallest magnitude of  was chosen that 
results in proper placement, to ensure that the contribution of the Z-
potential does not swamp out the energetics of interaction of the non-
covalent portion of the molecule. The optimal values selected were 3 Å, 
and  = 10 Kcal/mol. 
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Table 1. Calibration results of the double point attractor method using the 
crystal structure 1pwc. Values show the influence of different values δ and ε 
on docking accuracy (RMSD (Å) with respect to the experimental structure) 
and binding free energy ( B. E. ) (Kcal/mol).  
Widt
h(δ) 
RMSD
-ε-10 
RMSD
-ε-20 
RMSD
-ε-30 
RMSD
-ε-40 
RMSD
-ε-50 
B. E.- 
ε-10 
B. E.- 
ε-20 
B. E.- 
ε-30 
B. E.- 
ε-40 
B. E. - 
ε-50 
0.50 1.07 2.13 0.7 1.29 2.36 -2.92 0.39 2.04 3.07 5.38 
1 1.05 1.17 1.14 2.49 0.67 -5.48 -5.02 -2.52 -2.14 -3.67 
3 0.73 0.61 0.69 0.85 0.67 -6.23 -6.19 -5.95 -6.02 -6.08 
5 0.7 0.73 1.04 0.69 0.65 -6.37 -6.25 -6.28 -6.5 -6.13 
10 0.96 0.74 1.18 0.72 1.37 -6.38 -6.35 -6.37 -6.6 -6.34 
25 0.87 1.49 0.95 1.49 0.96 -6.35 -6.51 -6.36 -6.5 -6.27 
50 1.79 1.99 0.81 0.89 0.82 -6.61 -6.58 -6.89 -6.29 -6.6 
75 1.14 1.07 1.02 1.1 0.9 -6.27 -6.29 -6.29 -6.01 -6.51 
100 1.41 2.5 3.08 0.8 1.12 -6.1 -5.78 -6.39 -6.3 -6.03 
 
5.2.2 Flexible sidechain method 
 
In the flexible sidechain method, a ligand coordinate file is modified by 
connecting the two target residue atoms at the site of alkylation, with ideal 
chemical geometry. These two ligand atoms are then overlapped with the 
matching atoms in the receptor structure to establish the covalent bond 
with the residue before running the docking. Then, during the docking, the 
complex is treated as a fully flexible side chain, using the existing AutoDock 
method for modeling selected receptor flexibility. Cα and Cβ atoms are fixed 
in space, while all torsions of both ligand and residue (including Cα-Cβ) are 
allowed to rotate (Figure 1b). 
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5.2.3 Data set  
 
In order to compare results obtained with the two methods, we 
filtered the PDB to obtain a representative data set using the following 
criteria:  
 covalent ligand binding;  
 X-ray diffraction resolution ≤2.65 Å; 
 structurally diverse ligands, with torsional degrees of freedom 
between 5 and 22; 
 Ser or Cys covalent residue; 
 no co-factors in the binding site; 
 
The final data set includes 20 structures from 19 different protein 
families. Ligands in these complexes present a wide range of structural 
complexity, with torsional degrees of freedom ranging from 6 to 20, and 
molecular weight from 369 to 738 Daltons.  
 
5.2.4 Coordinate preparation and docking 
 
The two covalent protocols require different input preparation 
protocols. Ligand and receptor structures were retrieved from the Protein 
Data Bank and subsequently a single protein subunit has been selected and 
all waters and co-factors removed. AutoDockTools (ADT)9 was used to add 
hydrogens, calculate Gasteiger charges and generate PDBQT files. 
Regarding the two-point attractor method, the ligand was extracted 
from the PDB file and modified it by adding two extra atoms X and Z, 
corresponding to the two side chain terminal atoms (i.e., serine C, O). 
Hydrogens and charges were added, and the resulting PDBQT coordinates 
were randomized (orientation, translation and torsions) using AutoDock 
Vina.17 The grid parameter file (GPF) was modified to include the definition 
of the two Z-potentials for atoms X and Z. The potential centers were 
defined on the original coordinates of the residue atoms, and grid map 
calculated following the standard AutoDock protocol for ligand docking.  
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In the flexible sidechain method, the ligand file was created by adding 
two receptor atoms to the ligand coordinates in ideal chemical geometry, 
and then this file was used to superimpose the ligand on the appropriate 
residue in the target protein (Figure 1b). ADT was used to add hydrogens, 
calculate Gasteiger charges and generate a modified flexible ligand, using 
default methods. The resulting sidechain-ligand structure is treated as 
flexible during the docking simulation, sampling torsional degrees of 
freedom to optimize the interaction of the tethered ligand with the rest of 
the protein. Grid maps were calculated following the standard AutoDock 
protocol for flexible side chains.9 The torsions of the flexible residue have 
been randomized using AutoDock Vina17. 
Docking simulations were performed using the Lamarckian Genetic 
Algorithm. For the flexible residue method, dockings on the whole dataset 
were run with default LGA settings (50 poses generated). Due to the higher 
complexity of untethered two-point attractor method, results obtained with 
the default LGA settings (50 poses) were compared with extended search 
parameters (ga_population = 300, ga_num_evals = 106, 100 poses 
generated). Final results were clustered with AutoDock with 2.0 Å RMSD 
tolerance.  
 
5.3 RESULTS AND DISCUSSION 
 
The aim of this work was to provide a suitable method for the docking 
calculations of covalent complexes by modifying AutoDock. For this purpose 
we compared and evaluated the reliability of two different methods: the 
two-point attractor method and the flexible sidechain method. Accuracy 
was assessed by measuring the RMSD between the lowest energy pose and 
the experimental coordinates, and results with deviations below 3.0 Å were 
considered successful. The total number of result clusters (2.0 Å RMSD 
tolerance) and the number of poses in the lowest energy cluster were used 
to assess the reliability in finding the correct pose. For the two-point 
attractor method, the RMSD between the Cα and Cβ of the docked poses 
and the experimental coordinates were all less than 0.09 Å, so the method is 
effective for forming the covalent bond. RMSD results are included in 
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Figures 2 and 3 along with images of the best docked conformation for each 
complex. Data for RMSD and cluster size, and their relationship to flexibility 
of complexes, are presented graphically in Figures 2 and 3 and Tables 2-4.  
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Figure 2. Double point attractor method at 100 runs: best pose of compounds with the 
covalently bound residues (purple) compared with the crystallographic pose (green) of the 
ligands. RMSD values are given in parentheses. 
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Figure 3. Flexible sidechain method at 50 runs: best pose of compounds with the covalently 
bound residues compared with the crystallographic pose of the ligands. 
 
Overall, the two-point attractor method performed poorly, 
reproducing the experimental coordinates in 4 systems out of 20 (20% 
success rate). Energies improved slightly when going from default LGA 
settings (Table 3) to extended settings (Table 4), but no significant variations 
were found in the overall success rate. 
Moreover, accuracy appears to be correlated with the number of 
rotatable bonds of the ligand (Figure 4a), with only one successful result 
with ligands over 9 torsional degrees of freedom. Accuracy of the flexible 
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side chain method is considerably higher, reproducing experimental 
coordinates in 15 out of 20 systems (75% success rate). As expected, this 
method is less sensitive to the torsional complexity of the ligands, obtaining 
successful results up to 14 torsional degrees of freedom (Figure 4b).  
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Figure 4. Correlation between the torsional degrees of freedom and results RMSD: a) two-
point attractor method; b) flexible side chain method. The size of data points is roughly 
proportional to the number of conformations in the cluster of best predicted energy. 
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Overall, highly flexible ligands showed poorer reliability in finding the 
correct result, as observed in the larger number of scarcely populated 
clusters for very flexible ligands. Since the ligand is docked untethered with 
the two-point attractor method, it results in larger numbers of degrees of 
freedom, making the search implicitly more complex. Therefore, it is more 
prone to finding false positive poses that can be ranked higher than the 
correct pose, resulting in RMSD values as high as 6 Å. As expected, search 
efficiency is more effective with the flexible residue method than with the 
two-point attractor method. Both methods are successful with low torsional 
degrees of freedom (6, 7 and 8 for 2awz18, 3c9w19, 1pwc16, respectively), but 
they both fail with complex 3lok20 (7 torsions). This is due to the absence of 
a coordinating water between the ligand and residue Glu339 (data not 
shown). Also, neither method is successful in re-docking the complex 
1w3c,21 due to the large fraction of the ligand (i.e., thiophene and indole 
rings) exposed to the solvent. 
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Table 2. Double point attractor method obtained with default LGA settings 
(50 poses) 
PDB  
code 
Res
.  
(Å) 
Numbe
r of 
Clusters 
Poses 
in 
best 
cluste
r 
Lowes
t 
Energy 
(Kcal 
mol
-1
) 
RMSD 
of 
lowest 
energ
y (Å) 
Energ
y of 
lowes
t 
RMSD 
Lowes
t 
RMSD 
found 
RMS
D Cα 
and 
Cβ 
Rotatabl
e bonds 
3c9
w 
2.5 2 47 -6.7 1.07 -4.68 0.76 0.025 6 
2awz 2.1
5 
11 29 -6.38 1 -5.84 0.3 0.125 7 
3lok 2.4
8 
19 14 -7.89 5.55 -5.43 2.19 0.005 7 
1pw
c 
1.1 6 22 -6.23 0.73 -5.41 0.52 0.085 8 
3n8l 1.4 18 2 -4.86 5.71 -3.85 3.39 0.545 9 
3svv 2.2 36 3 -7.56 4.48 -4.33 4.26 0.09 9 
1qhr 2.2 14 7 -5.9 4.85 -4.75 4.65 0.09 11 
3pr0 2.2 16 8 -9.44 4.33 -8.88 3.63 0.25 11 
2wj1 1.8
4 
10 16 -12.72 3.14 -9.03 1.61 0.17 12 
3knx 2.6
5 
27 12 -11.28 4.69 -9.05 4.81 0.445 12 
3ur9 1.6
5 
37 1 -4.54 4.45 -3.46 4.03 0.17 12 
1qj6 2.2 27 4 -12.23 1.63 -12.12 1.1 0.04 13 
3n8s 2 22 8 -4.37 2.31 -4.22 1.73 0.1 13 
2obo 2.6 37 2 -6.05 5.43 -4.14 5.07 0.65 14 
4dcd 1.6
9 
43 1 -5.64 5.74 -4.11 5.32 0.37 14 
4f49 2.2
5 
37 6 -6.56 5.47 -4.41 3.01 0.05 14 
2a4q 2.4
5 
42 5 -9.31 5.23 -9.14 4.8 1.3 15 
2gvf 2.5 46 1 -6.46 6.17 -1.91 5.54 0.325 15 
1w3
c 
2.3
0 
45 1 -10.71 6.12 -9.00 2.10 0.485 16 
2f9u 2.6 49 1 -6.92 4.97 -4.44 4.7 0.745 20 
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Table 3. Double point attractor method obtained with extended LGA 
settings (100 poses) 
PDB  
code 
Res  
(Å) 
N of 
Clusters 
Poses 
in best 
cluster 
Lowest 
Energy 
(Kcal mol
-
1
) 
RMSD of 
lowest 
energy (Å) 
Energy 
of 
lowest 
RMSD 
Lowest 
RMSD 
found 
Rotatable 
bonds 
3c9w 2.5 2 99 -6.7 0.94 -6.39 0.6 6 
2awz 2.15 10 56 -6.27 0.93 -5.53 0.4 7 
3lok 2.48 18 30 -7.97 5.38 -6.6 2.64 7 
1pwc 1.1 6 62 -6.4 0.75 -5.92 0.55 8 
3n8l 1.4 28 16 3.68 4.86 -1.08 3.21 9 
3svv 2.2 42 9 -7.79 4.37 -6.87 3.67 9 
1qhr 2.2 29 27 -5.74 5.1 -5.16 4.5 11 
3pr0 2.2 13 45 -10.2 4.37 -9.12 3.66 11 
2wj1 1.84 11 96 -12.88 3.08 -11.84 1.94 12 
3knx 2.65 37 36 -11.83 4.7 -8.29 4.61 12 
3ur9 1.65 46 10 -5.44 4.07 -4.16 3.88 12 
1qj6 2.2 26 13 -12.55 8.05 -12.33 0.64 13 
3n8s 2 30 11 -5.04 2.09 -1.42 1.48 13 
2obo 2.6 45 15 -6.52 5.68 -4.04 5.02 14 
4dcd 1.69 67 2 -6.38 5.95 -3.96 5.28 14 
4f49 2.25 66 2 -7.7 4.33 -6.68 2.79 14 
2a4q 2.45 72 18 -10.37 5.24 -9.58 4.63 15 
2gvf 2.5 80 1 -9.08 5.93 -2.41 5.51 15 
1w3c 2.30 65 1 -11.05 6.94 -9.41 2.31 16 
2f9u 2.6 96 1 -7.19 4.54 -7.19 4.54 20 
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Table 4. Flexible docking results with standard LGA settings (50 poses) 
PDB 
code 
Res. 
(Å) 
N of 
Clusters 
Poses 
in best 
cluster 
Lowest 
Energy 
(Kcal 
mol
-1
) 
RMSD 
of 
lowest 
energy 
(Å) 
Energy 
of 
lowest 
RMSD 
Lowest 
RMSD 
found 
Rotatable 
bonds 
3c9w 2.5 1 50 -10.17 0.87 -10.17 0.86 6 
2awz 2.15 1 50 -10.82 0.74 -10.81 0.5 7 
3lok 2.48 5 17 -8.36 9.09 -7.58 5.31 7 
1pwc 1.1 6 42 -14.09 1.28 -11.98 0.95 8 
3n8l 1.4 5 21 -35 1.46 -12.2 1.38 9 
3svv 2.2 10 25 -12.25 1.78 -14.96 0.94 9 
1qhr 2.2 4 47 -13.64 1.9 -13.07 0.71 11 
3pr0 2.2 2 34 -15.2 2.91 -14.96 2.38 11 
2wj1 1.84 3 47 -15.67 2.96 -14.33 2.59 12 
3knx 2.65 4 31 -17.18 1.58 -16.2 1.11 12 
3ur9 1.65 9 33 -12.83 0.78 -12.82 0.75 12 
1qj6 2.2 8 29 -15.35 1.3 -15.18 0.7 13 
3n8s 2 9 9 -15.6 1.82 -14.52 1.59 13 
2obo 2.6 10 30 -16.89 0.84 -16.59 0.54 14 
4dcd 1.69 11 14 -15.13 1.44 -14.91 0.6 14 
4f49 2.25 11 7 -15.19 2.52 -14.81 1.47 14 
2a4q 2.45 25 8 -21.82 4.48 -19.79 1.71 15 
2gvf 2.5 22 5 -20.86 3.14 -18.75 2.52 15 
1w3c 2.30 23 6 -18.32 6.76 -17.20 2.87 16 
2f9u 2.6 36 1 -21.65 3.34 -20.65 0.93 20 
 
5.4 CONCLUSIONS 
 
We compared two methods for performing covalent dockings with 
AutoDock: a two-point attractor method and a modified protocol of the 
flexible receptor residues. The methods were tested on a diverse set of 
complexes in order to assess their relative performances. Overall, the 
flexible residue method provided better accuracy (75% success rate) than 
the two-point attractor method (20%). The success rate of both methods 
showed a correlation with the complexity of the ligands, decreasing 
accuracy with the increase of torsional degrees of freedom. The flexible 
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residue method provides the most effective approach in simulating covalent 
ligands.  
The two-point attractor method, on the other hand, allows 
incorporation of a certain degree of approximation in the position of the 
covalent attachment, which may be important for modeling significant 
motion in residues at the site--we are currently assessing this possibility. 
Finally, both methods provide examples of how AutoDock suite parameters 
can be customized to implement new methods and extend basic 
functionalities. Both methods are implemented in the current version of 
AutoDock (v.4.2.6), and tools and scripts for preparing input files are 
included in latest release of AutoDockTools (v.1.5.7-latest), all available at 
http://autodock.scripps.edu. 
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CONCLUDING REMARKS  
 
The application of structure-based methods to the different targets 
object of my PhD work allowed to reach important results that I am going to 
briefly summarize in few points: 
 I followed the investigation on dual Inhibitors of RT discovered 
previously by virtual screening approach. These compounds are able to 
inhibit both RT catalytic functions causing a complete block of RT. The 
mechanism of some new inhibitors has been examined in deep by means of 
biochemical and computational methods. These studies highlighted new and 
interesting mechanism. In particular these compounds seem to bind in two 
different sites opening the road to new allosteric RT inhibitors with a 
favourable resistance profile. This could lead to a reduction of combined 
drugs used in therapy and of toxic side effects. 
 Monoamine oxidase B is a target involved in many 
neurodegenerative disorders and in the production of reactive oxygen 
species (ROS). Therefore the increase number of elderly people affected by 
these disorders has led to an increased interest towards selective, potent 
and reversible MAO inhibitors. The information derived by computational 
studies guided the optimization of active inhibitors allowing to obtain 
compounds active in low nM range. I also validated both protocols of 
docking and MD obtaining good correlation between predicted and 
experimental binding energy. The protocol can be applied to other series of 
compounds to rationalize their activity or to find new scaffolds. 
 The emergence of Ebola virus outbreak prompted the development 
of a vaccine in the immediate. However, it would offer great advantage to 
find inhibitors able to block the virus and to reduce the mortality. Therefore, 
since our collaborators were able to obtain and purify the whole VP35 
protein, I first investigated the effect of single mutations in the dsRNA 
binding area and then applied a virtual screening workflow to find possible 
VP35 inhibitors. The VS protocol includes pharmacophore and consensus 
docking methods. We have found two compounds which show activity 
against this target in the low micromolar range. Although the studies are still 
in progress these results are encouraging and offer a base for further 
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investigation and optimization. Furthermore the same VS protocol can be 
applied to larger databases. 
 Computational tools are widely used by academy and 
pharmaceutical companies. Limitations on their application have to be 
considered and if possible overcome. Until few years ago docking 
approaches could not be applied to predict the binding of covalent species 
but only show the step before binding: the approaching process to the 
amino acid involved. Recently many companies and groups, involved in 
computational software development, invest energy in tools able to predict 
covalent binding event. 
One is the group of Prof Arthur Olson at the Scripps Institute. I was 
involved in the validation of two covalent docking protocols of the software 
Autodock and now these methods are available for the scientific 
community. 
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